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Abstract 
Due to heterogeneous tumour biology, the treatment response of locally advanced head and 
neck squamous cell carcinoma differs largely between patients, resulting in a mean 5-year 
survival of about 50%. In order to adapt the treatment to the properties of the tumour, the 
therapy resistance of the tumours must be assessed before treatment. In this thesis, gene 
expression data were analysed to identify novel gene signatures and models that allow for 
stratifying patients into risk groups with low and high risk of loco-regional tumour recurrence. 
To identify those signatures, methods from the field of machine learning were applied. For 
patients treated with postoperative radiochemotherapy, a 7-gene signature was developed 
and successfully validated. Furthermore, it was shown that several models based on 
different gene signatures may be equally suitable for patient stratification. A method is 
presented that combines those distinct prognostic models. In addition, gene-expression-
based biomarkers were transferred between different gene expressions measurement 
methods with the result that signatures showed less variability in patient stratification than 
single-gene biomarkers. 
Zusammenfassung 
Aufgrund der heterogenen Tumorbiologie variiert der Therapieerfolg bei lokal 
fortgeschrittenen Plattenepithelkarzinomen stark, woraus ein mittleres 5-Jahres-Überleben 
dieser Patienten von etwa 50% resultiert. Um die Therapie besser an die 
Tumoreigenschaften anzupassen, muss die Therapieresistenz der Tumoren vor der 
Behandlung bestimmt werden. In dieser Dissertationsschrift werden Methoden aus dem 
Bereich des maschinellen Lernens angewandt um Genexpressionsdaten zu analysieren, um 
so Signaturen und Modelle zu erzeugen die eine Klassifizierung der Tumoren in 
verschiedene Risikogruppen bezüglich der loko-regionären Tumorkontrolle erlauben. Für 
Patienten, die mit postoperativer Radiochemotherapie behandelt wurden, konnte eine 7-
Gen Signatur entwickelt und erfolgreich validiert werden. Außerdem konnte gezeigt werden, 
dass verschiedene Signaturen ähnlich gut zur Patientenklassifizierung geeignet sein 
können. Daher wurde eine Methode vorgeschlagen, die es erlaubt verschiedene 
prognostiche Modelle zu kombinieren. Weiterhin wurden verschiedene genbasierte 
Biomarker zwischen verschiedenen Genexpressionsmessmethoden verglichen. In den 
resultierenden Patienteneinteilungen zeigten Biomarker, die auf Signaturen basieren, eine 
geringere Variabilität als Biomarker, die auf einzelnen Genen basieren.  
IV 
Content 
Abbreviations .................................................................................................................... VII 
Figures .............................................................................................................................. IX 
Tables .............................................................................................................................. XII 
1 Introduction ................................................................................................................. 1 
2 Biological & Statistical Background .............................................................................. 4 
2.1 Head and Neck Squamous Cell Carcinoma .......................................................... 4 
2.1.1 Tumorigenesis ............................................................................................... 4 
2.1.2 Biomarkers .................................................................................................... 8 
2.2 Statistics ............................................................................................................. 14 
2.2.1 Survival analysis ......................................................................................... 14 
2.2.2 Model and data evaluation .......................................................................... 18 
2.2.3 Data sampling methods ............................................................................... 22 
2.3 Machine learning algorithms ............................................................................... 23 
2.3.1 Feature selection algorithms ....................................................................... 24 
2.3.2 Prognostic models ....................................................................................... 27 
2.4 Gene expression measurement methods ........................................................... 30 
2.4.1 Real-time polymerase chain reaction (RT-PCR) .......................................... 31 
2.4.2 nCounter® gene expression ........................................................................ 32 
2.4.3 In situ-synthesized oligonucleotide microarrays ........................................... 32 
3 Material and methods ................................................................................................ 35 
3.1 Patient cohorts ................................................................................................... 35 
3.1.1 Primary radiochemotherapy (pRCTx) cohorts .............................................. 35 
3.1.2 Postoperative radio(chemo)therapy (PORT-C) cohorts ............................... 36 
3.1.3 Clinical endpoints ........................................................................................ 38 
3.2 Gene expression analyses ................................................................................. 39 
3.2.1 HPV status .................................................................................................. 39 
3.2.2 Immunohistochemical staining..................................................................... 39 
3.2.3 RT-PCR measurements .............................................................................. 40 
3.2.4 nCounter® measurements .......................................................................... 40 
3.2.5 GeneChip® analyses (only training cohorts) ............................................... 41 
3.3 Machine learning framework .............................................................................. 41 
V 
3.3.1 Pre-processing of gene expression data ...................................................... 41 
3.3.2 Determination of the ensemble gene signature ............................................ 42 
3.3.3 Expanding the ensemble signature by highly correlated genes.................... 43 
3.3.4 Independent validation and patient stratification .......................................... 45 
4 Identification of gene expression signatures as prognostic biomarkers ...................... 46 
4.1 Hypoxia classification ......................................................................................... 46 
4.2 nCounter® gene expression based signatures ................................................... 50 
4.2.1 Patients treated with primary radiochemotherapy ........................................ 50 
4.2.2 Clinical Features .......................................................................................... 55 
4.2.3 Signature extension using clinical features .................................................. 64 
4.2.4 Patients treated with postoperative radiochemotherapy ............................... 65 
4.2.5 Signature extension using clinical features – Port-C .................................... 72 
4.3 GeneChip® gene expression-based signatures .................................................. 78 
4.3.1 Pre-selection ............................................................................................... 78 
4.3.2 Patients treated with primary radiochemotherapy ........................................ 79 
4.3.3 Patients treated with postoperative radiochemotherapy ............................... 87 
4.4 Combined models for PORT-C ........................................................................... 91 
4.4.1 Creation of a consensus model ................................................................... 92 
4.4.2 Consensus model based on 2 models ......................................................... 93 
4.4.3 Consensus model based on more than 2 models ........................................ 97 
4.4.4 Discussion and summary of model combination ........................................ 101 
5 Stability of gene expression-based biomarkers ........................................................ 102 
5.1 Reproducibility depending on time of nCounter® .............................................. 102 
5.2 Comparison of nCounter® and GeneChip® gene expression ........................... 106 
5.2.1 Introduction................................................................................................ 106 
5.2.2 Correlation analyses .................................................................................. 106 
5.2.3 Model and biomarker transfer .................................................................... 108 
6 Conclusion and outlook ........................................................................................... 123 
Zusammenfassung ......................................................................................................... 125 
Summary ........................................................................................................................ 128 
Appendix ........................................................................................................................ 130 
A. Supplementary Figures ........................................................................................ 130 
B. Supplementary Tables ......................................................................................... 133 
VI 
Bibliography ................................................................................................................... 147 
Acknowledgements ........................................................................................................ 188 
Erklärungen .................................................................................................................... 189 
 
  
VII 
Abbreviations 
AUC ....................................  Area under the curve  
BL .......................................  Baseline model 
CDK ....................................  Cyclin-dependent kinase  
cDNA ..................................  Complementary DNA  
𝑐𝑖.........................................  Concordance index 
CI ........................................  Confidence interval 
CHR / comb. HR .................  Combined high risk group  
CLR / comb. LR ..................  Combined low risk group 
CSC ....................................  Cancer stem cells  
CV ......................................  Cross validation  
DNA ....................................  Deoxyribonucleic acid 
DKTK ..................................  German Cancer Consortium  
DKTK-ROG .........................  German Cancer Consortium Radiation Oncology Group 
DM ......................................  Freedom from distant metastasis  
E2F .....................................  Transcriptome factors E2  
ECE ....................................  Extracapsular extension  
FAZA ..................................  18F-flouroazomycin arabinoside  
FFPE ..................................  Formalin-fixed paraffin-embedded  
FMISO ................................  Fluoromisonidazole  
FRET ..................................  Förster resonance energy transfer  
GC ......................................  GeneChip®  
GEO....................................  Gene Expression Omnibus  
GESA ..................................  Gene enrichment set analyses  
GTV ....................................  Gross tumour volume  
HNSCC ...............................  Head and neck squamous cell carcinoma  
HPV ....................................  Human papilloma virus 
HR ......................................  High risk  
IMR .....................................  Intermediate risk group 
LR .......................................  Low risk group 
LRC ....................................  Loco-regional tumour control  
MIFS ...................................  Mutual information feature selection  
MIM.....................................  Mutual information matrix  
MRMR ................................  Minimum redundancy maximum relevance  
VIII 
MWU-test............................  Mann-Whitney-U test  
nC .......................................  nCounter® 
nSCS ..................................  Normalized signature correlation score  
oob-data .............................  Out of the bag data  
OS ......................................  Overall survival  
p .........................................  p-value 
PCA ....................................  Principal component analysis  
PDF ....................................  Probability density function  
PORT .................................  Postoperative radiotherapy  
PORT-C ..............................  Postoperative radiochemotherapy  
pRTx ...................................  Primary radiotherapy  
pRCTx ................................  Primary radiochemotherapy  
RNA ....................................  Ribonucleic acid  
ROC ...................................  Receiver operator curves  
RSF ....................................  Random survival forest  
RT ......................................  Reverse transcriptase  
RT-PCR / PCR ...................  Real time - polymerase chain reaction  
Surv.-Regr. .........................  Survival regression 
train / t ................................  Training cohort 
valid / v ...............................  validation cohort 
𝜌 .........................................  Spearman rank correlation coefficient  
 
  
IX 
Figures 
Figure 2.1 Regions of the head and neck. ........................................................ 5 
Figure 2.2 Systematic DNA structure of the human papilloma virus .................. 6 
Figure 2.3 Alterations of the cell cycle induced by the E6 and E7 gene of HPV  7 
Figure 2.4 Kaplan-Meier estimator .................................................................... 16 
Figure 2.5 Bland-Altmann plot. ......................................................................... 18 
Figure 2.6 Probability distribution with p-value .................................................. 19 
Figure 2.7 Receiver operator curves (ROC) for 3 different classifications ......... 21 
Figure 2.8 Model prediction error for training and validation data...................... 22 
Figure 2.9 Decision tree used to classify cats and dogs ................................... 30 
Figure 2.10 Schematic illustration of nCounter® measurements ........................ 33 
Figure 2.11 Schematic illustration of the production of a GeneChip® ................. 34 
Figure 4.1 Model performances for the 5-gene signatures based on the 
nCounter® measurements of the pRCTx training cohort .................. 51 
Figure 4.2 Normalized signature correlation score for the 5-gene pRCTx 
signature.......................................................................................... 52 
Figure 4.3 Kaplan-Meier estimators of the 5-gene pRCTx signature for LRC of 
the training and validation cohort ..................................................... 53 
Figure 4.4 Kaplan-Meier estimators of LRC of the pRCTx training and 
validation cohort stratified by tumour volume ................................... 57 
Figure 4.5 Logistic regression regarding 2-year loco-regional tumour control ... 59 
Figure 4.6 Kaplan-Meier estimator for LRC of the pRCTx training and 
validation cohort stratified by CD44 protein status and SLC3A2 
expression ....................................................................................... 60 
   
X 
Figure 4.7 Kaplan-Meier estimator for LRC of the pRCTx training and 
validation cohort stratified by hypoxia-associated gene signatures .. 61 
Figure 4.8 Model performances for the 4-gene signatures based on the 
nCounter® measurements of the PORT-C training cohort ............... 67 
Figure 4.9 Importance score of genes associated with LRC ............................. 68 
Figure 4.10 Kaplan-Meier estimators of LRC of the PORT-C training and 
validation cohort stratified by the prognostic index of the 7-gene 
signature ......................................................................................... 70 
Figure 4.11 Kaplan-Meier estimators of LRC of the PORT-C training and 
validation cohort stratified by the prognostic index of the extended 
7-gene signature ............................................................................. 74 
Figure 4.12 Kaplan-Meier estimators of OS and DM of the PORT-C training 
and validation cohort stratified by the prognostic index of the 
extended 7-gene signature .............................................................. 78 
Figure 4.13 Model performances of the 5-gene and 6-gene signatures based 
on the GeneChip® measurements of the pRCTx training cohort ..... 83 
Figure 4.14 Kaplan-Meier estimators of LRC of the pRCTx training cohort 
stratified by the 6-gene signatures ................................................... 85 
Figure 4.15 Kaplan-Meier estimator for LRC of the PORT-C training cohort 
stratified by the prognostic index of the 5-gene and the extended 
5-gene signature ............................................................................. 88 
Figure 4.16 Kaplan-Meier estimator for LRC of the PORT-C training cohort 
stratified by combinations of LRC and hypoxia associated gene 
signatures ........................................................................................ 95 
Figure 4.17 Kaplan-Meier estimator for LRC of the PORT-C training cohort 
stratified by combinations of LRC associated gene signatures ........ 96 
Figure 4.18 Kaplan-Meier estimator for LRC of the PORT-C training cohort 
stratified by different combinations of biomarkers ............................ 100 
   
XI 
Figure 5.1 Distribution of Spearman rank correlation coefficients for repeated 
nCounter® measurements ............................................................... 103 
Figure 5.2 Comparison of Spearman rank correlation coefficients for repeated 
nCounter® measurements ............................................................... 105 
Figure 5.3 Distribution of Spearman rank correlation coefficients for 
nCounter®, GeneChip® and RT-PCR measurements ..................... 107 
Figure 5.4 Kaplan-Meier estimator for LRC of the PORT-C training cohort 
stratified by putative CSC markers (nCounter® and GeneChip® 
measurements)................................................................................ 113 
Figure 5.5 Kaplan-Meier estimator for LRC of the PORT-C training cohort 
stratified by putative CSC markers (nCounter® and GeneChip® 
measurements ................................................................................. 114 
Figure 5.6 Kaplan-Meier estimator for LRC of the pRCTx training cohort 
stratified by putative CSC markers (nCounter® and GeneChip® 
measurements)................................................................................ 116 
Figure 5.7 Kaplan-Meier estimator for LRC of the PORT-C training cohort 
stratified by hypoxia associated gene signatures (nCounter® and 
GeneChip® measurements) ............................................................ 117 
Figure 5.8 Kaplan-Meier estimator for LRC of the PORT-C training cohort 
stratified by the extended 7-gene signature, transferred from 
nCounter® to GeneChip® based gene expressions ........................ 120 
Supplementary 
Figure 1 
Kaplan-Meier estimator for LRC of the small tumours of the 
pRCTx training and validation cohort stratified by hypoxia-
associated gene signatures .......................................................... 130 
Supplementary 
Figure 2 
Kaplan-Meier estimator for LRC of the PORT-C training and 
validation cohort stratified by the combination of the LRC and 
hypoxia associated gene signatures ............................................. 131 
Supplementary 
Figure 3 
Kaplan-Meier estimator for LRC of the pRCTx training cohort 
stratified by hypoxia associated gene signatures (nCounter® and 
GeneChip® measurements) ......................................................... 132 
XII 
Tables 
Table 2.1 Contingency table for binary classifiers ...........................................  20 
Table 3.1 Patient characteristics of the pRCTx training and validation cohorts  37 
Table 3.2 Characteristics of the patients with HPV16 DNA negative tumours 
of the PORT-C training and validation cohort ..................................  
38 
Table 4.1 Cluster centres of the 𝑘-means hypoxia classification .....................  48 
Table 4.2 Means and standard deviations of the genes of the 15-gene 
hypoxia-associated signature ..........................................................  
49 
Table 4.3 Cox regression of the 5-gene pRCTx signature predicting LRC .......  52 
Table 4.4 Means and Medians of the genes of the 5-gene pRCTx signature 
predicting LRC.................................................................................  
55 
Table 4.5 Univariable Cox regressions based on the pRCTx validation cohort  56 
Table 4.6 Multivariate Cox regressions predicting LRC of the pRCTx training 
and validation cohort .......................................................................  
63 
Table 4.7 Multivariate Cox regressions predicting OS of the pRCTx training 
and validation cohort .......................................................................  
64 
Table 4.8 Cox regression of the extended 5-gene pRCTx signature predicting 
LRC .................................................................................................  
65 
Table 4.9 Highly correlated genes of the 4-gene PORT-C signature predicting 
LRC .................................................................................................  
69 
Table 4.10 Cox regression of the 7-gene PORT-C signature predicting LRC ....  70 
Table 4.11 Cox regression of the extended 7-gene PORT-C signature 
predicting LRC.................................................................................  
73 
Table 4.12 Means and Medians of the genes of the 7-gene PORT-C signature 
predicting LRC.................................................................................  
75 
XIII 
Table 4.13 Survival and cox regression of the extended 6-gene pRCTx 
signature predicting LRC identified by MRMR and survival 
regression ........................................................................................  
82 
Table 4.14 Cox regression of the extended 6-gene pRCTx signature predicting 
LRC identified by Net-Cox and Cox regression ................................  
85 
Table 4.15 Cox regression of the 5-gene PORT-C signature predicting LRC ....  88 
Table 4.16 Cox regression of the extended 5-gene PORT-C signature 
predicting LRC .................................................................................  
91 
Table 4.17 Assignment to combined risk groups ...............................................  92 
Table 5.1 Correlations and univariable Cox regressions of biomarkers 
assessed by different gene expression measurement methods .......  
110 
Table 5.2 Transfer of cut-offs from nCounter® to GeneChip® gene 
expression .......................................................................................   
111 
Table 5.3 Cross tables of patient stratifications determined from nCounter®, 
GeneChip® and RT-PCR analyses..................................................  
118 
Supplementary 
Table 1. 
Composition of the hypoxia-associated gene signatures ........... 133 
Supplementary 
Table 2 
Versions of used programs and packages ................................. 134 
Supplementary 
Table 3 
Patient characteristics of the PORT-C training and validation 
cohort ........................................................................................ 
135 
Supplementary 
Table 4 
Genes available in nCounter® and GeneChip® analyses for 
the pRCTx and PORT-C training and validation cohorts ............ 
136 
Supplementary 
Table 5 
Hyper-parameters used for feature selection algorithms and 
predictive models ....................................................................... 
139 
Supplementary 
Table 6 
Spearman rank correlation of the genes and clinical features of 
the extended 7-gene PORT-C signature .................................... 
140 
XIV 
Supplementary 
Table 7 
Cox regression of the (extended) 7-gene PORT-C signature 
predicting OS ............................................................................. 
141 
Supplementary 
Table 8 
Cox regression of the (extended) 7-gene PORT-C signature 
predicting DM ............................................................................ 
143 
Supplementary 
Table 9 
Lists used to pre-select the genes from GeneChip® analyses ... 145 
  
XV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The journey of a thousand miles begins with a single step. 
Lao Tzu 
XVI 
  
 Introduction 
1 
1 Introduction 
A patient diagnosed with cancer goes to the doctor and the treatment is completely adapted 
to every peculiarity of the disease, regardless how unique this peculiarity is – this is the 
overall goal of personalized medicine we would like to achieve. Cancer is one of these 
diseases. In Germany, every fourth case of death is related to cancer (Robert Koch-Institut, 
2017). One of the ten most frequently occurring cancer types is head and neck cancer 
(Duray et al., 2012), which may, for example, be caused by the consumption of alcohol and 
tobacco or by the infection with the human papilloma virus (HPV) (Marur et al., 2010). In 
particular, the number of head and neck cancers caused by the HPV infection has increased 
during the last decade (Marur et al., 2010).  
Patients with a locally advanced head and neck squamous cell carcinoma (HNSCC) have 
an overall survival rate of about 50% (Leemans et al., 2011). To this day, those patients are 
routinely treated with either primary or postoperative radiochemotherapy, depending on the 
resectability of the tumour. In randomized clinical trials it was shown that radiotherapy 
combined with chemotherapy improves loco-regional tumour control (LRC) as well as overall 
survival (OS) compared to radiotherapy alone (Bernier, Domenge et al., 2004; Cooper et al., 
2004; Fietkau et al., 2006). Besides the inclusion of chemotherapy there were further 
developments, which improved the treatment of HNSCC, such as the introduction of intensity 
modulated radiotherapy. However, the patients still respond very differently to the treatment 
due to their heterogeneous tumour biology. This heterogeneous tumour biology may act as 
a starting point for more personalized treatment.  
For personalized treatment, the tumours are classified based on special parameters called 
biomarkers. Those biomarkers are measurable parameters that indicate different biologic 
processes. They can be used to check the presence and evaluate the severity of a disease 
(Biomarkers Definitions Working Group., 2001). One of the most important, recently 
discovered biomarkers for locally advanced HNSCC is the infection with the HPV. For those 
HPV-infected HNSCC, an improved radiosensitivity was reported (Gupta et al., 2009; Kimple 
et al., 2013). To evaluate the impact of the infection for patients treated with primary (pRCTx) 
and postoperative radiochemotherapy (PORT-C), retrospective, multicentre studies of the 
German Cancer Consortium Radiation Oncology Group (DKTK-ROG) were conducted 
(Lohaus et al., 2014; Balermpas et al., 2016; Linge, Löck, Gudziol et al., 2016; Linge, Löck, 
Krenn et al., 2016; Linge, Lohaus et al., 2016; Tinhofer et al., 2016; Leger et al., 2017; Linge 
et al., 2018). For both cohorts, patients with HPV16 DNA positive tumours showed an 
improved LRC and OS. Furthermore, these studies were used to identify additional 
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biomarkers which may be used for patient stratification beyond the HPV status, e.g. the 
presence of cancer stem cells or gene expressions related to hypoxia (Balermpas et al., 
2016; Linge, Löck, Gudziol et al., 2016; Linge, Löck, Krenn et al., 2016; Linge, Lohaus et al., 
2016; Tinhofer et al., 2016). 
Tumour hypoxia has been shown to increase the radioresisitance of tumours. (Overgaard, 
2007). It was shown that tumours which were hypoxic before treatment led to lower LRC 
and OS after primary R(C)Tx compared to well oxygenated tumours (Nordsmark et al., 1996; 
Nordsmark et al., 2005). To ease the determination of the tumour-hypoxia status, several 
gene classifiers, which are based on hypoxia measurements with oxygen electrodes or 
hypoxia related changes on the transcriptional level, were developed (Lendahl et al., 2009; 
Buffa et al., 2010; Toustrup et al., 2011; Eustace et al., 2013; Toustrup et al., 2016). 
The described markers do not cover all aspects of the tumour and may be improved by 
including additional radiobiological mechanisms. These mechanisms may be explored by 
methods that allow the gene expression measurement of several thousands of genes 
simultaneously. All these genes may have additional information, which has not been taken 
into account yet. To analyse this tremendous amount of data, computer algorithms are 
obligatory – so called machine learning algorithms. These algorithms can be applied to 
discriminate the genes which influence the outcome from the genes that do not. For this 
task, one patient cohort is used to identify important genes and train a prognostic model, i.e. 
the model identifies the important characteristics of this cohort for a specific outcome, e.g. 
LRC or OS. To evaluate the performance of this model, it is applied to a second patient 
cohort, the validation cohort.  As a result, the machine learning algorithms create models 
that are based on different gene sets (gene signatures). These models can be used to stratify 
patients into distinct risk groups for future treatment adaptation. Furthermore, those 
algorithms are not limited to genetic data. They were already used to analyse e.g. medical 
imaging data, “radiomics”, (Kumar et al., 2012; Lambin et al., 2012; Aerts et al., 2014; Leger 
et al., 2017) or metabolomic data, “metabolomics” (Davis and Milner, 2004; Kind et al., 2007; 
Sreekumar et al., 2009).  
In this thesis, machine learning algorithms are applied to identify new gene signatures for 
HNSCC patients treated with either postoperative or primary radiochemotherapy. Two 
cohorts of the multicentre studies of the DKTK-ROG are used to identify gene signatures 
based on nCounter® and GeneChip® measurements. The identified signatures are 
discussed, compared and combined with markers, which are already used in clinical routine. 
For nCounter® measurements, independent validation cohorts are available that allow a 
validation of the obtained models. The gene expression measurements of the nCounter® 
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and GeneChip® data are compared with each other and with real-time PCR gene 
expressions with respect to transferability between those methods. Furthermore, a method 
for combining different machine learning models is presented. 
This thesis is structured as follows: In the next chapter a brief overview about the biology of 
HNSCC and known biomarkers is given. Afterwards, statistical methods are introduced, 
which are important for the machine learning algorithms. Lastly, the three measurement 
methods used to obtain the gene expression data (nCounter®, GeneChip® and real-time 
PCR analyses) are presented. 
The third chapter focusses on the materials and methods used. At first, the four patient 
cohorts are presented. Then, the general procedure of the data acquisition is presented, 
followed by the explanation of the machine learning framework that is used to identify the 
gene signatures and to create the models. 
The application of the machine learning framework and the resulting signature model 
combinations are the main topic of the fourth chapter. Based on the different measurement 
methods, gene signatures are identified and discussed regarding their biological relevance. 
In the last part of the chapter, the combination of different models is performed and 
discussed.  
In the fifth chapter, the reproducibility of nCounter® measurements and the transferability 
between the different measurement methods is presented and discussed. Different 
biomarkers were used exemplarily to transfer the results using nCounter® analysis to 
GeneChip® measurement results. 
In chapter six, the main results of chapters four and five are be summarised and an outlook 
is given.  
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2 Biological & Statistical Background 
In the following chapter, the biological background of Head and Neck Squamous Cell 
Carcinoma (HNSCC) with focus on its formation and popular biomarkers is presented. 
Afterwards, statistical methods used for describing and comparing (survival) patient data are 
briefly outlined. Popular machine learning algorithms, which are used to identify and process 
important features, are presented in the third section. Lastly, the genomic data acquisition 
methods are described. 
2.1 Head and Neck Squamous Cell Carcinoma 
2.1.1 Tumorigenesis 
HNSCC describe a vast number of tumours which differ in their response to treatment and 
in their risk factors (Genden et al., 2003; Pai and Westra, 2009; Rothenberg and Ellisen, 
2012). The following section will briefly introduce the formation of HNSCC with focus on the 
basic characteristics of HNSCC tumour progression. 
Tumour origin 
HNSCC have been described to arise from the epithelium lining the oral cavity, oropharynx, 
hypopharynx and larynx (Pai and Westra, 2009), see Figure 2.1. The epithelium is bordered 
by the lamina propria and an underlying basement membrane. Besides regulating 
differentiation and migration of epithelial cells, the basement membrane prevents the 
precancerous cells from penetrating the stromal cells below.  
The general tumorigenesis of HNSCC is a complex multistage process, which was described 
in a model of Califano et al. (Califano et al., 1996). Basically, tumorigenesis starts with 
chromosomal mutations in areas that are responsible for cell growth, motility or stromal 
interactions. Those changes induce an increasing number of genetic alterations, which 
follow loosely a sequential order. Furthermore, those molecular changes lead to microscopic 
changes in the epithelium starting from squamous hyperplasia (increased cell proliferation), 
followed by dysplasia (abnormal changes in the tissue) until an invasive carcinoma 
develops, i.e. the tumour cells penetrate the basement membrane (Califano et al., 1996). 
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Figure 2.1. Different subregions of the head and neck. HNSCC arise from the epithelium 
lining the oropharynx, hypopharynx, larynx and oral cavity. 
 
Tumour-treatment 
The treatment of HNSCC is usually based on the tumour size and spread which is usually 
assessed by the TNM staging1. While early stage HNSCC, i.e. small tumours without lymph 
node infiltration, are often curable, locally advanced HNSCC have a poorer outcome, 
represented by a 5-year survival rate of about 50% (Leemans et al., 2011; Misawa et al., 
2016) Hence, only locally advanced HNSCC will be considered in this thesis, which will be 
often referred to just as HNSCC. 
Operable locally advanced HNSCC are surgically removed and the former tumour area is 
irradiated afterwards (postoperative radiotherapy) to destroy any remaining tumour cells 
after surgery (Forastiere et al., 2001). Locally advanced tumours that cannot be treated by 
surgery without losing vital organ functions are usually being treated with primary 
radiotherapy (Forastiere et al., 2001). To improve the treatment results, the primary 
radiotherapy (pRTx) and postoperative radiotherapy (PORT) is usually combined with 
chemotherapy, which is referred to as primary radiochemotherapy (pRCTx) (Adelstein et al., 
1993; Adelstein et al., 2003; Huguenin et al., 2004) or postoperative radiochemotherapy 
(PORT-C) (Bernier, Domenge et al., 2004; Cooper et al., 2004; Fietkau et al., 2006).  
Human papilloma virus (HPV) induced HNSCC  
In general, HNSCC are very heterogeneous in their biology. However, tumours may be 
assigned to one or more groups with shared similarities, for example based on the  
                                               
1 TNM staging is used to classify tumours depending on tumour size (T), the infiltration of regional 
lymph nodes (N) and the presence (or absence) of distant metastases (M) 
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morphology. The tumour cells can show, e.g. basaloid morphology which is associated with 
a poor outcome of the patient (Pai and Westra, 2009). Nowadays, an important classification 
regarding the treatment outcome is into tumours which show the presence of human 
papillomavirus (HPV) family and tumours that do not. Cells which are infected with HPV 
show an increased radiosensitivity, which is crucial for the response to radiotherapy.  
(Gillison et al., 2000; Mirghani et al., 2015). 
 
HPV positive and negative tumours differ in several points. Most HPV negative tumours are 
connected to smoking or alcohol abuses and occur in patients older than 60 years (Leemans 
et al., 2011). They show frequent TP53 (also referred to as p53) mutations, a moderately 
differentiated keratinisation (Marur et al., 2010) and have poor prognosis. In contrast, the 
HPV positive tumours typically occur in patients younger than 60 years and have a 
favourable prognosis (Marur et al., 2010). They arise from tonsillar crypts (Husain and 
Neyaz, 2017), especially of the oropharynx (Pai and Westra, 2009), and present a 
nonkeratinizing histology (Chernock, 2012). Sexual behaviour is considered to be the main 
risk factor for HPV positive tumours (D’Souza et al., 2007). 
Starting from 1974, the correlation between cancer of the cervix and the presence of HPV 
family has been identified (zur Hausen et al., 1974; zur Hausen, 1977; Meisels et al., n.d.; 
Meisels and Fortin, n.d.). In 1983 and 1984 the viruses HPV16 and HPV18 could be isolated 
from tumour cells for the first time (Dürst et al., 1983; Boshart et al., 1984). The viruses of 
the family are circular double stranded DNA viruses, shown systematically in Figure 2.2. The 
virus infects basal layer cells, i.e. cells which can still proliferate from the epidermal or  
 
Figure 2.2. Systematic structure of the DNA of a human papillomavirus based on (zur 
Hausen, 2002). The ring structure of the virus opens at the yellow marked part for DNA 
integration. During the integration process, some parts of the viral DNA may be deleted 
(orange).  
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mucosal epithelial. Infection enhances proliferation and leads to an increased lateral 
expansion (Dürst et al., 1983; Boshart et al., 1984).  
HPV genes E5, E6 and E7 are responsible for the increased cell proliferation. E5 prevents 
apoptosis, the programmed cell death, of the cell after DNA damage and is more important 
in the early stages of infection. When the viral DNA is integrated in the hosts DNA, a part 
including the E5 gene is often deleted. For the late infection stage and the malignant 
transformation, the HPV genes E6 and E7 are more important. The most prominent changes 
which are induced by both genes are shown in Figure 2.3. 
The HPV oncoprotein E6 prevents cell apoptosis by interacting with the tumour suppressor 
protein p53 (Yim and Park, 2005). In general, the accumulation of p53 caused by DNA 
damage keeps the cell in G1 phase and induces the DNA repair or apoptosis (Marur et al., 
2010). However, the presence of E6 leads to a degradation of p53 and BAK, another protein 
which supports apoptosis (Jackson et al., 2000). Furthermore, E6 activates the telomerase 
and the SRC-family kinases, which allow the immortalization of the cell (Oda et al., 1999; 
Veldman et al., 2001).  
 
Figure 2.3. Alterations of the cell cycle induced by the E6 and E7 gene of the human 
papillomavirus that lead to immortality of the cell. Figure based on (zur Hausen, 2002). 
 
Biological & Statistical Background  
Head and Neck Squamous Cell Carcinoma  
8 
The tumour suppressor protein p16 (also known as p16ink4a, cyclin-dependent kinase (CDK) 
inhibitor 2A or multip le tumour suppressor 1) could still inhibit the mechanisms induced by 
E6 by prohibiting the cell from entering the S-Phase. However, the mechanisms induced by 
the HPV oncoprotein E7 lead to a functional inactivation of p16. By activating the genes 
cyclin A and E directly, E7 allows the cell cycle to proceed. E7 interacts with the tumour 
suppressor protein retinoblastoma protein (RB or pRb, RB1), a protein which can bind the 
transcriptome factors E2 (E2F). As a consequence of the interaction, RB is degraded, E2F 
is released and the amount of p16 is increased (Chellappan et al., 1992; Cheng et al., 1995). 
Furthermore, E7 seems to deactivate the abilities of the cyclin-dependant kinase inhibitors 
p21 (also WAF1 or CIP1) and p27 (KIP1), which are involved in apoptosis or can slow down 
the cell cycle, respectively. 
Summarizing, both oncoproteins E6 and E7 induced by HPV violate essential security 
mechanisms of the cell that could lead to apoptosis or prevent the cell from proceeding in 
the cell cycle. Furthermore, the interaction of both oncoproteins enables the immortalization 
of the cell. 
To assess HPV status different measurement methods are available (Linge et al., 2018). All 
measurement methods are highly correlated, but the assessment of HPV16 RNA or p16 
immunohistochemistry together with HPV16 DNA are generally recommended. 
2.1.2 Biomarkers 
Tumours have a very heterogeneous treatment response due to underlying biological 
differences. Biomarkers are measurable parameters that indicate different biologic 
processes. Hence, biomarkers can be used to assess the presence and to evaluate the 
severity of a disease (Biomarkers Definitions Working Group., 2001). In principle, the right 
set of biomarkers can be employed to adapt the treatment to the individual biological 
characteristics of a tumour. In this thesis the biomarkers of interest are established clinical 
parameters, used and assessed in clinical routine, and molecular biomarkers derived from 
gene expression measurements. In this section a few known biomarkers and their effect on 
treatment outcome for HNSCC will be presented. 
Tumour location 
As described in Section 2.1.1, HNSCC are found in different locations. Especially 
carcinomas arising from the oropharynx or oral cavity are of interest since those origins are 
reported to be correlated with the treatment outcome. Tumours arising from the oral cavity 
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were reported to be more radio-resistant than other HNSCC (Peters et al., 1993; Lohaus et 
al., 2014). 
Oropharyngeal carcinomas are more likely to be HPV positive. This is due to the adjacent 
lymphoid tissue (Waldheyer’s ring) and the resulting netlike composition of the epithelium, 
which is optimized for the transport of intruding antigens to the lymphoid tissue (Abbey and 
Kawabata, 1988). In contrast to cervical cancer, the netlike structure of the epithelium offers 
an insufficient protection and allows the HPV to enter the tissue directly (Perry, 1994; Pai 
and Westra, 2009). The HPV can easily proceed to the internal environment of the tonsillar 
base, one of the main origins for HPV positive HNSCC (Gillison et al., 2000; Klussmann et 
al., 2003; Begum et al., 2005; El-Mofty and Patil, 2006). Several studies showed a 
favourable prognosis of HPV positive oropharyngeal tumours compared to the HPV negative 
ones.  
Extracapsular extension (ECE)  
Extracapsular extension (also extracapsular spread) is considered one of the most important 
factors regarding the prognosis for several cancer types, e.g. prostate (Baco et al., 2015) or 
HNSCC (Bernier et al., 2005). When single tumour cells leave the solid primary tumour, they 
accumulate in the adjacent lymph nodes. If tumour cells penetrate the capsule of the lymph 
node, the probability of achieving loco-regional tumour control (LRC) is reduced and the risk 
of an early disease related death is significantly increased (Mermod et al., 2016). Even 
though it is possible to obtain the ECE-status from medical imaging, those methods are not 
reliable (Steinkamp et al., 2002). Therefore, ECE-status is evaluated by experienced 
pathologists, who assess the resected lymph nodes regarding tumour cell infiltration and 
microscopic spread (Ferlito et al., 2002). Thus, the parameter can be determined for patients 
who received nodal resection. In general, patients with a positive ECE-status have a higher 
risk for loco-regional failures than patients with a negative ECE-status. 
Tumour volume 
Several clinical studies underlined the prognostic power of the tumour volume, also in 
addition to clinical staging, and revealed a correlation between tumour volume and cancer 
stem cells (CSC) (Dubben et al., 1998; Bradley et al., 2002; Mendenhall et al., 2014). The 
risk for a relapse or a disease related death is correlated with the tumour volume (Dubben 
et al., 1998; Krause et al., 2017). The resectability is linked to the tumour volume, in general 
bigger tumours are more difficult to remove than small tumours. Furthermore, bigger 
tumours with a high CSC density are often more aggressive and have a higher risk to 
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develop areas with insufficient vascularisation resulting in hypoxia or necrosis. These 
regions are known to have a higher radio-resistance compared to the surrounding tumour 
tissue. Taking everything into account it is to state that a big tumour with a high CSC density 
increases the risk for a failed treatment (Baumann et al., 2008). 
Cancer stem cells (CSC) 
Stem cells have two important abilities, they can remain in an undifferentiated state after 
several cell division cycles (self-renewal) and they can differentiate into different cell types 
(potency). Baumann et al. described a cancer stem cell as “a cell within a tumour that 
possesses the capacity to self- renew and to generate the heterogeneous lineages of cancer 
cells that comprise the tumour” (Baumann et al., 2008). According to the CSC model, CSC 
can perform symmetrical and asymmetrical cell division (like normal stem cells) leading to 
two daughter CSC or one daughter CSC and a progenitor cell, respectively (Clarke et al., 
2006). In contrast to the progenitor cell, each resulting daughter CSC has the same abilities 
as its forgoing cell and can cause tumour growth and spread. Thus, just a single surviving 
CSC can lead to treatment failure after the therapy (Baumann et al., 2008; Coppes and 
Dubrovska, 2017; Peitzsch et al., 2017). Preclinical studies indicate that the presence of 
CSC influence the response to radiotherapy, e.g. CSC seem to support the recovery of the 
tumour between different treatment fractions, which effectively leads to an increased 
radioresistance (Thames et al., 1982; Petersen et al., 2001; Petersen et al., 2005). In the 
last years, several genes were identified as putative biomarkers for CSC. In the following, 3 
putative candidates for CSC markers that are used in this thesis will be presented briefly: 
CD44, MET and SLC3A2 (Rygaard et al., 1993; Feral et al., 2005; de Jong, Pramana, van 
der Wal et al., 2010; Sun and Wang, 2011; Bütof et al., 2013; Martens-de Kemp et al., 2013; 
Lim et al., 2014; Krause et al., 2017). 
CD44 is considered as CSC marker in different tumour types, such as HNSCC (Prince et 
al., 2007; Baumann and Krause, 2010; de Jong, Pramana, van der Wal et al., 2010; Faber 
et al., 2011; Brunner et al., 2012; Bütof et al., 2013) gastric tumours (Takaishi et al., 2009) 
and pancreatic tumours (Li et al., 2007). CD44 is included in several pathways important for 
the organism like lymphocyte activation, cytokinesis, haematopoiesis or cell junctions. 
The protein CD98 is a protein heterodimer, i.e. it is a macromolecular complex consisting of 
a transmembrane heavy chain (encoded by SLC3A2) and a light chain (encoded bySLC7A5) 
(Verrey et al., 2004; Feral et al., 2005). CD98 is associated with increased cell proliferation 
and decreased apoptosis and its overexpression has been identified in several cancer types 
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(Cantor and Ginsberg, 2012). In a study of Martens-de Kemp et al., in which they implanted 
tumours with high and low CD98 expression in mice, CD98 was identified as potential CSC 
marker (Martens-de Kemp et al., 2013). The tumours with a high expression of CD98 
showed an increased tumour growth indicating the presence of CSC abilities. In a further 
study of the same group, Rietbergen et al. compared patients with oropharyngeal cancer 
with high and low expressions of CD98 (Rietbergen et al., 2014). They found an increased 
progression-free and overall survival in the patients with low CD98 expression in the tumour. 
To examine the tumour forming capacity associated with MET, the group of Lim et al. 
transplanted tumours into mice. Tumours with a knocked down MET did not show a tumour 
growth in the mice and the levels of other known CSC markers (CD44 and ALDH1) were 
decreased as well (Lim et al., 2014). In a different study, Sun et al. showed that a decrease 
of MET led to a decrease of other CSC (Sun et al., 2014). MET is reported to be associated 
with apoptosis, proliferation and an increased chemotherapy resistance (Salgia, 2017).  
Tumour hypoxia 
Tumours with an insufficient oxygenation status, hypoxic tumours, are more radio-resistant 
than normoxic tumours (Nordsmark et al., 2005; Overgaard, 2007; Overgaard, 2011). 
Several studies have shown that hypoxic HNSCC have a poorer outcome than normoxic 
HNSCC when treated with R(C)Tx (Vaupel and Mayer, 2007; Linge, Lohaus et al., 2016; 
Linge, Löck, Gudziol et al., 2016). Treatment may be adapted for hypoxic tumours, for 
example through increasing tumour oxygenation, radio-sensitising agents or by increasing 
the radiation dose (Overgaard et al., 1998; Overgaard et al., 2003; Overgaard et al., 2005). 
However, these methods may increase the risk of side effects (Metwally et al., 2014). 
Therefore, it is necessary to identify the hypoxic tumours.  
When the oxygen supply is low, cells change their metabolism to “low oxygen” state. In this 
mode, cells use the glycolysis as main source of ATP production instead of the oxidative 
phosphorylation. They change their gene expression to enter this mode. Furthermore, they 
signalize the lack of oxygen to their environment, which causes an increased vascularisation 
to restore the oxygen supply (Semenza, 2003; Simon et al., 2008; Smith et al., 2008; 
Weidemann and Johnson, 2008; Lendahl et al., 2009). Lack of oxygen in a tumour can be 
measured directly via oxygen electrodes  (Nordsmark et al., 1994; Nordsmark and 
Overgaard, 2004), indirectly by utilizing the changed metabolic processes visualized by 
hypoxia staining (pimonidazole (Raleigh et al., 1999)) or with positron emission tomography 
(Gross et al., 1995; Evans et al., 2000; Kaanders et al., 2002; Isa et al., 2006; Rischin et al., 
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2006; Mortensen et al., 2010) (fluoromisonidazole (FMISO) (Baumann et al., 2016) or 18F-
flouroazomycin arabinoside (FAZA) (Tran et al., 2015)) or by evaluating biologic markers, 
which are characteristic for an hypoxic environment (Overgaard et al., 2005; Moon et al., 
2007; Le and Courter, 2008).  
Most of these methods are too expensive or too circumstantial to find their way into clinical 
routine. Therefore, genomic signatures based on hypoxia measurements were developed. 
The three hypoxia-associated gene signatures for patients with HNSCC studied here, 
consist of 15, 26 and 30 genes, shown in Supplementary Table 1. 
15-gene hypoxia signature 
Toustrup et al. developed and subsequently validated a hypoxia-associated signature for 
HNSCC (Sørensen et al., 2010; Toustrup et al., 2011; Toustrup et al., 2016). This final 
signature contains 15 genes and is therefore referred to as 15-gene hypoxia signature.  
To identify the gene signature, different human cell lines were exposed to different pH and 
oxygen concentrations. 29 genes were selected based on their gene expression that was 
higher under hypoxic conditions but that was not influenced by the pH concentration 
(Sørensen et al., 2010; Toustrup et al., 2011). Afterwards a xenograft study was performed 
to validate the findings of the cell line experiments. Quantitative PCR measurements showed 
that the 29 genes were upregulated in hypoxic tumour regions (Toustrup et al., 2011). In the 
next step, biopsies of HNSCC were classified as hypoxic and normoxic based on electrode 
measurements (Raleigh et al., 1999; Nordsmark and Overgaard, 2004). The expression of 
the 29 genes was measured in the biopsies. The electrode and gene expression 
measurements were combined to find an optimal subset of genes to classify the patients 
(Sørensen et al., 2010; Toustrup et al., 2011).  
The obtained 15-gene hypoxia signature was used to stratify the patients of the DAHANCA 
5 trial into hypoxic and normoxic subgroups. Each subgroup was either treated with a 
placebo or Nimorazole. Whereas the hypoxic group benefitted from Nimorazole, there was 
no difference in the less hypoxic group indicating that the signature is prognostic and 
predictive (Toustrup et al., 2011). In a further validation, the stratification performed on the 
DAHANCA5 trial was successfully applied to patients from the DAHANCA18 and 24 trials 
as well as the IEAE HypoX study (Overgaard, 2007; Sørensen et al., 2010; Toustrup et al., 
2016). The genes of the 15-gene classificatory are presented in the second column of 
Supplementary Table 1. 
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26-gene hypoxia signature 
To identify genomic hypoxia networks, Buffa et al. used a seed-based approach to perform 
a statistical analyses on previously published cohorts of patients with breast cancer or 
HNSCC (Winter et al., 2007; Buffa et al., 2010). Tumour material of each cohort was 
extracted before chemo-, radio- or an adjuvant radiotherapy. Gene data was obtained using 
the Affymetrix U133A, B or plus2 platform. Starting with previously identified hypoxia genes, 
a reduced subset of 51 genes was selected. Furthermore, 42 genes could be validated using 
independent cohorts of patients with lung cancer, breast cancer or HNSCC. 
Based on this 51-gene set, Eustace et al. developed a 26-gene hypoxia signature, which is 
described in detail in (West et al., 2009; Eustace et al., 2013). They applied the signature to 
patients with laryngeal and bladder cancer. Patients who were predicted to have hypoxic 
tumours may benefit from a hypoxia modifying treatment, which would indicate the predictive 
value of the signature. Four genes are included in both, the 15-gene and 26-gene signature, 
see Supplementary Table 1. 
30-gene hypoxia signature  
Based on the database of the NCBI Gene Expression Omnibus (GEO), Lendhal et al. 
selected a set of 30 genes that was supposed to identify more and less hypoxic tumours 
(Lendahl et al., 2009). The NCBI GEO database contained over 150 data sets which show 
the transcriptional change directly or its consequences due to hypoxia. The 30 selected 
genes, presented in the last columns of Supplementary Table 1, were further analysed in 
vitro using 5 different cell-lines. Eighteen of 30 genes did only change their expression from 
normoxic to hypoxic conditions in some cell lines indicating a cell specific hypoxia relation. 
The other 12 genes changed their expression in each cell type indicating more universal 
hypoxia genes (Lendahl et al., 2009). 
In this thesis, the 3 presented hypoxia-associated gene signatures were used to stratify the 
HNSCC patients into groups of less and more hypoxic based on different gene expression 
measurements (nCounter® and GeneChip® analyses). Unfortunately, the gene DHX34 was 
not available in the nCounter® measurements. Consequently, all classifications based on 
the 30-gene signature were performed without DHX34, i.e. only the other 29 genes were 
used. 
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2.2 Statistics 
This section provides a brief introduction to the analysis of survival data. Subsequently, 
general statistical methods needed to interpret and evaluate results will be presented. 
2.2.1 Survival analysis 
The first part of the section focusses on survival analyses and general statistics. To describe 
the survival data, the survival function will be introduced along with a method to illustrate 
and to compare different survival functions.  
The survival function 
The main interest of survival analyses is to answer the question, how long does it take until 
a given event occurs in a certain portion of a population. Roughly, the time until this event 
occurs is called survival time (Lee and Wang, 2003). Typical events of interest are the 
appearance of side effects, a relapse or the death of a patient. From the statistical point of 
view, the time dependent event risk is described by four related functions: the survival 
function 𝑆(𝑡), the probability density function 𝑓(𝑡), the cumulative distribution function 𝐹(𝑡) 
and the hazard function ℎ(𝑡) (Lee and Wang, 2003).  
The survival function 𝑆(𝑡) describes the probability that an event occurs after the time 𝑡 
𝑆(𝑡) = 𝑃(event occurs after 𝑡) =  𝑃(𝑇 > 𝑡), 0 < 𝑡 <  ∞, (1) 
where 𝑇 represents the survival time, i.e. time when the event of interest occurs. 
Furthermore, the survival function can be expressed by the complementary event: “the event 
of interest occurs before or at time 𝑇”, 
𝑆(𝑡) = 1 − 𝑃(event occurs before or at time 𝑡) =  1 − 𝑃(𝑇 ≤ 𝑡) = 1 − 𝐹(𝑡),
0 < 𝑡 <  ∞. 
(2) 
The survival time 𝑇 is a continuous random variable and is defined by the probability density 
function 𝑓(𝑡),  
𝑓(𝑡) = lim
Δ𝑡→0
 
𝑃(𝑇 > 𝑡, 𝑇 ≤ 𝑡 + ∆𝑡)
Δ𝑡
, 0 < 𝑡 <  ∞. (3) 
Where 𝑃(𝑇 > 𝑡, 𝑇 ≤ 𝑡 + ∆𝑡) is the probability that the event occurs between 𝑡 and 𝑡 + ∆𝑡.  
Based on the probability density function 𝑓(𝑡), which is also called the unconditional failure 
rate, the conditional failure rate or hazard function ℎ(𝑡) can be defined as  
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ℎ(𝑡) = lim
Δ𝑡→0
 
𝑃 (𝑇 > 𝑡, 𝑇 ≤ 𝑡 + ∆𝑡 |𝑇 ≥ 𝑡) 
Δ𝑡
 (4) 
or  
ℎ(𝑡) =
𝑓(𝑡)
1 − 𝐹(𝑡)
=
𝑓(𝑡)
𝑆(𝑡)
, 0 < 𝑡 <  ∞. (5) 
 
Censoring of patients 
In cancer therapy, one possible endpoint may be overall survival 5 years after the treatment. 
However, not all patients may be able to complete the follow-up until this time point. While 
some patients may die in this time interval, others may drop out, either through competing 
events or for other reasons. Such patients are censored (David Collett, 2003). Among other 
things, this drop-out can be caused by other risk factors, which are called competing risks. 
However, the censored data still contains information about the “not-occurring” of an event. 
Therefore, a patient may have one of the following outcomes: 
a The event of interest occurred during the follow-up. 
b The event of interest did not occur during the follow-up period. 
c Patients were censored before the end of the follow-up period. 
The patients of the groups b and c are treated equally as censored patients, either after the 
follow-up period (b) or according to their censoring time (c). 
Kaplan-Meier method 
The Kaplan-Meier method is commonly used to illustrate survival data, see Figure 2.4. The 
method estimates the survival function 𝑆(𝑡) stepwise between the different survival times 
𝑇𝑖 (𝑖 = 1…𝑛) of the 𝑛 patients (David Collett, 2003). If none of the patients was censored, 
𝑆(𝑡) can be simply written as 
𝑆(𝑡) =
𝑛 − 𝑜𝑡≤𝑇
𝑛
, 0 < 𝑡 <  ∞ (6) 
where 𝑜𝑡≤𝑇 is the number of events that occurred before 𝑡. Calculating 𝑆(𝑡) for each 𝑇𝑖 results 
in a step function (Lee and Wang, 2003).  
The calculation must be expanded to take censored patients into account. The patients are 
ordered according to their survival time or censoring time. According to the order, a rank 𝑟 
is assigned to each patient. Now, a partial survival function ?̂?(𝑇𝑖) is calculated for each event 
with the survival time 𝑇𝑖 <  𝑡 using their ranks 𝑟𝑖 (without ties) (Lee and Wang, 2003) 
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?̂?(𝑇𝑖) =
𝑛 − 𝑟𝑖
𝑛 − 𝑟𝑖 + 1
, 0 < 𝑡 <  ∞. (7) 
To obtain the survival function 𝑆(𝑡) all ?̂?(𝑇𝑖), 𝑡 ≤ 𝑇𝑖 are multiplied 
𝑆(𝑡) = ∏ ?̂?(𝑇𝑖)
𝑇𝑖≤𝑡 
= ∏
𝑛 − 𝑟𝑖
𝑛 − 𝑟𝑖 + 1
𝑇𝑖≤𝑡 
, 0 < 𝑡 <  ∞. (8) 
Censoring is usually marked as “+” in the diagram, see Figure 2.4.  
If there are no censored patients, the equations (6) and (8) are identical, i.e. it can be 
considered as special case of equation (8) (Lee and Wang, 2003). 
Log-rank test 
Different methods and tests to compare survival functions are available, such as the 
generalized Wilcoxon test from Gehan (Gehan, 1965b; Gehan, 1965a), or Peto and Peto 
(Peto and Peto, 1972; Lee and Wang, 2003) or the Cox-Mantel test. The latter is often 
referred to as log-rank test. All three methods can handle censored data. The Cox-Mantel 
test is the most common test and consists of 3 steps (Lee and Wang, 2003). In the first step, 
the distinct survival times 𝑇𝑖 of both groups 1 and 2 are sorted together in ascending order. 
Afterwards, at each time  𝑇𝑖 the number of total events 𝑚𝑖  
 
Figure 2.4. Kaplan-Meier estimator of two groups (low and high risk group). The survival 
functions over follow-up period of 5 years (60 months) are shown. Events are represented 
by a step in the function and censorships are marked with a “+”. After one year the 
remaining patients at risk are presented in the table below. The survival functions are 
compared using the log-rank test and he result is shown in the bottom left corner with p 
= 0.002. 
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𝑚𝑖 = #(events group 1, with 𝑇 = 𝑇𝑖) + #(events group 2, with 𝑇 = 𝑇𝑖) (9) 
and the number of patients of both groups 𝑛1,𝑖 and 𝑛2,𝑖 surviving longer than 𝑡𝑖 is counted. 
Based on the total number of remaining patients at risk 𝑞𝑖 = 𝑛1,𝑖 + 𝑛2,𝑖, the amount of 
patients in group two 𝐴𝑖 = 𝑛2,𝑖 𝑟2,𝑖⁄  is calculated. In the last step, the testing variable 𝐶 is 
calculated as the quotient of 𝑈 and √𝐼, which are defined as 
𝑈 = 𝑛2,𝑇1 − ∑ 𝑚𝑖𝐴𝑖
𝑇𝑖∈{𝑇1…𝑇𝑘}
 (10) 
With the variance 
𝐼 =  ∑
𝑚𝑖(𝑞𝑖 − 𝑚𝑖) 𝐴𝑖(1 − 𝐴𝑖)
𝑞𝑖 − 1
𝑇𝑖∈{𝑇1…𝑇𝑘}
 (11) 
Finally, 𝐶 = 𝑈 √𝐼⁄  is compared to the null hypothesis 𝐶 = 0 using the standard normal 
distribution. 
Bland-Altman Analysis 
To compare and illustrate the difference of two measurements 𝑒1 and 𝑒2 of the same patient, 
a Bland-Altman-analysis can be performed (Bland and Altman, 1986; Bland and Altman, 
1999). Therefore, the difference  
Δ𝑒 =  𝑒1 − 𝑒2 (12) 
of both measurements is shown depending on the mean measurement result 
?̅? =
𝑒1 + 𝑒2
2
. (13) 
For each patient and each paired measurement, the data point (?̅?, Δ𝑒) is shown in a 
Cartesian coordinate system together with the 95%-confidence interval of all Δ𝑒, shown in 
Figure 2.5. 
The Bland-Altman analysis can give a better overview of the discrepancies between different 
measurements compared to sole “correlation” analysis. Those analyses lack in identifying 
statistical shifts and the results may be misleading (Bland and Altman, 1986; Bland and 
Altman, 1999). 
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Figure 2.5. Bland-Altman-Analysis. A measurement was performed twice (using different 
method) for each patient. The difference between the measurement results is shown 
depending on the mean result of both measurements. The mean difference (dashed line) 
and the corresponding 95% confidence intervals (dotted lines) are marked (Bland and 
Altman, 1986; Bland and Altman, 1999). 
 
2.2.2 Model and data evaluation 
Mann-Whitney-U test  
The Mann-Whitney-U test (MWU-test) is a non-parametrical statistical test, which is used to 
evaluate whether two different samples 𝑆1, 𝑆2 with 𝑛1, 𝑛2 elements belong to the same 
population (Wilcoxon, 1945; Mann and Whitney, 1947; Gravetter and Wallnau, 2012). 
Therefore, the values of both samples are combined, sorted and ranks 𝑟 are assigned 
starting from the lowest value with 𝑟 = 1. The sum of the ranks 𝑅𝑖 = ∑ 𝑟𝑠𝑠∈𝑆𝑖 , 𝑖 = 1, 2 and the 
mean rank ?̅? is calculated for both samples. The test evaluates if the null hypothesis, the 
ranks are distributed similarly, should be rejected. The corresponding test variable 𝑈𝑖, 
𝑈𝑖 = 𝑛1𝑛2 +
𝑛𝑖(𝑛𝑖 + 1)
2
− 𝑅𝑖     (𝑖 = 1, 2), (14) 
is calculated for both samples using the sample sizes 𝑛1 and 𝑛2 and the sum of the ranks 
𝑅1, 𝑅2 of the samples 𝑆1 and 𝑆2, respectively. The smaller 𝑈𝑖-value is defined as 𝑈, 
𝑈 = min(𝑈1, 𝑈2). (15) 
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If both samples include less than 10 cases, 𝑈 is compared with the critical value of the U-
statistic to check for significance. For 𝑛1,2 > 10 the significance of 𝑈 can be evaluated using 
the critical value of the standard normal distribution after z-standardisation,  
𝑧𝑈 =
𝑈 − ?̅?
𝜎𝑈
=
𝑈 −
𝑛1𝑛2
2
√ 1
12(𝑛1𝑛2(𝑛1 + 𝑛2 + 1))
. 
(16) 
Statistical significance 
Most statistical tests check whether to accept or reject a null hypothesis, e.g. if two samples 
belong to the same distribution. Incorrect decisions are classified as type I or type II error, 
see also Table 2.1 (Glantz, 2012; Bronstejn et al., 2016). Accepting a wrong null hypothesis 
is considered as type II error, i.e. a false negative result. The rejection of a true null 
hypothesis is called type I error, a so called false positive result. The significance level 𝛼 is 
used to describe the type I error rate and is usually set to 𝛼 = 0.05. 
When a statistical test is performed, a p-value can be obtained using the underlying 
probability distribution. An example is shown in Figure 2.6. There, the marked area between 
−∞ and 𝑡, represents the p-value. The p-value and the significance level are compared. If p 
≤ 𝛼, the null hypothesis is rejected (Altman, 1991; Trampisch and Windeler, 2000; Rosner, 
2011).  In this thesis, p-values below 0.05 will be considered as significant and p ∈ 
[0.05,0.10) will be considered as “trend to significance”. 
 
Figure 2.6. Probability density function (PDF) of the standard normal distribution. The test 
variable xc of a one sided test is marked, along with the corresponding p-value (blue area 
under the PDF). 
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Evaluating classification methods 
Statistical models can be used to classify patients in two distinct groups. The model will be 
evaluated based on its performance, the ability to classify the patients correctly. Depending 
on the data, different models can be applied for stratification based on the either binary or 
continuous model prediction. 
Models that classify the patients directly into two distinct groups are also called binary 
classifiers. For a rough evaluation of binary classifiers, the real and predicted outcomes are 
compared, see Table 2.1. The values which were predicted correctly as positive or negative 
are called true positive (𝑇𝑃) or true negative (𝑇𝑁), respectively. A real positive predicted as 
negative is called false (𝐹𝑁) negative, and vice versa. For a more detailed evaluation of 
binary classifiers, the sensitivity and specificity are calculated. The sensitivity, also known 
as true positive rate, describes the conditional probability of a predicted positive result, 
conditioned by being “real positive”. The specificity is the conditional probability of a negative 
prediction conditioned by being “real negative”. The corresponding formulas are shown in 
the last row of Table 2.1. 
Table 2.1. Contingency table of possible outcome for binary classifiers. The Reality-
columns show the real characteristics, whereas the Prediction-rows show the predicted 
characteristics of the model. In the inner part of the table, the possible combinations of 
real and predicted outcome are shown. Based on the values of the table, the sensitivity 
and specificity can be calculated, shown in the last row. 
  Reality 
  Real positive (𝑅𝑃) Real negative (𝑅𝑁) 
Prediction 
Predicted positive (𝑃𝑃) True positive (𝑇𝑃) 
False positive  
(𝐹𝑃, type I error) 
Predicted negative (𝑃𝑁) 
False negative 
(𝐹𝑁, type II error) 
True negative (𝑇𝑁) 
  Sensitivity: Specificity 
  
𝑇𝑃
𝑇𝑃 + 𝐹𝑁
=
𝑇𝑃
𝑅𝑃
 
𝑇𝑁
𝑇𝑁 + 𝐹𝑃
=
𝑇𝑁
𝑅𝑁
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Figure 2.7. Receiver operator curves (ROC) for 3 different classifications. The sensitivity 
is plotted against 1-specificity for each classification. The area under the curve (AUC) is 
used for evaluation of the model. The dashed line represents an AUC of 0.5. The green 
and blue ROC (a & b) show a good model performance. The orange ROC (c) represents 
an anti-predictive model. 
 
One of the more detailed evaluation methods for continuous classifiers and binary outcome 
is the AUC, the area under the receiver operator curve (ROC) (Bamber, 1975). The ROC 
depicts the sensitivity against 1-specificity, see Figure 2.7. A non-prognostic classifier will 
give a curve around the diagonal, resulting in an AUC of approximately 0.5. A perfect model 
yields a ROC going straight to the top left corner and has an AUC of 1.0 (Nam and 
D’Agostino, 2002). The AUC can only deal with classifications without censorship. 
For models based on survival data, e.g. the later presented Cox regression model, 
discrimination is evaluated using different methods, such as the concordance index (c-index 
or 𝑐𝑖) which is commonly used.  (Harrell et al., 1996) 
The model assigns a value 𝑋𝑖, called score, to each patient. Furthermore, each patient has 
a survival time 𝑇𝑖, describing when the event of interest or censoring occurs. To calculate 
the 𝑐𝑖, all pairs of patients 𝑖, 𝑗 are compared. The pair is called either concordant, if 𝑋𝑖 < 𝑋𝑗 ⇒
𝑇𝑖 < 𝑇𝑗, discordant, if 𝑋𝑖 > 𝑋𝑗 ⇒ 𝑇𝑖 < 𝑇𝑗, or tied, if 𝑋𝑖 = 𝑋𝑗 (Pencina and D’Agostino, 2004). 
The concordant 𝑛𝑐, discordant 𝑛𝑑 and tied pairs 𝑛𝑝 are counted and the 𝑐𝑖 is calculated using 
𝑐𝑖 = 1 −
𝑛𝑐 +
1
2𝑛𝑝
𝑛𝑐 + 𝑛𝑑 + 𝑛𝑝
. (17) 
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Only pairs including at least one event are considered. While a perfectly predicting model 
leads to a 𝑐𝑖 = 1.0, poorly performing models yield a 𝑐𝑖 around 0.5.  
Models yielding a continuous score can be transferred to a binary classification using a cut-
off. The values below the cut-off are classified as one group, whereas the remaining patients 
belong to the other group. However, the subsequent binary classification is often associated 
with information loss and is, therefore, not favourable (Rastegari et al., 2016). 
2.2.3 Data sampling methods 
The key to a good model is the underlying data, which was used to create the model: the 
better the data, the better the model. The necessary quality of the data, i.e. the amount of 
available information, depends on the given task. To create a complex model with 10 or 
more parameters, more data is needed compared to the creation of a basic model just 
including on 2 or 3 parameters. 
The process of model creation is called model training. During this process the parameters 
of the model are fitted and the model adapts to the given data (training data). Subsequently, 
unknown data (validation data) are used to assess the generalisability of the model. This 
step is referred to as model validation. If the model’s generalisability is low, the model is too 
adapted to the training data (overfitted). Especially models with numerous degrees of 
freedom compared to the amount of training data are at risk of overfitting. 
 
Figure 2.8. Model prediction error on the training (blue) and validation data set (green) for 
models with increasing model complexity, e.g. by allowing more features. 
 
The most reliable validation strategy is the external validation that uses completely 
independent data. If external validation data sets are not available, an internal validation 
data may provide a general understanding of model generalisability, too. Those techniques 
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may also be used during the model training to determine model parameters or relevant 
biomarkers (Collins et al., 2015; Moons et al., 2015; Zwanenburg and Löck, 2018). 
Bootstrapping 
Data may undergo random subsampling to generate ‘new’ additional data sets in a 
procedure called bootstrapping. Therefore, 𝑛 samples are drawn randomly with repetition 
out of the 𝑛 available data points. On average, about 63.2% of the samples are drawn at 
least once. The remaining 36.8% samples remain out of the bag (of drawn samples) and will 
be referred to as out of the bag data (oob-data). The bootstrap of 𝑛 samples can, for 
example, be used for model training and the remaining for model validation (James et al., 
2013). This process may be repeated to reduce variability. 
𝒌-fold cross-Validation 
Cross validation (CV) is similar to bootstrapping. CV divides a set of 𝑛 samples ‘randomly’ 
into 𝑘 distinct sets (𝑘-fold CV) of equal size. Though, the ‘randomly’ generated subsamples 
are not completely random since the generation can be conditioned to inherit special 
characteristics of the original sample (stratified CV). Of the 𝑘 distinct sets, 𝑘 − 1 sets are 
used for training of the model and the remained set is used for validation. This procedure is 
repeated 𝑘 times until each set was used for validation once. In general, it is not 
recommended to choose 𝑘 > 10 because the results are comparable with 𝑘 = 𝑛 − 1 (leave-
one-out CV), which is, in contrast, much easier to handle for the algorithm (James et al., 
2013). 
2.3 Machine learning algorithms 
The following section provides an overview of the machine learning algorithms used in this 
thesis. To create a machine learning model, two steps are usually applied. In the first step, 
feature selection algorithms are applied to select important features. Subsequently, the 
important features are used to train a prognostic model.  
In general, machine learning algorithms can be divided roughly into supervised and 
unsupervised algorithms or learners. Unsupervised algorithms, such as principal component 
analysis (PCA) or 𝑘-means clustering, do not need information about the outcome or result. 
Those algorithms are often used to identify similar patterns, e.g. similar gene expressions. 
In contrast, the result or outcome is explicitly considered by supervised algorithms. The 
prognostic models used in this thesis belong to the group of supervised algorithms. 
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2.3.1 Feature selection algorithms 
To improve the performance of the prognostic model’s training, features with no or redundant 
information should be removed. Feature selection algorithms are used for separating 
important features from the less important ones. In the following subsection different feature 
selection algorithms are presented. Basic feature selection algorithms that include only 
information about context of single features and outcome are referred to as univariable 
feature selection algorithms. In contrast, more complex algorithms are called multivariate 
feature selection algorithms that include metrics about the interaction of different features. 
Pearson correlation 
The correlation or linear dependency between two features 𝑋 and 𝑌 can be described by the 
Pearson product-moment correlation coefficient or Pearson correlation coefficient 𝑟. The 
Pearson correlation coefficient ranges from -1 up to 1 and is defined as 
𝑟𝑗 = 
∑ (𝑋𝑖𝑗 − ?̅?𝑗)(𝑌𝑖 − ?̅?)
𝑛
𝑖=1
√∑ (𝑋𝑖𝑗 − ?̅?𝑗)
2𝑛
𝑖=1 ∑ (𝑌𝑖 − ?̅?)
2𝑛
𝑖=1
, 
(18) 
with the importance 𝑠𝑗 =  1 − |𝑟𝑗| (Rodgers and Nicewander, 1988). 
Here, 𝑋𝑖𝑗 represents feature 𝑋𝑗 of sample 𝑖 (𝑖 = 1…𝑛, 𝑗 = 1…𝑝) from a total amount of 𝑛 
patients with 𝑝 features and the corresponding outcome 𝑌𝑖. For survival data, the outcome 
consists of a time period (𝑌𝑖 = 𝑇𝑖) and an event variable (𝛿𝑖).  The time period is the difference 
between the first day of radiotherapy and the date at which a patient was censored (𝛿𝑖 = 0) 
or an event occurred (𝛿𝑖 = 1). Only times at which an event occurred (𝛿𝑖 = 1) are considered 
in the evaluation of 𝑟𝑗. Censored times are not used for calculation.  
The feature ranking is the result of ordering the 𝑠𝑗 values ascendingly. The feature with the 
smallest 𝑠𝑗, i.e. the feature with the highest correlation is the most important. The Pearson 
correlation only shows the correlation between one feature and the outcome. Correlation 
between the features is not assessed by this feature selection method. 
Spearman rank correlation 
The Spearman rank correlation coefficient 𝜌𝑗 is defined as the Pearson correlation 
coefficient of the rank 𝑅𝑖𝑗 assigned to the feature value 𝑋𝑖𝑗 and the outcome  𝑌𝑖. Each feature 
𝑋𝑗 is sorted and ranked based on its value across all patients. Afterwards, the value of 𝑋𝑖𝑗 is 
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replaced by its rank 𝑅𝑖𝑗 ∈ (1…𝑛). The Spearman rank correlation coefficient can be 
calculated using the created ranks 𝑅𝑖𝑗 and the corresponding outcome 𝑌𝑖: 
𝜌𝑗 = 
∑ (𝑅𝑖𝑗 − ?̅?𝑗)(𝑌𝑖 − ?̅?)
𝑛
𝑖=1
√∑ (𝑅𝑖𝑗 − ?̅?𝑗)
2𝑛
𝑖=1 ∑ (𝑌𝑖 − ?̅?)
2𝑛
𝑖=1
. 
(19) 
The correlation of the ranks can lead to an identification of more general monotonic 
behaviours while the Pearson coefficient works best for linear dependencies (Spearman, 
1910). The calculation of the Spearman correlation coefficient for survival data and the final 
feature selection is performed as described for the Pearson correlation coefficient above. 
The Spearman rank correlation does not include information among the features. 
Mutual information matrix (MIM) 
The MIM method computes the relevance of feature 𝑋𝑗 for describing the outcome 𝑌 based 
on an approximation of the mutual information 𝐼𝑗: 
𝐼𝑗(𝑋𝑗 , 𝑌) =  −
1
2
ln (1 − 𝜌(𝑋𝑗, 𝑌)
2
), (20) 
where 𝜌 describes the correlation between the feature 𝑋𝑗 and the outcome 𝑌. The choice of 
𝜌 depends on the given data. If 𝑌 represents time-to-event data, the concordance index (𝑐𝑖), 
which is similar to the Somers’ Dxy index, is recommended as 𝜌: 
𝜌 = 2 ⋅ (𝑐𝑖 − 0.5). (21) 
Features with the highest mutual information are most relevant (De Jay et al., 2013). 
Mutual information feature selection (MIFS) 
The MIFS algorithm searches for features containing additional information which is not 
included in already selected features. Therefore, the mutual information 𝐼 is calculated as 
described for MIM between each feature 𝑋𝑗 and the outcome 𝑌. To select the optimal 
signature 𝑆 of features 𝑠, the optimization function 
𝑂𝑗 = 𝐼(𝑋𝑗 , 𝑌) − 𝛽 ∑𝐼(𝑠, 𝑋𝑗)
𝑠∈𝑆
 
(22) 
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has to be maximized iteratively. The last term of this function penalizes features 𝑋𝑗 with a 
high correlation to the already selected features. In each iteration step, one new feature is 
added to the signature 𝑆. The signature is extended until a predetermined number of 
features is reached. The parameter 𝛽 controls the balance between already selected 
features and candidate features. Battiti et al. suggested to choose 𝛽 = 1 (Battiti, 1994). 
Minimum redundancy maximum relevance (MRMR) 
The MRMR algorithm uses two conditions to find the optimal feature signature: a redundancy 
and a relevance condition similar to the MIFS. Both are based on mutual information. The 
redundancy criterion 𝑊 is represented by the mutual information between all selected 
features 𝑠 and 𝑡 within the signature 𝑆, 
𝑊(𝑠, 𝑡) =
1
|𝑆|2
∑ 𝐼(𝑠, 𝑡)
𝑠,𝑡 ∈𝑆
, 
(23) 
|𝑆| denotes the number of features in the signature 𝑆. The redundancy shall be minimal to 
increase the power of the signature. The relevance criterion 𝑉 represents the classification 
power of all selected features with respect to the outcome 𝑌, 
𝑉(𝑠, 𝑌) =
1
|𝑆|
∑𝐼(𝑠, 𝑌)
𝑠∈𝑆
. 
(24) 
The relevance shall be maximal. The target function 𝑂𝑠, 
𝑂𝑠 = 𝑉(𝑠, 𝑌) − 𝑊(𝑠, 𝑡), (25) 
is maximized with respect to the current signature size |𝑆|, starting from |𝑆| = 1 until a 
predetermined signature size is reached (Ding and Peng, 2005; Peng et al., 2005). 
Univariable Cox regression 
For each feature a univariable Cox proportional hazard regression (see page 27) is 
performed and the resulting model is evaluated using the 𝑐𝑖. The 𝑐𝑖 are sorted and the 
features leading to the best performing models (highest 𝑐𝑖) are selected first.  
Net-Cox (Feature selection) 
The simple Cox regression is extended by elastic net parameters (see page 28) and is 
applied to the training data to fit a multivariate Cox model. The features are selected 
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according to the magnitude of the corresponding coefficients within the model. The features 
with the largest magnitude are selected first (Agresti, 2002).  
Variance filter 
The variance filter is based on the mutual information inherent in each gene, similar to the 
feature selection algorithms described on page 25. Briefly, the filter is based on the 
assumption that genes with a high variance may contain more information than genes with 
a low variance, e.g. variance = 0. This filter selected the 200 genes with the highest variance 
and dismissed the remaining genes. 
Univariable filter 
The univariable filter performed a univariable Cox regression with each feature for the 
endpoint of interest, in this section LRC. Subsequently, all genes were ordered according to 
the p-value of their hazard ratio. All genes with a p-value below 0.3 were considered for the 
following analyses.  
2.3.2 Prognostic models 
Based on the selected features, models can be created to predict the outcome. These 
models will be used to stratify patients into low and high risk groups. The results of this thesis 
are mainly based on four different prognostic models, which will be presented in this section. 
All models have in common that they can deal with survival data and that they perform 
supervised learning. 
Cox proportional hazard regression 
The Cox proportional hazard regression (Cox regression) is based on the assumption that 
the hazard function ℎ(𝑡) can be expressed as the product of an unspecified time-dependent 
baseline hazard function ℎ0(𝑡) and a time-independent expression: 
ℎ(𝑡) = ℎ0(𝑡)𝑒
 ?⃗? ?⃗⃗? . (26) 
The time-independent product of 𝑝 features 𝒙𝒊⃗⃗  ⃗ = (𝑥𝑖1, … , 𝑥𝑖𝑝) and regression coefficients ?⃗⃗? =
(𝛽1, … , 𝛽𝑝) can be interpreted as the relative risk of each patient 𝑖 or is referred to as 
prognostic index, 
𝒙𝒊⃗⃗  ⃗?⃗⃗? = ∑𝑥𝑖𝑗𝛽𝑗
𝑝
𝑗=1
. (27) 
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The regression coefficients are determined by maximizing the Log-Likelihood, 
𝐿𝐿(?⃗⃗? ) = ∑𝛿𝑖 (∑𝛽𝑗𝑥𝑖𝑗
𝑝
𝑗=1
− ln [ ∑ exp(∑𝛽𝑗𝑥𝑘𝑗
𝑝
𝑗=1
)
𝑝
𝑘:𝑇𝑘≥𝑇𝑖
])
𝑛
𝑖=1
, (28) 
(Cox, 1972; Kalbfleisch and Prentice, 2002) for all patients 𝑖 (𝑖 = 1…𝑛) taking into account 
if an event occurred, 𝛿𝑖 = 1, or if the patient was censored, 𝛿𝑖 = 0. 
Net-Cox 
To prevent the Cox-regression model from overfitting and to decrease the impact of 
redundant parameters, the model can be extended using the elastic net regularization. The 
linear combination of two penalty terms 𝐿1(𝜆1, ?⃗⃗? ) and 𝐿2(𝜆2, ?⃗⃗? ) are added to the Log-
Likelihood of the Cox regression, equation (28): 
ℒ(𝜆1, 𝜆2, ?⃗⃗? ) = 𝐿𝐿(?⃗⃗? ) + 𝐿2(𝜆2, ?⃗⃗? ) + 𝐿1(𝜆1, ?⃗⃗? ) = 𝐿𝐿(?⃗⃗? ) − 𝜆2 ∑𝛽𝑗
2
𝑝
𝑗=1
− 𝜆1 ∑|𝛽𝑗|
𝑝
𝑗=1
. (29) 
The adapted Log-Likelihood equation contains two positive parameters 𝜆1 and 𝜆2 which 
correspond to the 𝑙1- (lasso) and the 𝑙2-norm (ridge regression), respectively. Both terms 
allow a weighting of importance of features. The lasso term reduces the number of features 
in the model by setting  𝛽𝑗 = 0 for less important features. The ridge term reduces the 𝛽𝑗 of 
unimportant features to small but non-zero values. Both terms can be applied at the same 
time and balanced using the factor 𝛼 with 
1 − 𝛼 = 𝜆1, (30) 
𝛼 = 𝜆2. (31) 
For both penalty terms, the importance of the different regression parameters can be 
evaluated using the magnitude of the parameters 𝛽𝑗. A bigger |𝛽𝑗| is equivalent to a more 
important feature (Gui and Li, 2005; Zou and Hastie, 2005; Engler and Li, 2009; Goeman, 
2010; Simon et al., 2011). 
Survival regression - Weibull regression model 
The semiparametric Cox model can be used to stratify patients into distinct risk groups, but 
it gives only limited information about expected failure times. This issue can be solved by 
replacing the unspecified baseline hazard ℎ0(𝑡) with a suitable hazard function, like the 
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Weibull function. The Weibull distribution is a continuous probability distribution used, for 
example, in failure analyses for technical devices or insurances and is given by 
f(𝑡) =
𝑎
𝑏
 (
𝑡
𝑏
)
𝑎−1
 ∙ 𝑒
−(
𝑡
𝑏
)
𝑎
. (32) 
It can be interpreted as product of a hazard function 
ℎ(𝑡) =
𝑎
𝑏
 (
𝑡
𝑏
)
𝑎−1
 (33) 
and the corresponding survival function 
𝑆(𝑡) = 𝑒
−(
𝑡
𝑏
)
𝑎
. (34) 
Parameters 𝑎 and 𝑏 are shape and scale parameters. The hazard function can be written 
as: 
ℎ(𝑡, 𝜷,⃗⃗  ⃗ ?⃗? , 𝜆) = 𝜆𝑡𝜆−1𝑒−𝜆 ?⃗⃗?
 ?⃗?  (35) 
(Hosmer et al., 2008). By comparing the hazard functions (33) and (35), it results  
𝑎 = 𝜆, (36) 
𝑏 = 𝑏(𝑥) = 𝑒 ?⃗⃗?
 ?⃗? = 𝑒𝛽0 𝑒𝛽1𝑥1  𝑒𝛽2𝑥2 … . (37) 
The survival regression model (Surv.-Regr.) in R fits a Weibull function using the 
intercept 𝛽0, the regression coefficients 𝛽𝑖 and the survival regression scale 𝜎 = 𝑎
−1 as fit 
parameters. 𝜎 is a variance-like parameter on the log-time scale for the given outcome data 
(Hosmer et al., 2008). The scalar product ?⃗⃗? ?⃗? , functions as a risk-like factor which can be 
used to stratify patients.  
The regression parameters of a Cox regression and a survival regression should be similar 
after the multiplication of the regression parameters and the fit parameter ?⃗⃗? 𝑪𝒐𝒙 = 𝑎 ?⃗⃗? 𝒔𝒖𝒓𝒗. 
Decision trees in a random survival forest (RSF) 
A decision tree is a tree shaped decision support system that can be applied to stratify a 
sample. A common example is the stratification of pictures showing cats and dogs, see 
Figure 2.9. In each splitting node, a splitting rule is applied that stratifies the “incoming” 
sample into two subsamples until final classification (e.g. into group 1 and 2) is assigned. 
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The resulting paths are referred to as branches. Different branches can lead to the same 
final classification. A tree is called random decision tree if one step of the creation includes 
a randomization. An ensemble of random decision trees creates a random (decision) forest. 
The random survival forest is inspired by Breiman’s random forest. A bootstrap sample is 
drawn from the training data. The bootstrap sample is used to build a decision tree by 
splitting the data at different levels (nodes). The available features at the splitting nodes are 
randomly selected from all features. The splitting rules depend on the data as well as on the 
purpose of the decision tree, e.g. it can be a greedy algorithm applied to one randomly drawn 
feature or based on log-rank tests of dichotomized features for survival data. Finally, different 
trees built on different randomly drawn bootstraps are combined to obtain an ensemble 
prediction. In contrast to Breiman’s random forest, the random survival forest can handle 
survival data. (Breiman, 2001; Ishwaran and Kogalur, 2007; Ishwaran et al., 2008; Ishwaran 
and Kogalur, 2016). 
 
Figure 2.9. Decision tree. A sample can be stratified according to several splitting rules 
to identify similar groups within the sample, e.g. cats or dogs. 
 
2.4 Gene expression measurement methods 
The genetic profile of tumour tissue differs from the normal, healthy tumour surrounding 
tissue. HNSCC are very heterogenous, i.e. two tumours arising from the same origin can 
have different genetic profiles. The tumours response to the therapy is partly related to its 
genetic profile. To identify the genetic profile, alternative methods are available. The 
methods used to acquire the data in this thesis will be presented in the following sections, 
Split rule 1
Split rule 2
Group 1 Group 2
Group 1
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first starting with the clinical gold standard, the real time - polymerase chain reaction (RT-
PCR). Afterwards, two different methods are presented, based on the nCounter® gene 
expression measurement of nanoString and whole transcriptome analyses performed using 
in situ-synthesized oligonucleotide microarrays (GeneChip®) of Affymetrix. The 
measurements were performed by clinician scientists within the DKTK. 
2.4.1 Real-time polymerase chain reaction (RT-PCR) 
DNA synthesis based on RNA 
The RT-PCR is a method to amplify and measure DNA expression of a tissue sample. If 
ribonucleic acid (RNA) is available instead of DNA, the RNA has to be transformed. 
Therefore, reverse transcriptase (RT), an enzyme which can produce complementary DNA 
(cDNA) out of nucleotides, is used. Small pieces of cDNA (primers) serve as a starting point 
for the RT. Those primers bind to specific regions of the RNA of the sample. When the 
synthesis is finished, the complete cDNA strand is hybridized with the RNA and the RNA 
has to be removed by a ribonuclease. The DNA is then synthesised based on the cDNA 
using the corresponding DNA polymerase and primer. 
The three steps of PCR 
PCR consists of three steps – melting, primer annealing and elongation. During the melting 
process, the DNA is heated to dissolve the hydrogen bonds leading to two separate DNA 
strands. Then, the temperature is lowered, and primers are added, one for each strand.  The 
primers link to the corresponding DNA strand and the third step, the elongation, begins. The 
DNA polymerase starts from the primer to synthesize the complementary DNA strand. After 
the step is done, the amount of DNA is doubled, and the process can start all over again to 
increase the amount of DNA. 
During RT-PCR, fluorescent molecules are added. These molecules bind to the target DNA 
leading to an increased fluorescence after each cycle. The fluorescence can be based on 
different principles, such as the Förster resonance energy transfer (FRET). The FRET 
probes consist of two parts a donor and an acceptor. For this thesis, TaqMan gene 
expressions assays were used, which are a special case of the FRET. Usually, the 
fluorescent signal of the donor increases while the signal of the acceptor decreases with 
increasing distance between donor and acceptor. The fluorescence is proportional to the 
amount of DNA. A TaqMan probe consists of a reporter (donor) and a quencher (reporter). 
When the quencher is near to the reporter, the quencher inhibits the fluorescent properties 
of the reporter. During the PCR sequence, the TaqMan probe hybridizes with the DNA 
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strand. When the special Taq polymerase constructs the cDNA and reaches the reporter, it 
dissolves the reporter from the TaqMan probe. The increasing distance to the quencher 
stops the inhibiting properties and allows fluorescence of the reporter.  
2.4.2 nCounter® gene expression 
The nCounter® System of nanoString (nanoString Technologies, Seattle, WA, USA) can be 
used to identify any type of nucleic acid. A brief description of the process using the example 
of RNA identification will be provided since the data acquired for this thesis were based on 
RNA expression analyses. The analysis consists of four steps that are illustrated in Figure 
2.10. Briefly, in the first step, two gene-specific probes are added to the solution, namely the 
reporter and the capture probe. Both probes include a complementary RNA sequence 
allowing hybridizing with a specific area of the target RNA. Subsequently, the 
complementary RNA sequence is coupled to a fluorescent colour-coded tag (reporter probe) 
and an affinity tag (capture probe), see Figure 2.10 A. In the second step, unbound probes 
are removed, and the remaining, hybridized probes are brought onto a panel coded with a 
reagent corresponding to the affinity tag. The capture probe adheres to the surface of the 
panel, (Figure 2.10 B). An electrical field is applied leading to alignment and unfolding of the 
hybridized probes (Figure 2.10 C). Lastly, the targeted sequences are identified by their 
unique fluorescent colour-coded tag (Figure 2.10 D). The expression level of a gene is 
obtained by counting the corresponding colour-coded tags. For a detailed description see 
(Geiss et al., 2008). 
2.4.3 In situ-synthesized oligonucleotide microarrays 
Biological processes are steered by several genomic pathways simultaneously. The first 
publication of the complete human genome (Consortium, 2001) revolutionized the way 
scientists interpret the translation between genetic information and biological mechanisms 
(Dalma‐Weiszhausz et al., 2006).  Different approaches have been developed to assess 
thousands of gene expressions simultaneously, e.g. using microarray assays. Several types 
of microarray assays are available (Miller and Tang, 2009). For the measurements used in 
this thesis, the microarray assay GeneChip® from Affymetrix (Thermo Fisher Scientific Inc., 
Waltham, MA, USA) was used. In the following, the basic concept of in situ-synthesized 
oligonucleotide microarrays will be described, based on the GeneChip®. A very detailed 
explanation of the GeneChip® functionality is presented in (Dalma‐Weiszhausz et al., 2006) 
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Figure 2.10. Schematic illustration of nCounter® expression measurement based on 
(Geiss et al., 2008). (A) The capture and reporter probe bind to the specific area of the 
target RNA. (B) The capture probes bind to the surface of a coded panel. (C) A voltage is 
applied to align the molecules and the aligned molecules are bound to the surface. (D) 
The fluorescent colour tags are read out. 
 
The GeneChip 
The gene-chip is the main component of in situ synthesized oligonucleotides microarrays. 
The production process of a GeneChip® by Affymetrix is depicted in Figure 2.11. A quartz 
wafer is coated with a chemical stable surface (Figure 2.11 A), which can be destabilized by 
light. Using a photolithographic mask, some areas (pixels) are destabilized (Figure 2.11 B) 
allowing nucleotides to attach to the surface. When the illumination stops, a new protection 
layer is formed above the nucleotides (Figure 2.11 C). This procedure is repeated with 
different lithographic masks and the four different nucleotides until the probe sequences are 
finished (Figure 2.11 D). In the end, each illuminated pixel contains thousands of identical 
oligonucleotides. The amount of information which can be obtained later in one experiment 
can be increased by decreasing the space between the pixels. Finally, the wafer is cut into 
squares and put into cartridges (Dalma‐Weiszhausz et al., 2006). 
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The probe-processing 
Pre-processing may differ due to nucleic acids that are to be analysed. In general, the nucleic 
acids are purified (the parts of interest are isolated), amplified using cDNA (see section 
2.4.1), labelled (marked with a special molecule) and fragmented (split into smaller parts). 
In the case of RNA analyses, complementary RNA strands, labelled with biotin, are created 
based on the synthesized DNA strands. Finally, the RNA strands are fragmented by 
hydrolysis into smaller parts and can now be hybridized with the oligonucleotides on top of 
the wafer (Dalma‐Weiszhausz et al., 2006). 
Data acquisition 
The labelled RNA fragments, now all fixed to the GeneChip, are combined with a fluorescent 
reagent, like streptavidin-phycoerythrin conjugate (SAPE). The SAPE links to the biotin 
label. A laser with a spot size equal to the pixel size of the lithographic mask (compare 
subsection “The GeneChip”) stimulates the fluorescence pixel by pixel. Based on the emitted 
fluorescence and the location of the oligonucleotides on the wafer, the corresponding gene 
expressions can be calculated (Dalma‐Weiszhausz et al., 2006). 
 
   
 
Figure 2.11. Schematic illustration of the production of a GeneChip® based on (Dalma‐
Weiszhausz et al., 2006). A wafer with a coated surface (A) is partially illuminated using a 
lithographic mask. A Some pixels of the chemically stable surface are destabilized by the 
light (B). New nucleotides to attach to the destabilized surface in the illuminated areas (C). 
The process (B, C) is repeated until the target length is reached for each pixel (D).  
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3 Material and methods 
In the first two parts of this chapter a general overview about the patient cohort and the data 
acquisition will be given. The third part describes the machine learning framework that was 
used to analyse the data. The used programs and versions are presented in Supplementary 
Table 2. 
3.1 Patient cohorts 
The analyses in this thesis are based on 4 patient cohorts with histologically proven, locally 
advanced HNSCC. Patients were either treated with primary (pRCTx) or with postoperative 
radio(chemo)therapy (PORT-C). A separate training and a validation cohort was available 
for each treatment modality. The training cohorts are used to identify biomarkers and create 
the prognostic models. The validation cohorts will be used to assess the performance of the 
biomarkers and validate the models. All patients were treated with curative intent at one of 
the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) partner sites. The 
patients of the two validation cohorts were treated at the DKTK partner site Dresden. 
3.1.1 Primary radiochemotherapy (pRCTx) cohorts 
The pRCTx training cohort consists of 158 patients who received primary 
radiochemotherapy (pRCTx) with a median dose of 72.0 Gy (range 68.4 Gy to 74.0 Gy) 
based on cisplatnium or mitomycin-C between 2005 and 2011 at six partner sites of the 
DKTK-ROG. The cohort is presented in detail in (Linge, Lohaus et al., 2016). 
The pRCTx validation cohort was composed of 92 patients who were presented earlier in 
(Linge et al., 2019). All patients of the pRCTx validation cohort were treated between 1999-
2015 and had to meet the following inclusion criteria: at least 18 years old, not already 
included in the training cohort and treated using pRCTx or primary radiotherapy (pRTx). 43 
patients of the validation cohort were treated between 2006 and 2013 in a registered and 
approved mono-centre single-arm non-randomised observational imaging trial 
(www.clinicaltrials.gov, NCT00180180, Bundesamt für Strahlenschutz, Z5 – 22461/2 – 
2004-061, EK166082004) with a median dose of 72 Gy (range 69.0 Gy to 72.0 Gy) (Zips et 
al., 2012; Löck et al., 2017). The other 49 patients were received pRCTx with a median dose 
of 70.6 Gy (range 70.0 Gy to 76.8 Gy), between 1999 and 2006 or 2009 and 2015. All 92 
patients of the resulting validation cohort were treated at the DKTK partner site Dresden. 
The patient characteristics of both cohorts, i.e. the training and the validation cohort, are 
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presented in Table 3.1 (Linge, Lohaus et al., 2016; Linge et al., 2019). Experienced radiation 
oncologists (training: Fabian Lohaus, Chiara Valentini, validation: Fabian Lohaus) 
segmented the primary and nodal gross tumour volume (GTV) retrospectively, using 
RayStation 6 (Raysearch Laboratories, Stockholm Sweden) and an in-house software 
solution (Zips et al., 2012) in the CT scans. To evaluate loco-regional recurrences, the 
treatment plan and the radiological images (CT, MRI or PET-CT) showing the recurrences 
were reviewed by an experienced radiation oncologist (training and validation: Fabian 
Lohaus) (Linge, Lohaus et al., 2016; Linge et al., 2019). 
The patients of the validation cohort presented with significantly larger primary tumour 
volumes (p = 0.003), less tumours arising from the oropharynx (training cohort (t): 50.6% vs 
validation cohort (v): 25.5%) and more tumours arising from the oral cavity (t: 17.1% vs v: 
33.7%). While the 2-year rates of LRC was similar in both cohorts (t: 62.6% vs v: 63.5%, 
p = 0.67), more patients of the validation cohort deceased within the first 2 years (OS t: 
59.6% vs v: 50.7%, p = 0.003). 
3.1.2 Postoperative radio(chemo)therapy (PORT-C) cohorts 
The PORT-C training cohort consisted of 221 patients, treated between 2004 and 2012. The 
PORT-C validation cohort included 142 patients who were treated between 1999 and 2006 
and were not already included in the training cohort. Both cohorts are described in detail in 
(Lohaus et al., 2014; Linge, Löck, Krenn et al., 2016; Linge, Löck, Gudziol et al., 2016; Linge 
et al., 2018; Schmidt et al., 2018) and are shown in Supplementary Table 3. All patients 
were treated with curative intent according to standard protocols. While all patients of the 
training cohort received a cisplatinum-based PORT-C treatment, the patients of the 
validation cohort received a PORT either with or without chemotherapy (Lohaus et al., 2014; 
Linge, Löck, Krenn et al., 2016). Most analyses focus on the HPV16 DNA negative patients, 
since the presence of HPV16 is already known as strong prognostic biomarker (Lohaus et 
al., 2014; Linge, Löck, Krenn et al., 2016). The characteristics of the HPV16 DNA negative 
patients of the training and validation cohort are presented in Table 3.2.  
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Table 3.1. Patient characteristics for the patients treated with primary radiochemotherapy, 
pRCTx, of the training and validation cohort are shown and compared. 
Neg. – negative; pos. – positive, miss. – missing; * Comparison based on log-rank test for 
time-to-event data, + 95% confidence interval. 
 Training cohort Validation cohort  
    
 2005-2011 1999-2015  
Characteristics Median (range) Median (range)  
Follow-up (months) 54.4 (10.9-81.1)+ 59.0 (7,7-131.9)+ 0.064* 
Age (years) 58.6 (39.2-81.9) 56 (39.8-82.1) 0.30 
Dose (Gy) 72.0 (68.4-74.0) 72.0 (69.0-76.6) 0.007 
Volume Tumour (cm³) 26.8 (4.4-175.8) 33.9 (5.1-322.6) 0.003 
Volume LN (cm³) 8.2 (0-300.0) 7.2 (0-272.6) 0.94 
Volume total (Tumour+LN) 
(cm³) 
41.0 (5.6-351.7) 53.0 (7.9-344.7) 0.042 
CD44 0.60 (-0.79-3.36) 0.38 (-1.20-1.64) 0.008 
SLC3A2 -3.17 (-5.86-(-1.27)) -2.56 (-4.19-(-1.26)) 0.83 
  Patients (%) Patients (%) p-value 
Gender Male / female 133 / 25 84.2 / 15.8 76 82.6 / 17.4 0.75 
Localization Oropharynx 80 50.6 24 26.1  
Oral cavity 27 17.1 30 32.6  
Hypopharynx 51 32.3 30 32.6  
Larynx 0 0 8 8.7 <0.001 
N-stage 0 / 1 28 / 7  17.7 / 4.4 12 / 7 13.0 / 7.6  
2 / 3 115 / 8 72.8 / 5.1 68 / 5 73.9 / 5.4 0.60 
HPV16 DNA 
status 
Neg. / pos. 137 / 20 86.7 / 12.7 78 / 9 89.7 / 10.3  
Missing 1 0.6 5 5.4 0.58 
p16 protein Neg. / pos.  125 / 24 79.1 / 15.2 80 / 12 87.0 / 13.0  
 missing 9 5.7 0 0 0.52 
CD44 protein Neg. / pos. 28 / 108 17.7 / 68.4 5 / 76 5.4 / 82.6  
 Missing 22 13.9 11 12.0 0.004 
Loco-regional recurrences 61 38.6 31 33.7 0.62* 
Distant metastases 29 18.4 12 13.0 0.53* 
Deaths 78 49.4 56 60.9 0.084* 
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Table 3.2. Patient characteristics for the patients with HPV16 DNA negative tumours 
treated with postoperative radio(chemo)therapy, PORT(-C), of the training and validation 
cohort.  
* Comparison based on log-rank test for time-to-event data, + 95% confidence interval. 
 Training cohort Validation cohort  
 2004-2012 1999-2006  
Patients with HPV16 DNA negative tumours 
Characteristics Median (range) Median (range) p-value 
Follow-up (months) 57.4 (11.5 – 94.5)+ 62.1 (24.7 – 153.0)+ <0.001* 
Age (years) 56.5 (32.0 - 74.0) 52.3 (36.3 – 70.6) 0.005 
Dose (Gy) 64.0 (56.0 – 68.0) 64.0 (60.0 – 66.0) 0.006 
  
Number 
of pts 
(%) 
Number 
of pts 
(%)  
Gender Male / female 101 / 29  77.6 / 22.4 105 / 16 86.8 / 13.2 0.061 
Chemo-
therapy 
Yes / no 130 / 0 100.0 / 0.0 31 / 90 25.6 / 74.4 <0.001 
Localization Oropharynx 58 44.6 26 21.5  
 Oral cavity 49 37.7 75 62.0  
 Hypopharynx 23 17.7 13 10.7  
 Larynx 0 0.0 7 5.8 <0.001 
ECE-status Neg. / pos. 62 / 68 47.7 / 52.3 82 / 39 67.8 / 32.2 0.001 
Loco-regional recurrences 26 20.0 35 28.9 0.096* 
Distant metastases 31 23.8 29 24.0 0.72* 
Deaths 54 41.5 73 60.3 0.042* 
 
 
3.1.3 Clinical endpoints 
All analyses were performed using loco-regional tumour control (LRC) as the primary 
endpoint and overall survival (OS) and freedom from distant metastasis (DM) as secondary 
endpoints. The time-to-event for each endpoint was calculated starting from the first day of 
radiotherapy until the event occurred or the patient was censored. OS was regarded as 
competing risk to LRC and DM, which led to censoring. In contrast, LRC and DM events did 
not lead to censoring. Survival analyses were performed using Kaplan-Meier statistics. 
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3.2 Gene expression analyses 
In the following subsection the different gene expression analyses, performed on the 
cohorts, are presented. Due to insufficient tumour material or the changing hypothesis driven 
composition of the nCounter® analyses panel, the set of available genes may differ between 
the different cohorts. In short, all measurements were performed based on formalin-fixed 
paraffin-embedded (FFPE) blocks of the primary tumour specimens (PORT-C) or of tumour 
biopsies (pRCTx). The tumour samples were first subjected to haematoxylin and eosin 
staining to histologically confirm the presence of squamous cell carcinoma. Subsequently, 
the slides were prepared under standardized procedures for immunohistochemistry, 
extraction of RNA and genomic DNA for further analyses.  
3.2.1 HPV status 
Genomic DNA was extracted from 5-μm FFPE sections using the QIAamp DNA FFPE tissue 
kit (Qiagen) to obtain the HPV status of the (training and validation). The analyses and 
genotyping of HPV DNA were performed using the LCD-Array HPV 3.5 kit (CHIPRON 
GmbH, Berlin, DE) according to the manufacturer’s instruction. For further information see 
the publications (Lohaus et al., 2014; Linge et al., 2018). 
3.2.2 Immunohistochemical staining 
The expression status of p16 and CD44 was obtained using histochemical staining. The 
sample preparation for the training cohort is described in detail in (Linge, Lohaus et al., 2016; 
Linge, Löck, Gudziol et al., 2016). The validation cohort was processed similarly. Briefly, the 
CINtec Histology kit (Roche mtm laboratories AG, Basel, CH) was used according to the 
manufactures’ instructions to analyse the p16 status. An overexpression of p16 (p16 
positivity) was defined as ≥70% intense tumour staining (Linge, Lohaus et al., 2016; Linge, 
Löck, Gudziol et al., 2016). 3µm sections of the primary tumour biopsies were prepared to 
assess the expression status of CD44 (Linge, Lohaus et al., 2016; Linge, Löck, Gudziol et 
al., 2016). The sections were incubated with monoclonal mouse anti-human CD44 antibody 
(Clone DF1485; Dako). The negative control slides were incubated with the corresponding 
IgG antibody control (Dako). Two independent observers evaluated the blinded samples 
with an inter-observer variability of <5% for all immunohistochemically analysis (Linge, 
Lohaus et al., 2016; Linge, Löck, Gudziol et al., 2016). 
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3.2.3 RT-PCR measurements 
RT-PCR was performed for patients of the PORT-C training cohort for 39 genes including 
the 15- and 26-gene hypoxia signature and the CSC markers, see section 2.1.2. 37 of the 
39 gene expressions, analysed using TaqMan gene expression assay and were also 
assessed using nCounter® and GeneChip® analyses. The performed analyses were 
described in more detail previously by (Linge, Löck, Gudziol et al., 2016). For RT-PCR, the 
ABI StepOne Plus RT-PCR System (Life Technologies) was used. All RT-PCR reactions 
were performed on a single PCR plate for each patient. The obtained gene expressions 
were normalized to the mean of the reference genes ACTR3, B2M, GNB2L1, NDFIP1, 
RPL11 and RPL37A. Different reference genes were reported for the 15-gene and 26-gene 
hypoxia gene signature. Before the hypoxia classification was performed based on the 
hypoxia gene signatures, the corresponding set of reference genes were used to normalize 
the raw data. 
3.2.4 nCounter® measurements 
The gene expression analyses using nCounter® elements technology (nCounter® 
Technologies, Seattle, WA, USA) was described previously in (Linge, Löck, Krenn et al., 
2016; Linge, Löck, Gudziol et al., 2016). Briefly, the RNA was mixed with gene-specific 
reporter and capture probes and incubated at 62 °C for 22 hours. Afterwards, samples were 
kept at 4 °C for a maximum of 18 hours and put into the nCounter system. The raw counts 
were logarithmised and normalized by subtracting the mean of the log-transformed counts 
of the reference genes ACTR3, B2M, GNB2L1, NDFIP1, POLR2A, RPL11 and RPL37A. 
Some of the samples had to be excluded from the analysis due to too low RNA yield or 
insufficient tumour material (Linge, Löck, Krenn et al., 2016; Linge, Löck, Gudziol et al., 
2016).  
The expression levels of shared set of 178 genes were evaluated by nCounter® analyses 
for all four cohorts (Linge, Löck, Gudziol et al., 2016; Schmidt et al., 2018). After a literature 
research, genes were included that were found to be associated with sensitivity or resistance 
to radio(chemo)therapy: genes involved in proliferation, invasion and metastasis; tumour 
hypoxia-associated genes; genes encoding for putative CSC markers and DNA repair as 
well as genes that have been associated with cisplatinum-resistance, see Supplementary 
Table 4.  
Due to an invalid probe design and a change in the composition of the gene set, a subset of 
genes was not assessed in all cohorts, e.g. CD44 and CD44v6 were lacking in the PORT-C 
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training cohort (Linge, Löck, Gudziol et al., 2016). Unless these genes are required for 
discussion, they are omitted from the analyses.  
3.2.5 GeneChip® analyses (only training cohorts) 
For GeneChip® analyses, the Human Transcriptome 2.0 Array (Affymetrix, Inc., Santa 
Clara, CA, USA) was used for all samples. For each array, 10 ng of RNA was used as 
sample input. Sample processing was performed according to the instructions of the 
manufacturer. Quality control of the results was performed using the software Transcriptome 
Analysis Console 4.0 (Applied Biosystems, Waltham, Massachusetts, USA).  
3.3 Machine learning framework 
Within our work group we developed a machine-learning framework, which allows us to 
apply and compare different feature selection algorithms and prognostic models. The 
framework can handle different data sources, such as medical imaging (radiomics) or gene 
expression measurements (genomics). The identification of a biomarker signature and a 
prognostic model consists of four main steps. Briefly, the gene expression data is 
preprocessed, i.e. too low expressed genes are excluded from the analyses, the gene 
expressions are z-transformed to a mean of 0 and a standard deviation of 1 (training cohort) 
or transformed based on the means and standard deviations of the training cohort (validation 
cohort), respectively. Then, an ensemble signature is determined based on the training 
cohort using repeated 3-fold internal cross validation. To increase the robustness of the 
obtained signature, highly correlated genes are included in the third step. Finally, the 
signature is validated using an external validation cohort and the patients are stratified based 
on the model. The framework was already used and presented in publications (Leger et al., 
2017; Schmidt et al., 2018). 
3.3.1 Pre-processing of gene expression data 
For nCounter® based gene expression data, the raw counts were normalized as described 
in section 2.4.2. All genes with a median expression below twice the median of the negative 
controls or with an invalid probe design were omitted from further investigations. The 
expression of each gene was normalized (z-transformed) to a mean of 0 and a standard 
deviation of 1 for the corresponding training cohort. This normalization transforms the gene 
expressions to similar magnitudes, which is favourable for most machine-learning 
algorithms. Based on the means and standard deviations of the training cohort, the gene 
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expressions of the validation cohort were transformed which may result in means and 
standard deviations differing from 0 or 1. 
3.3.2 Determination of the ensemble gene signature 
After pre-processing has been performed, the goal is to identify an ensemble gene signature, 
which is highly correlated with the considered endpoint. Additionally, a prognostic model 
must be selected. Therefore, a 3-fold internal cross validation was performed on the training 
cohort, i.e. the training cohort was randomly divided into 3 equally sized subgroups. Two of 
these subgroups were used for training (internal training sample) and the remaining for 
internal validation (internal validation sample). This was repeated for each possible 
permutation, leading to 3 different results per random division.  
The 3-fold cross validation was repeated 333 times, leading to 999 different internal training 
and validation data sets. For each of the 999 internal training data sets a feature selection 
algorithm was applied to find the most important set of genes (internal gene signature). 
Subsequently, each internal training data set and its internal gene signature was used to 
train a prognostic model. Each trained model was then validated using the corresponding 
internal validation sample. To evaluate model performances the 𝑐𝑖 (see section 2.2.1) was 
calculated for each internal training and validation data set.  
Ensemble signature 
Each of the 999 cross-validation samples may lead to a different internal gene signature. 
Therefore, an ensemble signature was defined based on the occurrence 𝑜𝑗 and the 
importance of each gene 𝑗 within the 𝑚 = 999 cross validation runs. Each model only 
includes a predefined number of genes (signature size). The occurrence 𝑜𝑗 represents how 
often the gene 𝑗 was included in the signature. The importance of gene 𝑗 is represented by 
the rank 𝑟𝑙𝑗 assigned by each feature selection algorithm in each cross validation run 𝑙 and 
the mean internal validation 𝑐𝑖𝑗̅̅̅̅  of the prognostic models which include the gene 𝑗. Based on 
those metrics an importance score is defined for each gene 𝑗, 
(importance score)𝑗 = 
∑ √𝑟𝑙𝑗
𝑚
𝑙=1
𝑜𝑗
2 ∗ (1 − 𝑐?̅?𝑗)
2
, (38) 
which is based on the enhanced Borda score (Wald et al., 2012).  
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Finally, the features are ordered according to their importance score. The features with the 
lowest importance score are selected until the predetermined signature size is reached. This 
set is called the ensemble signature.  
The procedure above was repeated using different feature selection algorithms, gene 
signature sizes (from 1 to 10) and prognostic models. The used parameters of the feature 
selection algorithms and prognostic models are presented in Supplementary Table 5. One 
signature was obtained for each signature size, feature selection algorithm and prognostic 
model. 
An additional step was necessary to select the final combination of signature and prognostic 
model. Prognostic models with the corresponding signatures were trained on 1000 bootstrap 
samples of the entire training cohort. The out of the bag (oob) data was used for internal 
validation of the signature-model combination (James et al., 2013), leading to a mean 𝑐𝑖oob̅̅ ̅̅ ̅̅ . 
Since the training cohort was already used to identify the signature, the resulting 𝑐𝑖 are 
usually very high due to a certain overfit.  
However, the 𝑐𝑖oob̅̅ ̅̅ ̅̅  can be used to compare the performance of the different prognostic 
models and signatures, and to identify an optimal signature size. With increasing signature 
size, the 𝑐𝑖oob̅̅ ̅̅ ̅̅  usually increases and finally reaches a plateau or even decreases. The start 
of the plateau region was chosen as optimal signature size. The combination with the best 
validation 𝑐𝑖oob̅̅ ̅̅ ̅̅  was chosen to be the ensemble signature and prognostic model combination 
for further steps. 
In the case of same 𝑐𝑖oob̅̅ ̅̅ ̅̅  for different signature sizes or models, the simpler model and 
smaller signature were preferred since simple models are easier to interpret and models 
using more parameters tend to overfit the data (James et al., 2013). 
3.3.3 Expanding the ensemble signature by highly correlated genes 
To increase the robustness of the final ensemble gene signature obtained in section 3.3.2, 
additional genes, which were highly correlated with one of the signature genes, were 
included in the final gene signature. For each signature gene additional genes were added 
based on the normalized signature correlation score (nSCS) which considers the correlation 
of the added gene and all genes within the signature.  
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Normalized signature correlation score (𝒏𝑺𝑪𝑺) 
To increase the robustness of the ensemble gene signature 𝑆, the signature should be 
extended by additional genes, which are highly correlated with one of the signature genes 𝑠 
(Cantini et al., 2018). Therefore, a signature correlation score 𝑆𝐶𝑆𝑠,𝑥 is introduced, which is 
based on a redundancy criterion 𝑊𝑠,𝑥 defined as the Pearson correlation between the feature 
expression 𝑋𝑠 of gene 𝑠 within the signature and the expression 𝑋𝑥 of gene 𝑥 not included 
in the signature. The redundancy of gene 𝑥 should be maximal for one feature 𝑠∗ of the 
signature and minimal for all others features ?̃? (?̃? ∈ ?̃? = 𝑆\{𝑠∗}) included in the signature. 
The correlation score 𝑆𝐶𝑆𝑠∗,𝑥 between one signature gene 𝑠
∗ and the additional gene 𝑥 is 
calculated from redundancy 𝑊𝑠∗,𝑥 and the mean redundancy 𝑊?̃?,𝑥   of the other signature 
genes ?̃? and gene 𝑥, 
𝑆𝐶𝑆𝑠∗,𝑥 = |𝑊𝑠∗,𝑥| −
𝛼
|?̃?|
∑|𝑊?̃?,𝑥|
?̃?∈?̃?
. 
(39) 
The parameter 𝛼 is used to control the balance between the redundancy of the genes of 
interest and the mean redundancy with the other signature genes. Furthermore, the 𝑆𝐶𝑆𝑠∗,𝑥 
is normalized to the signature correlation score of the signature gene 𝑠∗ with itself, 𝑆𝐶𝑆𝑠∗,𝑠∗, 
𝑛𝑆𝐶𝑆𝑠∗,𝑥 =
𝑆𝐶𝑆𝑠∗,𝑥
𝑆𝐶𝑆𝑠∗,𝑠∗
=
|𝑊𝑠∗,𝑥| −
𝛼
|?̃?|
∑ |𝑊?̃?,𝑥|?̃?∈?̃?
1 −
𝛼
|?̃?|
∑ |𝑊?̃?,𝑥|?̃?∈?̃?
. (40) 
The 𝑛𝑆𝐶𝑆 is calculated for each combination of genes within and outside of the signature. 
As a result, to each gene of the ensemble signature highly correlated additional genes are 
associated. A threshold in 𝑛𝑆𝐶𝑆 defines how many additional genes are found. With 
decreasing threshold more genes are included in the signature. Finally, gene in the signature 
𝑠∗ is replaced by its metagene, which is calculated as the median gene expression of the 
signature gene and the corresponding highly correlated additional genes. 
Extending of the ensemble signature and finalizing the model 
The 𝑛𝑆𝐶𝑆 was varied from 1.0 (no additional genes included) to 0.5 (many additional genes 
included) in steps of 0.05 and the according metagenes were calculated, i.e. the median of 
the corresponding genes. The mean 𝑐𝑖oob̅̅ ̅̅ ̅̅  was calculated from 1000 bootstrap samples of 
the whole training cohort for every 𝑛𝑆𝐶𝑆 cut-off. The extended signature with the highest 
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mean 𝑐𝑖oob̅̅ ̅̅ ̅̅  was used as the final gene signature for the considered clinical endpoint. The 
selected statistical model was trained on the training cohort using this final gene signature 
leading to the final prognostic model along with its training 𝑐𝑖train. 
3.3.4 Independent validation and patient stratification 
Finally, the model was validated and used to stratify the training and validation cohort into a 
high and a low risk group, respectively, as described below. 
For validation, the final model is applied unchanged to the validation cohort resulting in a 
validation 𝑐𝑖valid. If the final model included metagenes, they were calculated before. Briefly, 
all genes included in the metagene are z-transformed using their mean expression and 
standard deviation within the training cohort. Subsequently, the metagene, i.e. the median 
of the selected genes, is calculated. Furthermore, the model is applied to 1000 bootstrap 
samples of the validation cohort to obtain the 95% confidence interval of the validation 𝑐𝑖valid. 
The validation is successful if the lower border of the 95% confidence interval is above 0.5. 
The patients can be stratified into groups with a high or low chance of event of interest based 
on model prediction. Those groups are, therefore, called high and low risk groups. The 
model assigns a risk score, e.g. the prognostic index, to each patient, which can then be 
used to stratify the patients into these groups. Since the risk score is continuous, a proper 
cut-off needs to be determined based on the training cohort. We used the same strategy to 
obtain the cut-off as Linge et al. had used (Linge, Löck, Gudziol et al., 2016). Briefly, 1000 
bootstrap samples of the training cohort were stratified at every possible cut-off. The 
resulting groups in each bootstrap sample were compared by a log-rank test. The fraction 
of significant results (power) from all bootstrap samples was calculated for each cut-off. Cut-
offs with less than 20% of the patients in the smaller group were rejected and the cut-off with 
the highest power was chosen as optimal cut-off (Linge, Löck, Gudziol et al., 2016). For 
validation, the cut-off value, determined in the training cohort, was applied to the validation 
cohort. 
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4 Identification of gene expression signatures as 
prognostic biomarkers 
Gene expression measurements were performed to develop gene signatures to identify 
different risk groups regarding the endpoints LRC and OS using the results from nCounter® 
and GeneChip® analyses. In this chapter, the machine learning framework presented in 
chapter 3.3 is applied to the gene expression data obtained by the two gene expression 
measurement methods. In section 4.1, the framework is applied to the nCounter® gene 
expressions of the patients treated with primary and postoperative radiochemotherapy. The 
results for both cohorts are then validated using the independent validation cohorts. In 
section 4.2, the same framework is applied to the GeneChip® expression data of both 
training cohorts. In section 4.3, the obtained gene signatures are extended with established 
clinical features, and the models based on nCounter® measurements are validated. Then, 
different prognostic models will be combined in section 4.4. In each section, the results of 
the corresponding cohort and measurement method will be discussed. Finally, in section 
five, all results will be combined and compared. 
4.1 Hypoxia classification 
In this thesis, different hypoxia-associated gene signatures were used to stratify patients into 
groups with more and less hypoxic tumours. The stratifications were performed using 𝑘-
means clustering, which combines patients with similar gene expressions into different 
groups. 
The classifications used in this thesis are based on the corresponding training cohort, i.e. 
the 𝑘-means algorithm was applied to the PORT-C and the pRCTx training cohort to identify 
the cluster centres (Linge, Löck, Gudziol et al., 2016; Linge, Lohaus et al., 2016). The same 
cluster centres were applied to the validation cohorts, respectively (Lendahl et al., 2009; 
Toustrup et al., 2011; Eustace et al., 2013; Toustrup et al., 2016). 
Original classification 
The original cluster centres given in (Toustrup et al., 2011; Toustrup et al., 2016) are 
presented in the first columns of Table 4.1. The stratification is based on the Euclidian 
distance 𝐷𝑖 between the expression 𝑥 of each gene 𝑔 (of the 15-gene signature 𝐺) and the 
corresponding centre 𝑐𝑖 for both groups 𝑖 of ‘more’ and ‘less’ hypoxic tumours: 
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𝐷𝑖 = ∑
(𝑥𝑔 − 𝑐𝑖)
2
𝑠𝑑
𝑔∈𝐺
. (41) 
In addition to the 𝑘-means approach, each difference is divided by the common standard 
deviation 𝑠𝑑. The distances 𝐷more and 𝐷less are calculated and the patient is assigned to the 
group with the smallest distance 𝐷. If the difference 
|𝐷less − 𝐷more|
max(𝐷less, 𝐷more)
 (42) 
is smaller than 10%, Toustroup et al. suggested to assign the patient to an intermediate risk 
group. 
The same classification was applied to the PORT-C and pRCTx cohorts. As a result, in both 
cohorts only a small group of patients was identified as more hypoxic (PORT-C: n = 22; 
pRCTx: n = 36) or as intermediate risk (PORT-C: n = 19; pRCTx: n=18) if they showed a 
difference less than 10% between the less and more hypoxic group. The remaining patients 
were assigned to the less hypoxic group (PORT-C: n=154; pRCTx: n=84). This difference 
may be caused by differences in the gene expression measurement methods. 
Therefore, both cohorts’ gene expressions were transformed to a similar magnitude as the 
cohort of the original publication based on the given mean gene expressions and their 
standard deviations (Toustrup et al., 2016). Briefly, the gene expressions of both cohorts 
were z-transformed to mean 0 and standard deviation 1 and then transformed to the scale 
of the reported expressions through multiplication by the reported standard deviation. 
Subsequently, the reported mean was added. The used mean and standard deviation values 
are presented in Table 4.2. Based on the new gene expressions, the classification was 
performed again. For PORT-C 117 of 195 patients were assigned to the more hypoxic group, 
while the other patients were assigned to the intermediate risk (n = 15) or less hypoxic group 
(n = 64). For the pRCTx cohort, 135 patients were classified as more hypoxic and the 
remaining 3 patients were assigned to the as intermediate risk (n = 1) and less hypoxic group 
(n = 2). 
These differences may be explained with help of the mean gene expression of the different 
genes, presented in Table 4.2. Most mean gene expressions of the PORT-C and pRCTx 
cohort differ from the previously published values. This may be caused by the more 
advanced disease states of the patients compared to the original publications (Lendahl et 
al., 2009; Toustrup et al., 2011; Eustace et al., 2013; Toustrup et al., 2016). Based on these 
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results, the application of the previously published cluster centres does not seem to be 
reasonable and a new classification was performed. 
Table 4.1. Cluster centres of the k-means algorithm that was applied to stratify the cohorts 
into more and less hypoxic. The original centres of Toustrup et al. are presented in the 
first three columns (Toustrup et al., 2011; Toustrup et al., 2016). In the next columns the 
obtained cluster centres of the postoperative (PORT-C) and primary (pRCTx) training 
cohort are shown, respectively (Linge, Löck, Gudziol et al., 2016; Linge, Lohaus et al., 
2016). 
Gene 
More 
hypoxic 
Less 
hypoxic 
Common 
standard 
deviation 
More 
hypoxic 
Less 
hypoxic 
More 
hypoxic 
Less 
hypoxic 
 𝑐more 𝑐less 𝑠𝑑 𝑐more 𝑐less 𝑐more 𝑐less 
 Toustrup et al. PORT-C pRCTx 
ADM -0.75 -2.35 1.40 -1.28 -2.63 -1.34 -2.46 
ALDOA -0.67 -1.55 1.46 1.37 0.84 1.24 0.62 
ANKRD37 -4.16 -5.65 0.70 -4.06 -4.81 -3.89 -4.64 
BNIP3 -0.63 -1.52 1.24 -3.12 -4.06 -2.64 -3.87 
BNIP3L -0.46 -1.09 0.49 -1.84 -2.17 -1.60 -2.04 
EGLN3 -0.55 -1.56 1.56 -3.00 -4.49 -2.60 -4.09 
FAM162A -0.64 -1.29 0.51 -2.47 -2.91 -2.01 -2.60 
KCTD11 -2.08 -3.13 1.85 -1.81 -2.78 -1.35 -2.29 
LOX -1.09 -2.43 1.92 -2.79 -3.99 -3.02 -3.83 
NDRG1 2.36 0.83 1.98 1.46 -0.09 1.97 0.14 
P4HA1 -4.88 -6.36 1.37 -3.69 -4.26 -3.69 -4.32 
P4HA2 -2.71 -4.21 0.90 -2.41 -3.21 -2.16 -2.91 
PDK1 -1.71 -2.31 0.48 -3.55 -3.59 -3.12 -3.24 
PFKFB3 0.46 -0.24 1.14 -1.75 -2.36 -1.39 -2.01 
SLC2A1 1.96 0.53 1.77 0.02 -1.48 0.44 -1.27 
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Adapted classifications 
For the PORT-C cohorts Linge et al. showed that an adapted classification to two distinct 
hypoxia-associated patient groups that differed in loco-regional tumour control (Linge, Löck, 
Gudziol et al., 2016; Linge, Löck, Krenn et al., 2016). Even though the independent 
validation of the 15-gene hypoxia signature was not successful, the patients with more 
hypoxic tumours had a poorer outcome. Regarding the pRCTx cohort, a significant 
difference was observed for small tumours with volume ≤ 19cm³ (Linge, Lohaus et al., 2016). 
The cluster centres are shown in Table 4.1. The cluster centres of the PORT-C and the 
pRCTx cohort are in general similar for the more and less hypoxic groups, respectively. 
Compared to the centres presented by Toustrup et al. bigger differences occur, e.g. for LOX 
or PFKFB3.  
Table 4.2. Gene expressions of the 15-gene signature. The original mean gene 
expressions (𝑥𝑔̅̅ ̅) of Toustrup et al. are presented with the standard deviation (𝑠𝑑) in the 
first two columns (Toustrup et al., 2011; Toustrup et al., 2016). In the next columns the 
mean gene expressions and standard deviations of the PORT-C and pRCTx training 
cohort are shown, respectively (Linge, Löck, Gudziol et al., 2016; Linge, Lohaus et al., 
2016). 
Gene 𝒙𝒈̅̅ ̅ 𝒔𝒅 𝒙𝒈̅̅ ̅ 𝒔𝒅 𝒙𝒈̅̅ ̅ 𝒔𝒅 
 Toustrup et al. PORT-C pRCTx 
ADM -2.51 1.24 -1.83 1.03 -1.79 0.96 
ALDOA -1.28 1.07 1.16 0.52 0.99 0.52 
ANKRD37 -5.14 1.08 -4.36 0.91 -4.19 0.95 
BNIP3 -1.49 1.36 -3.50 0.92 -3.13 0.98 
BNIP3L -0.60 0.71 -1.97 0.46 -1.77 0.52 
EGLN3 -1.47 1.45 -3.60 1.09 -3.20 1.24 
FAM162A -1.21 0.88 -2.65 0.69 -2.25 0.68 
KCTD11 -2.52 1.24 -2.20 0.82 -1.73 0.79 
LOX -2.04 1.42 -3.27 1.11 -3.34 1.15 
NDRG1 0.55 1.41 0.83 1.11 1.23 1.19 
P4HA1 -6.08 0.99 -3.92 0.62 -3.94 0.66 
P4HA2 -3.52 1.09 -2.73 0.76 -2.46 0.80 
PDK1 -1.80 1.08 -3.57 0.62 -3.17 0.63 
PFKFB3 -0.05 0.93 -2.00 0.69 -1.64 0.72 
SLC2A1 0.93 1.49 -0.58 1.11 -0.25 1.28 
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4.2 nCounter® gene expression based signatures 
4.2.1 Patients treated with primary radiochemotherapy 
Results of the machine learning framework 
In this section, the machine learning framework is applied to the patients treated with pRCTx, 
see Table 3.1. The target endpoint for the analyses was loco-regional tumour control (LRC): 
Therefore, the 205 gene expressions, obtained via nCounter® analyses, were evaluated. 
During the pre-processing step, the genes FGFR2, ERCC4 and TAF7L were removed since 
their median expression was below twice the median of the negative controls. The 
expressions of all remaining genes were z-normalized (see 3.3.1). The mean gene 
expressions and corresponding standard deviations were stored. They will be used later to 
normalize the validation cohort’s gene expressions. Ensemble signatures were created 
using 3-fold internal cross validation repeated 333 times for signature sizes 1 up to 8. This 
led to a 𝑐𝑖 ranging from 0.51 to 0.61, presented exemplarily for signature size 5 in Figure 4.1 
(A). Based on 250 bootstrap samples of the training cohort, the created ensemble signatures 
were used to train the prognostic models. The resulting oob-𝑐𝑖 ranged from 0.51 to 0.73. 
The 𝑐𝑖 distribution over the different feature selection algorithms and prognostic models for 
signature size 5 are presented in Figure 4.1 (B). Results with the highest 𝑐𝑖 were obtained 
for the combination Net-Cox (feature selection algorithm), Cox-Regression (prognostic 
model) and signature size 5. The resulting signature consisted of PDK1, STAT3, MMP10, 
RAD51 and EPHA1. 
To improve the robustness of the signature, highly correlated genes were included, as 
described in subsection 3.3.3. The results are shown in Figure 4.2. The nSCS varied from 
0.5 (many additional genes) up to 1.0 (no additional genes) in steps of 0.05. For 
nSCS > 0.65, the 𝑐𝑖 is at its maximum and reaches a plateau. The signature does not include 
additional genes in this plateau, i.e. no additional genes were added to the signature, since 
they would decrease the performance for the training cohort. 
Finally, the ensemble signature (PDK1, STAT3, MMP10, RAD51 and EPHA1) was used to 
create a final Cox model on the entire training cohort, shown in detail in Table 4.3. To assess 
the 95%-CI of the 𝑐𝑖, the model was additionally trained on 250 bootstrap samples of the 
training cohort. Finally, the model was applied to the validation cohort to obtain the validation 
𝑐𝑖 and 250 bootstrap samples of the validation cohort to obtain its 95%-CI. The training 𝑐𝑖train 
0.75 (0.70-0.81) was higher than the validation 𝑐𝑖valid 0.45 (0.36-0.55). The model was not 
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validated successfully, since the validation 𝑐𝑖 was below 0.5 indicating an inverse behaviour 
of the model on the validation cohort compared to the training cohort. This inverse prediction 
is visible in the Kaplan-Meier estimates, too (see Figure 4.3). The predicted “high risk” 
groups have a better outcome, even though, not significantly different than the predicted 
“low risk” patient subgroup in validation. 
 
Figure 4.1. Model performances of ensemble signatures with size 5. Shown are the 
results of the internal validation of 3-fold cross validation repeated 333 times on the 
training cohort with signature size 5 (A). Based on the cross validations, ensemble 
signatures were created and tested using 250 bootstrap samples (B). The different feature 
selection algorithms and prognostic models are shown together with their corresponding 
mean concordance index and its 95%-confidence interval. 
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Figure 4.2. Signature extension of the 5-gene pRCTx signature. With increasing nSCS, 
less genes are added to the signature, until it is only the 5-gene signature without any 
extension. For each nSCS between 0.5 and 1.0 the model corresponding to the extended 
signature was created and internally validated using 250 bootstrap samples. The cioob, 
resulting out of this internal validation is shown. 
 
Table 4.3. Coefficients of the Cox regression of the 5-gene signature predicting LRC for 
patients treated with primary radio(chemo)therapy. 
Gene β Exp(β) = HR p-value 
EPHA1 0.430 1.537 0.003 
MMP10 0.464 1.590 <0.001 
PDK1 -0.428 0.652 0.008 
RAD51 -0.472 0.624 0.002 
STAT3 -0.569 0.566 <0.001 
𝑐𝑖 (95%-CI) (training) 0.75 (0.70-0.81) 
𝑐𝑖 (95%-CI) (ext. validation) 0.45 (0.36-0.55) 
Internal validation 𝑐𝑖 (95%-CI) based on bootstrap samples 
𝑐?̅?bag (95%-CI) 0.76 (0.70-0.81) 
𝑐?̅?oob (95%-CI) 0.73 (0.64-0.81) 
 
 
Discussion of the obtained 5-gene signature 
The obtained 5-gene signature failed to predict the endpoint LRC in the validation cohort, 
indicating that the signature may not be generalized. This may be due to overfitting, a bad 
gene selection or cohorts with differing clinical characteristics. According to a simple rule of 
thumb, overfitting is unlikely as 5-8 events per feature were available for the model. In the 
cohort 55 of 138 patients had a loco-regional recurrence, i.e. 6-10 parameters would be the 
upper limit.  
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Figure 4.3. Kaplan-Meier estimators of the primary training (A) and validation cohort (B) 
stratified using the 5-gene signature. Patients with a prognostic index ≤ -0.35 were 
assigned to the low risk group. The Kaplan-Meier estimators were compared using the 
log-rank test and the corresponding p-value is shown. 
 
Despite the above findings, the selected genes seem to be suitable to describe this endpoint 
at least for the training cohort. In HNSCC PDK1 is upregulated under hypoxic conditions by 
the hypoxia-inducible factor to reduce the mitochondrial oxygen consumption. The 
upregulation of PDK1 leads to a decreased conversion of pyruvate to acetyl coenzyme A, 
which is an essential part of the citric acid cycle (Kim et al., 2006; Papandreou et al., 2006). 
Wigfield et al. presented a retrospective analysis of the PDK1 amount in 140 HNSCC 
patients (Wigfield et al., 2008), where they showed an upregulation of PDK1 is correlated 
with a poorer outcome. However, while the framework selected PDK1, its coefficient in the 
Cox model assigned to the gene is negative, see Table 4.3, i.e. an upregulation would lead 
to a favourable outcome. In contrast to PDK1, the calculated coefficient of MMP10 seems 
to be suitable since its upregulation was shown to be correlated with a poorer outcome 
(Deraz et al., 2011). The expression of MMP10 is known to be correlated with tumour spread, 
i.e. tumour growth, invasion and metastasis (Deraz et al., 2011). However, the coefficient of 
STAT3 has a direction contrary to expectations. For HNSCC, higher expressions of STAT3 
in the tumour areas were reported compared to the surrounding healthy tissue. STAT3 is 
involved in the growth and survival of the tumour by inhibiting apoptosis and higher 
expressions are detrimental to the therapy outcome (Sriuranpong et al., 2003; Leeman et 
al., 2006). RAD51 is part of the DNA damage repair mechanisms of a cell (Jackson and 
Bartek, 2009; Petermann et al., 2010). It is upregulated when damages of the DNA strand, 
like double strand brakes or cross links, occur. The effect of the RAD51-expression level 
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was evaluated for several tumour types with different results. Several studies have shown 
that a high expression goes along with a poor outcome, e.g. in lung cancer (Qiao et al., 
2005; Allera-Moreau et al., 2012), oesophageal squamous cell carcinoma (Li et al., 2011) or 
colorectal adenocarcinoma (Tennstedt et al., 2013). Welsh et al. showed for 68 patients with 
glioblastoma that high levels of RAD51 were associated with a favourable outcome (Welsh 
et al., 2009). The reasons for these differences regarding the impact of RAD51 are not 
understood yet (Seelbach and Dikomey, 2014). For the primary RCT training cohort the 
multivariate model contained a negative coefficient for RAD51, indicating a high expression 
of RAD51 is correlated with a favourable outcome. EPHA1 is known to be upregulated in 
HNSCC (Lin et al., 2004), but there are no studies considering the gene expression as a 
biomarker for HNSCC. In contrast, for colorectal cancer a high expression of EPHA1 relates 
to a favourable outcome (Dong et al., 2009; Herath et al., 2009). According to the presented 
multivariate model, a high expression would lead to a higher prognostic index indicating a 
poorer outcome.  
Summing up the results of the model building process, only one of five selected genes 
behaves similarly to previous publications: MMP10. Even though some studies are based 
on different tumour entities, this might explain the lack of generalization visible in the 
validation process. 
Differences between the cohorts are another possible explanation. Three of five genes are 
expressed significantly different in both cohorts, see Table 4.4, which may be caused by 
batch effects. The tumours of the validation cohort are significantly bigger in volume 
(p = 0.003). Tumour volume belongs to the most important parameters as explained in detail 
in section 2.1.2. Furthermore, in the publication of Linge et al. it was shown that some of the 
stratification results are only valid for small tumours (Linge, Lohaus et al., 2016). 
Unfortunately, there are too few small tumours ( ≤ 19cm³) in the validation cohort to perform 
a proper validation, taking only the patients with a small tumour into account.  
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Table 4.4. Mean x̅ and median x̃ gene expressions of the final 5-gene signature are shown 
together with the corresponding standard deviation (sd) and the range of the training and 
validation cohort. The p-value is based on the Mann-Whitney-U test and significant 
differences were marked with bold font. 
Gene Training cohort Validation cohort p-value 
 ?̅? (𝑠𝑑) ?̃? (range) ?̅? (95%-CI) ?̃? (range)  
EPHA1 -4.67 (0.75) -4.63 (-6.64-(-3.03)) -4.26 (0.95) -4.16 (-9.72-(-2.21)) <0.001 
MMP10 -4.29 (1.97) -4.36 (-8.49--8.49) -3.83 (2.3) -3.67 (-8.92--8.92) 0.13 
PDK1 -3.5 (0.62) -3.55 (-4.93-(-1.74)) -3.5 (0.73) -3.45 (-5.26-(-1.42)) 0.83 
RAD51 -5.73 (0.66) -5.72 (-7.31-(-3.73)) -5.45 (0.79) -5.42 (-6.95-(-3.1)) 0.011 
STAT3 -1.45 (0.41) -1.49 (-2.86-(-0.02)) -1.72 (0.45) -1.71 (-3.16-(-0.78)) <0.001 
 
 
4.2.2 Clinical Features 
Several clinical features are known to be suitable for stratification of patients (Bernier, Hall 
et al., 2004; Sano et al., 2018). Tumour origin or the HPV status are only two example 
biomarkers that are already used for classification of patients into low and high risk groups. 
In a recent study (Linge, Lohaus et al., 2016) for the pRCTx training cohort several potential 
biomarkers were analysed using univariable Cox regression. Patients were significantly 
stratified regarding LRC according to the expression of putative CSC markers CD44, MET 
and SLC3A2, their tumour volume and their p16 status. The features that showed a 
significant p-value in the univariable Cox regression were used to create multivariate 
models. All presented models included the baseline model, consisting of three features: p16 
status (assessed by immunohistochemistry), logarithm of the tumour volume and N-stage 
(0,1 vs 2,3). The multivariate models contained additional parameters next to the baseline 
model: hypoxia status based on the 15-, 26- and 30-gene hypoxia signatures (Lendahl et 
al., 2009; Toustrup et al., 2011; Eustace et al., 2013; Toustrup et al., 2016) or putative CSC 
marker expressions. In a last step, a multivariate logistic regression was performed 
regarding the loco-regional control 2 years after the beginning of the treatment.  
In the following section, the results of the validation of the aforementioned biomarkers will 
be presented and discussed, which were also recently published  (Linge et al., 2019).  
Univariable validation of biomarkers 
For the validation, only those features were considered that showed a significant association 
to LRC or OS in the univariable Cox regressions on the training cohort. These features were 
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used to perform univariable Cox regressions based on the validation cohort. The results of 
the regressions are presented in Table 4.5. Regarding LRC, the logarithm of the volume of 
the lymph nodes and the total tumour showed a statistical trend. The significant impact of 
the logarithmised primary tumour volume (training cohort (t): HR = 1.44, p = 0.028) was not 
validated in the validation cohort (validation cohort (v): HR = 1.30, p = 0.24), even though, it 
is an accepted prognostic biomarker for patients with HNSCC (Dubben et al., 1998; Soliman 
et al., 2013; Krause et al., 2017). The corresponding patient stratification of both cohorts is 
shown in Figure 4.4. 
Table 4.5. Univariable Cox regression based on the validation cohort. For the endpoints 
loco-regional tumour control (LRC) and overall survival (OS) the hazard ratios (HR) are 
shown with the corresponding 95% confidence intervals (95%-CI). The p-values are 
marked using bold font for significant results. Furthermore, the p-values that were 
significant in the training cohort are marked via * and non-converging models are marked 
with †  (Linge et al., 2019). 
Parameter Loco-regional tumour control Overall survival 
 HR (95%-CI) p-value HR (95%-CI) p-value 
Oral cavity vs others 1.36 (0.64-2.92) 0.43 1.76 (1.02-3.03) 0.040 
N-stage (0,1 vs 2,3) 3.63 (1.10-12.00) 0.030 3.42 (1.46-7.99) 0.005* 
p16 0.78 (0.24-2.57) 0.68* 0.85 (0.36-1.98) 0.71* 
HPV16 DNA 1.13 (0.34-3.74) 0.85 1.19 (0.51-2.79) 0.68 
ln(GTV) 1.30 (0.84-2.03) 0.24* 1.53 (1.11-2.10) 0.009* 
ln(LN) 1.38 (1.06-1.80) 0.020 1.21 (1.01-1.46) 0.040* 
ln(GTVtot) 1.61 (1.00-2.60) 0.050* 1.75 (1.25-2.46) 0.001* 
CD44 protein -† -* 2.24 (0.54-9.25) 0.26* 
CD44 1.30 (0.73-2.33) 0.38 1.80 (1.16-2.79) 0.009* 
MET 1.05 (0.66-1.68) 0.83 0.85 (0.60-1.20) 0.35 
SLC3A2 1.29 (0.66-2.5) 0.46* 1.41 (0.86-2.31) 0.17 
15-gene hypoxia signature 1.89 (0.90-3.99) 0.09 2.06 (1.19-3.58) 0.010 
26-gene hypoxia signature 1.56 (0.64-3.81) 0.33 1.13 (0.62-2.07) 0.69 
30-gene hypoxia signature 1.68 (0.82-3.47) 0.16 1.18 (0.70-1.99) 0.55 
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Figure 4.4. Kaplan-Meier estimators of the primary training and validation cohort stratified 
by tumour size. The training (A) and validation pRCTx cohort (B) were stratified into 
patients with small (≤ 19 cm³) and big tumours (> 19 cm³). The cut-off (19 cm³) was 
determined on the training cohort (Linge, Lohaus et al., 2016) and then applied to the 
validation cohort (Linge et al., 2019). The Kaplan-Meier estimators were compared using 
the log-rank test and the corresponding p-value is shown. 
 
The influence of the lymph node volume on the univariable Cox regression differed between 
both cohorts. In the training cohort it did not show significant influence on LRC (t: HR = 1.06, 
p = 0.62). However, in the validation cohort it was very important in the univariable 
regression (v: HR = 1.38, p = 0.020). This may be explained by the bigger tumours of the 
pRCTx validation cohort. Even for experienced radiation oncologists it may be hard to 
distinguish between lymph nodes and primary tumour, which subsequently, can have an 
influence on the prescribed dose distribution. Lymph nodes receive in general a smaller 
dose than the primary tumour, which may cause different treatment outcome. However, the 
total volume was significantly related to LRC in the training cohort (t: HR = 1.57, p = 0.008) 
and showed a statistical trend in the validation cohort (v: HR = 1.61, p = 0.050). All volume 
parameters of the validation cohort were significantly related to the secondary endpoint OS 
as in the training cohort. 
Additionally, a logistic regression was performed using the 2-year LRC as binary endpoint 
and the primary tumour volume as a feature (AUC = 0.65), leading to similar performance 
on the validation cohort (AUC = 0.59 (0.43-0.74)), see Figure 4.5. This confirms the 
importance of the tumour volume as biomarker. The N-stage was also found to be a highly 
relevant clinical marker for both LRC and OS endpoints. 
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A tumour is considered to be HPV-driven if it is positively tested for HPV16 DNA and p16 
(Linge et al., 2018). In the training cohort the p16 status alone was already significantly 
related to LRC and OS. However, in the validation cohort p16 status was not significantly 
related to both endpoints. This may be explained by the small cohort size or the number of 
oropharyngeal tumours (t: 50% vs. v: 25%) since oropharyngeal tumours are more likely 
caused by an HPV infection, see section 2.1.1. In the training cohort, 16 patients had an 
oropharyngeal tumour with positive p16 status and 11 of them were also positively tested 
for HPV16 DNA. In the validation cohort only 5 patients with tumours arising from the 
oropharynx had a p16 positive tumour. Only 2 of those 5 were also tested positive for HPV16 
DNA. Hence, the number of HPV driven tumours is much lower in the validation cohort 
compared to the training cohort. 
Besides the p16 status and tumour volume, the study of Linge et al. (Linge, Lohaus et al., 
2016), assessed the prognostic power of hypoxia-associated gene signatures (Lendahl et 
al., 2009; Toustrup et al., 2011), gene expressions of putative CSC markers (CD44 and 
SLC3A2) and of the CD44 protein for the pRCTx training cohort. Due to the small number 
of patients with a CD44 negative tumour that showed no loco-regional recurrences (n = 5), 
CD44 protein was not validated, see Table 4.5. Still, the CD44 protein may be a very 
powerful biomarker since none of the 5 patients with a CD44 negative tumour had a loco-
regional recurrence, see Figure 4.6 (A, B). CD44 was also found to be highly significant for 
OS, based on the univariable regression analysis in both cohorts, training (HR = 1.81, 
p = 0.006) and validation (HR = 1.80 p = 0.009). The other putative CSC marker SLC3A2 
did not lead to a significant stratification for LRC and OS, even though the subgroup with a 
low SLC3A2 expression demonstrated better outcome, see Figure 4.6 (C, D). 
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Figure 4.5. Logistic regression regarding 2-year loco-regional control (LRC). The lines 
show the models that were obtained using the training cohort (Linge, Lohaus et al., 2016). 
The first row depicts the model using only the primary tumour volume as parameter, 
whereas, in the model shown in the second row the p16 and CD44 status were included 
as well. For visualisation, the patients of the training (A, C) and validation cohort (B, D) 
were grouped. In the validation cohort no patients with p16+ and CD44- were available  
(Linge et al., 2019). 
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Figure 4.6. Kaplan-Meier estimators of loco-regional control of the pRCTx cohort, 
stratified based on their CD44 protein status (A, B) and the expression of the putative CSC 
marker SLC3A2 with cut-off -3.125 (C, D). In the first column the training cohort is shown 
(Linge, Lohaus et al., 2016), whereas, the second column shows the validation cohort 
(Linge et al., 2019).. In the bottom left corner, the p-value of the log-rank test is shown   
 
The hypoxia-associated gene signatures were used to stratify the patients of the validation 
cohort into groups of more and less hypoxic patients based on the cluster centres of the 
training cohort. No significant differences between both cohorts were found, see Figure 4.7. 
The stratification was also performed, only considering patients with a small tumour (≤ 19 
cm³), see Supplementary Figure 1. Again, no significant difference was found, in contrast to 
the training cohort (Linge, Lohaus et al., 2016). This may be explained by the low number 
(n = 18) of small tumours.  
For all signatures, independent of the tumour volume, the patients of the more hypoxic 
subgroup showed in general a poorer outcome than the patients classified as less hypoxic, 
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even though this difference was not significant. The Kaplan-Meier estimates of the training 
and validation cohorts were similar, indicating that the signatures may nevertheless be 
applicable for patient stratification. A larger validation cohort is needed to evaluate the value 
of the signatures as biomarkers. This will be performed in the ongoing prospective 
HNprädBio study of the DKTK-ROG within the next years  (Linge et al., 2019). 
 
Figure 4.7. Kaplan-Meier estimators of loco-regional control of the pRCTx cohort, 
stratified into more and less hypoxic tumours based on the 15-gene (A,B), 26-gene (C,D) 
and 30-gene signature (E,F) (Lendahl et al., 2009; West et al., 2009; Sørensen et al., 
2010; Toustrup et al., 2011; Eustace et al., 2013; Toustrup et al., 2016). In the first column, 
the training cohort is shown (Linge, Lohaus et al., 2016), whereas the second column 
shows the validation cohort (Linge et al., 2019). In the bottom left corner, the p-value of 
the log-rank test is shown. 
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Multivariate validation of biomarkers 
For the training cohort, several multivariate Cox regressions were performed, based on 
different features that were significant in the univariable Cox regressions for LRC, OS and 
DM. All models were based on a baseline model including the logarithm of the primary 
tumour, the p16 status (0 vs 1) and the N-stage (0,1 vs. 2,3). Besides this baseline model, 
further models were trained that included additional features. In the first step one of the 
following features was added: CD44 protein, the gene expressions of CD44 or SLC3A2 or 
the different signature-based hypoxia classifications. In the second step, two features were 
added: one putative CSC marker gene expression and one hypoxia signature were added. 
Lastly, two features and the interaction between hypoxia and tumour volume were included 
in the model. For each model, the 𝑐𝑖 was calculated based on the whole training and 
validation cohort and the 95%-CI was assessed based on 1000 bootstrap samples of each 
cohort. The results are summarized for the primary endpoint LRC in Table 4.6 and the 
secondary endpoint OS in Table 4.7. 
The multivariate models performed in general better for OS than for LRC. A reason may be 
that death was more common than loco-regional failure during the follow up. A higher event 
rate can improve the quality of the resulting model. The baseline model performed well in 
the validation cohort but was only validated successfully for OS (LRC: 𝑐𝑖 = 0.59 (0.49-0.70), 
OS: 𝑐𝑖 = 0.63 (0.55-0.71)). The OS baseline model performed similarly in the training and 
validation cohort, indicating a good performance in general, i.e. low overfitting and a good 
generalisability of the model. The inclusion of further features improved the performance for 
all models in the training cohort, see Table 4.6. This is expected since more features allow 
for a higher adaption to the data. The inclusion of CD44 protein and CD44 gene expression 
improved the model performance for LRC and did not seem to overfit the training data. Both 
models, including CD44 protein (𝑐𝑖 = 0.62 (0.51-0.72)) and CD44 gene expression (𝑐𝑖 = 0.61 
(0.50-0.72)), was validated successfully. Similar results were obtained for the secondary 
endpoint OS. Models containing CD44 protein or CD44 gene expression led to the best 
performing results in the validation cohort. 
The multivariate logistic regression model was validated with success, too. In the training 
cohort, 2-year LRC improved for patients with CD44 negative tumours. The validation was 
not performed for those CD44 negative tumours due to the lack of patients: no patient with 
a p16 positive and CD44 negative tumour was available and no patient with p16 negative 
and CD44 negative tumour had a loco-regional recurrence during the 2 years after the 
beginning of treatment. The other risk groups with CD44 positive tumours in validation 
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matched with the trained model, see Figure 4.5. The results of the Cox regressions and of 
the logistic regression underline that CD44 protein and the CD44 gene expression are 
promising candidates as biomarkers for LRC (de Jong, Pramana, van der Wal et al., 2010). 
The other biomarkers, i.e. the hypoxia-associated gene signatures and SLC3A2, showed 
worse results than CD44. Especially the models with more than 4 features showed a lower 
𝑐𝑖valid compared to the 𝑐𝑖train, which may indicate overfitting. 
 
Table 4.6. Results of multivariate Cox regression predicting loco-regional tumour 
control (LRC) for the training cohort and the validation cohort (Linge et al., 2019). The 
performance of each model was assessed using the concordance index ci. Confidence 
intervals and significance were assessed based on 1000 bootstrap samples of the training 
or validation cohort, respectively. Significant p-values are marked via bold font. 
 Training cohort Validation cohort 
 𝒄𝒊 (95% CI) p-value 𝒄𝒊 (95% CI) p-value 
Baseline (BL): N-stage, p16, lnGTV 0.64 (0.56-0.71) <0.01 0.59 (0.49-0.70) 0.09 
BL, CD44 0.66 (0.59-0.75) <0.01 0.62 (0.50-0.73) 0.046 
BL, CD44 0.64 (0.58-0.72) <0.01 0.61 (0.50-0.72) 0.046 
BL, SLC3A2 0.65 (0.59-0.73) <0.01 0.58 (0.49-0.67) 0.09 
BL, 15-gene hypoxia signature,  
15-gene hypoxia signature * lnGTV 
0.63 (0.58-0.73) <0.01 0.54 (0.43-0.65) 0.50 
BL, 30-gene hypoxia signature,  
30-gene hypoxia signature * lnGTV 
0.62 (0.58-0.73) <0.01 0.59 (0.48-0.69) 0.12 
BL, 15-gene hypoxia signature,  
15-gene hypoxia signature * lnGTV, 
SLC3A2 
0.66 (0.62-0.75) <0.01 0.56 (0.45-0.66) 0.29 
BL, 30-gene hypoxia signature,  
30-gene hypoxia signature * lnGTV, 
SLC3A2 
0.66 (0.61-0.75) <0.01 0.60 (0.49-0.70) 0.07 
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Table 4.7. Results of multivariate Cox regression predicting overall survival (OS) for the 
training cohort and the validation cohort (Linge et al., 2019). The performance of each 
model was assessed using the concordance index ci. Confidence intervals and 
significance was assessed based on 1000 bootstrap samples of the training or validation 
cohort, respectively. Significant p-values are marked via bold font. 
 Training cohort Validation cohort 
 𝒄𝒊 (95% CI) p-value 𝒄𝒊 (95% CI) p-value 
Baseline (BL): N-stage, p16, lnGTV 0.68 (0.62-0.75) <0.01 0.63 (0.55-0.71) <0.01 
BL, CD44 0.71 (0.65-0.78) <0.01 0.65 (0.56-0.73) <0.01 
BL, CD44 0.68 (0.62-0.75) <0.01 0.69 (0.61-0.76) <0.01 
BL, SLC3A2 0.67 (0.62-0.74) <0.01 0.65 (0.57-0.73) <0.01 
BL, 15-gene hypoxia signature,  
15-gene hypoxia signature * lnGTV 
0.68 (0.62-0.75) <0.01 0.60 (0.52-0.68) 0.02 
BL, 30-gene hypoxia signature,  
30-gene hypoxia signature * lnGTV 
0.69 (0.63-0.75) <0.01 0.63 (0.54-0.71) <0.01 
BL, 15-gene hypoxia signature,  
15-gene hypoxia signature * lnGTV, 
CD44 
0.68 (0.63-0.76) <0.01 0.66 (0.58-0.74) <0.01 
BL, 30-gene hypoxia signature,  
30-gene hypoxia signature * lnGTV, 
CD44 
0.69 (0.64-0.76) <0.01 0.70 (0.61-0.77) <0.01 
 
 
4.2.3 Signature extension using clinical features 
In the previous sections a gene signature was developed, and multiple clinical biomarkers 
were investigated. Even though the gene signature did not perform well, it may be possible 
to improve stratification by combining genetic and clinical features. Therefore, the signatures 
that were identified without including clinical biomarkers were added to the baseline model 
containing N-stage, p16 status and the logarithm of the GTV. It was very unlikely that this 
would improve the stratification, since the gene signature was anti-predictive in the validation 
cohort, see section 4.2.1. 
Gene expression and clinical features 
The baseline Cox model trained by Linge et al. (Linge, Lohaus et al., 2016) was extended 
by the genetic signature obtained in section 4.2.1 consisting of PDK1, STAT3, MMP10, 
RAD51 and EPHA1. Due to missing clinical parameters in 10 of the 138 patients with 
available nCounter® measurements, the normalization of the features was repeated for the 
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128 patients. Briefly, the mean and standard deviation of each gene expression was 
calculated, and the gene expressions of the training cohort were z-normalized. The gene 
expressions of the validation cohort were normalized using the means and standard 
deviations of the training cohort. The results for the complete model, based on gene 
signature and clinical parameters, are presented in Table 4.8. The simple combination of 
gene signature and clinical features did not improve the validation result (𝑐𝑖 = 0.47 (0.37-
0.57)). 
Table 4.8. Coefficients of the Cox regression model of the 5-gene signature for prediction 
of LRC in patients treated with primary radio(chemo)therapy. Significant p-values are 
marked via bold font. In the bottom part of the table performance of the Cox regression 
evaluated by the ci in the training cohort (internal validation) and on the validation cohort 
(ext. validation). For the interval validation and the 95% concordance index (95%-CI) 250 
bootstraps were performed. 
Gene β Exp(β) = HR p-value 
EPHA1 0.427 1.533 0.004 
MMP10 0.424 1.529 0.006 
PDK1 -0.474 0.622 0.005 
RAD51 -0.478 0.620 0.004 
STAT3 -0.457 0.633 0.003 
N-stage 0.456 1.578 0.23 
p16 -0.651 0.522 0.30 
lnGTV -0.027 0.974 0.90 
𝑐𝑖 (95%-CI) (training) 0.76 (0.72-0.83) 
𝑐𝑖 (95%-CI) (ext. validation) 0.47 (0.37-0.57) 
Internal validation 𝑐𝑖 (95%-CI) based on bootstrap samples 
𝑐?̅?bag (95%-CI) 0.78 (0.72-0.83) 
𝑐?̅?oob (95%-CI) 0.71 (0.61-0.81) 
 
 
4.2.4 Patients treated with postoperative radiochemotherapy 
For the patients treated with PORT-C only the 130 patients with HPV16 DNA negative 
tumours, see Table 3.2, were considered for analyses since HPV16 DNA status was already 
known to be a strong prognostic biomarker. This was presented earlier for the training 
(Lohaus et al., 2014) and validation cohort (Linge, Löck, Krenn et al., 2016). The 
development of a 7-gene signature predictive for LRC in these patients and its validation 
was presented in (Schmidt et al., 2018). 
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7-gene signature predicts LRC for HPV16 DNA negative tumours 
The same analysis steps as presented previously for the pRCTx cohorts, were performed 
including pre-processing, the signature development including model training and the 
validation of the signature. 171 genes obtained via nCounter® analyses were evaluated. 
During pre-processing, the genes FGFR2, PROM1 and TAF7L were removed since their 
median expression was below twice the median of the negative controls and the expressions 
of all remaining genes were z-normalized (see 3.3.1). The mean gene expressions and the 
corresponding standard deviations were stored for the validation. Afterwards, feature 
selection and internal 333 times repeated 3-fold CV was performed to identify potential 
signature genes (signature size 1 to 10). The resulting mean validation 𝑐𝑖 ranged from 0.57 
to 0.68 and was similar between different feature selection methods and statistical models. 
The results for signature size 4 are shown in Figure 4.8 A since the models with this 
signature size showed the best performance. The ensemble signatures, consisting of the 
highest ranked genes for each feature selection algorithm and model combination, were 
composed and used to create models based on 1000 bootstrap samples of the whole 
training cohort. The best results were obtained for signature size 4 and the corresponding 
mean 𝑐𝑖oob are shown in Figure 4.8 B. The highest mean 𝑐𝑖oob (𝑐𝑖oob = 0.78) was obtained 
for a signature that included the 4 genes SERPINE1, CD24, HILPDA and TCF3 for several 
combinations of feature selection algorithms and prognostic models. The Cox regression 
was finally chosen, since the performance was similar to that of the other models, but it has 
the advantage of being easy to interpret and is commonly known. 
An importance score was assigned to each gene based on the feature selection algorithm 
and prognostic model, which describes the importance of the genes for predicting LRC, see 
Figure 4.9. SERPINE1 showed the lowest importance score (most important) and the 
importance score of the other 3 genes were similar. In the next step, additional genes were 
added to the signature to improve the robustness of the model. For nSCS values (see 
section 3.3.3) ranging from 0.5 to 1.0, genes highly correlated to one gene of the signature, 
shown in Table 4.9, were used to form metagenes. The modified signatures, now created 
out of the metagenes, were used to train Cox models based on 1000 bootstrap samples. 
The corresponding 𝑐𝑖oob are shown in the last row of Table 4.9. The best results were 
obtained for the nSCS of 0.70. Hence, the final signature consists of the genes CD24, TCF3 
and HILPDA as well as the median expression of SERPINE1, INHBA, ACTN1 and P4HA2. 
This signature will be referred to as the 7-gene signature. 
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Figure 4.8. Performance of different feature selection algorithms and prognostic models 
for signature size 4. A Results of 3-fold internal cross validation repeated 333 times with 
signature size 4. B Results for the selected ensemble signatures based on the oob-data 
of 1000 bootstrap samples. For each mean concordance index, its 95%-confidence 
interval is shown (Schmidt et al., 2018). 
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Figure 4.9. Importance score for genes associated with loco-regional tumour control. The 
most important genes (lowest score) for the prediction of loco-regional tumour control of 
the training cohort are shown with their importance score, based on MRMR feature 
selection and the Cox regression model. The black dashed line indicates the cut-off 
leading to the 4-gene ensemble signature (Schmidt et al., 2018). 
 
The 7-gene signature was used to train the final Cox model based on the whole training 
cohort (130 HPV16 DNA negative tumours), resulting in a 𝑐𝑖 of 0.81 (95% CI: 0.75-0.88). 
The model parameters are shown in Table 4.10. Furthermore, the model was validated using 
the validation cohort. The gene expressions in the validation cohort were normalized based 
on the gene expressions of the training cohort. Subsequently, the metagene was calculated 
and the final model was applied. Validation was successful, 𝑐𝑖 = 0.69 (0.60-0.77). 
The Cox model assigns a prognostic index to each patient, provided by the linear predictor. 
Based on this prognostic index the patients of the training cohort with HPV16 DNA negative 
tumours were assigned into groups of low and high risk of loco-regional tumour recurrence. 
Based on 1000 bootstrap samples of the training cohort, all possible cut-offs were applied 
to stratify the patients. The best cut-off was chosen as 0.10, leading to the highest fraction 
of patient stratifications with a significant difference in LRC (992/1000), see section 3.3.4. 
The corresponding Kaplan-Meier estimators of the patients of the training and validation 
cohort are shown in Figure 4.10. In both cohorts, the low risk groups had a significantly better 
LRC than the high risk groups (training cohort: p < 0.001, validation cohort: p = 0.001), even 
though the distribution of patients of the validation cohort into low and high risk differed 
compared to the training cohort. The HPV16 DNA positive patients are shown as a third risk 
group in addition to the low and high risk groups in Figure 4.10. For the training cohort, the 
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low risk group of patients with HPV16 DNA negative tumours was similar to the patients with 
HPV16 DNA positive tumours, while larger differences were visible for the validation cohort. 
 
Table 4.9. Adding highly correlated genes to increase the robustness of the signature. 
The mean out-of-the-bag validation 𝑐𝑖oob̅̅ ̅̅ ̅̅  and its 95% confidence interval (CI) (last column) 
of the training cohort is shown depending on the normalized signature correlation score 
(nSCS). In each row more genes are added to the 4-gene signature for loco-regional 
tumour control with decreasing nSCS. The genes that enter the signature are shown up 
to the row of the corresponding nSCS, e.g. for nSCS = 0.6, the HILPDA metagene is 
constructed out of HILPDA and ADM, whereas, for nSCS = 0.55 the same metagene is 
constructed out of HILPDA, ADM and ANKRD37. The 𝑐𝑖oob̅̅ ̅̅ ̅̅  represents the internal 
validation performance of the signature model combination and the combination with the 
highest 𝑐𝑖oob̅̅ ̅̅ ̅̅  (at nSCS = 0.70) was chosen (Schmidt et al., 2018). 
nSCS CD24 TCF3 HILPDA SERPINE1 (95% CI) 
≥ 0.8     0.78 (0.71-0.92) 
0.75    INHBA 0.78 (0.71-0.93) 
0.7    ACTN1, P4HA2 0.79 (0.71-0.92) 
0.65    MMP13, PLAU 0.79 (0.70-0.92) 
0.6   ADM 
ANXA5, FN1, 
FOSL1, LOXL2, 
MMP2 
0.78 (0.70-0.92) 
0.55  
E2F1, 
RAD51 
ANKRD37 
DCBLD1, ITGB1, 
LGALS1, LOX 
0.74 (0.63-0.89) 
0.5  
CHEK2, 
FGF2, 
MCM6, 
RIBC2 
ANGPTL4, 
BNIP3L, 
VEGFA 
CAV1, MMP2, 
SLC16A1, TIMP2 
0.74 (0.63-0.89) 
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Table 4.10. Coefficients of the Cox regression of the final 7-gene signature predicting LRC 
for patients treated with primary radio(chemo)therapy. META(SERPINE1) is constructed 
out of the median gene expression of SERPINE1, INHBA, P4HA2 and ACTN1 (Schmidt 
et al., 2018). Significant p-values are marked via bold font. In the bottom part of the table, 
the performance of the Cox regression evaluated by the ci in the training cohort (internal 
validation) and in the validation cohort is shown. For the internal validation and the 95% 
confidence interval (95%-CI), 1000 bootstraps were performed. 
Gene β Exp(β) = HR p-value 
HILPDA 0.392 1.480 0.0049 
META(SERPNE1) 0.757 2.132 0.012 
TCF3 -0.618 0.539 0.017 
CD24 -0.348 0.706 0.072 
𝑐𝑖 (95%-CI) (training) 0.81 (0.75-0.88) 
𝑐𝑖 (95%-CI) (ext. validation) 0.69 (0.60-0.77) 
Internal validation 𝑐𝑖 (95%-CI) based on bootstrap samples 
𝑐𝑖bag̅̅ ̅̅ ̅̅  (95%-CI) 0.82 (0.75-0.88) 
𝑐𝑖oob̅̅ ̅̅ ̅̅  (95%-CI) 0.79 (0.71-0.92) 
 
 
 
Figure 4.10. Kaplan-Meier estimators of loco-regional tumour control for the patients of 
the PORT-C cohorts (A: training, B: validation). The patients with a prognostic index 
smaller than 0.10 were assigned to the low risk group. The Kaplan-Meier estimators of the 
low and high risk group were compared with a log-rank test, which is shown in the left 
corner. The patients with HPV16 DNA positive tumours are shown as additional risk group 
(Schmidt et al., 2018). 
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Discussion of the 7-gene signature 
A 7-gene signature was identified to stratify patients with a HPV16 DNA negative HNSCC 
who were treated with PORT-C into groups with low and high recurrence risks. The signature 
contains the genes SERPINE1 (also known as PAI-1), INHBA, ACTN1 and P4HA2 
combined into a single metagene due to their high mutual correlation, as well as the 
individual genes CD24, TCF3 and HILPDA (also known as HIG2). 
Pavón et al. have shown in a prospective clinical study with 190 patients that SERPINE1 is 
related to a poor treatment outcome, including loco-regional recurrences, as well as poor 
survival (Pavón et al., 2015). Furthermore, SERPINE1 is involved in an increased cell 
proliferation and migration and an increased resistance against apoptosis induced by 
cisplatinum (Pavón et al., 2015; Pavón et al., 2016). In a xenograft study of Bayer et al., an 
overexpression of SERPINE1 before therapy was correlated with reduced local tumour 
control after therapy (Bayer et al., 2008). SERPINE1, INHBA, P4HA2 and HILPDA are 
induced by HIF1 - the hypoxia inducible factor 1 -and lead to extracellular matrix remodelling 
(Kietzmann et al., 1999; Gilkes et al., 2013; Depoix et al., 2017). In previous publications a 
functional association was shown between SERPINE1 and INHBA (Yue-Hong Wang et al., 
2014) and SERPINE1 and ACTN1 (Menicanin et al., 2009). P4HA2 and HILPDA were also 
included in the 15- and 26-gene hypoxia-associated signatures, presented in chapter 2.1.2 
(Toustrup et al., 2011; Eustace et al., 2013). Furthermore, HILPDA is reported to enhance 
invasion and proliferation (Mao et al., 2016). These results are in line with the positive 
coefficients that were assigned to HILPDA and the metagene in the Cox regression model 
(Table 4.10), indicating an increased risk with increasing expression. 
Regarding CD24, there are conflicting results. For some tumour entities like cervical or 
breast cancer, a high expression of CD24 was reported to be involved with increased tumour 
progression and growth (Lee et al., 2009), cisplatinum resistance (Modur et al., 2016) or a 
decreased progression free survival (Smith et al., 2006; Lee et al., 2009). However, Fugle 
et al. reported a better survival for a patient with oral carcinoma and CD24 overexpression 
(Fugle et al., 2016). They also showed that the progression of oral cavity cancer can be 
correlated with the lack of the surface protein CD24, which caused an immunosuppressive 
CD11b+Gr1+ myeloid cell population. In summary, the effect of a CD24 overexpression is 
unclear. The results of this thesis for HNSCC indicate that an overexpression of CD24 is 
related to a reduced risk of recurrence, in line with the findings of Fugle et al. (Fugle et al., 
2016).  
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This is the first study to link TCF3 to recurrence in HNSCC (Schmidt et al., 2018). Therefore, 
its role in HNSCC needs to be analysed in further studies. However, it was reported to be 
important for cell signalling (Zhang et al., 2012), cell migration and wound repair (Miao et 
al., 2014). In this thesis an increased amount of TCF3 led to a decreased prognostic index, 
indicating an improved loco-regional control, which may be explained by the suppression of 
self-renewal genes (Yi et al., 2008). 
4.2.5 Signature extension using clinical features – Port-C 
PORT-C stratification based only on clinical features 
For the training cohort the importance of additional biomarkers regarding LRC, such as 
tumour localization or the ECE-status, was shown (Lohaus et al., 2014; Linge, Löck, Gudziol 
et al., 2016). Now, the performance of a model based on those clinically established 
biomarkers shall be compared with the performance of the gene signature obtained 
previously. 
As explained in section 2.1.2, HNSCC can arise from different regions belonging to the wide 
“head and neck region”. Tumours arising from the oral cavity, typically have a poorer 
outcome than the other tumours (Lohaus et al., 2014). The feature “arose from oral cavity” 
(yes = 1, no = 0) was selected as a binary localisation feature. A simple Cox regression was 
performed based on the two binary features: ECE-status and localisation, resulting in a 
model with a decent performance for the training cohort: 𝑐𝑖 = 0.61 (0.53-0.74) that was 
confirmed in the validation cohort: 𝑐𝑖 = 0.66 (0.57-0.74).  
However, even though the model was validated, the gene signature based model performed 
better on the validation cohort (𝑐𝑖 = 0.69). This may be explained by a better performance of 
the gene signature in general. On the other hand, this may also be based on a characteristic 
of the 𝑐𝑖: The 𝑐𝑖 compares the prognostic indices assigned by the Cox regression and the 
corresponding times of survival. For 2 binary features a and b only 4 scores are possible, 
based on the combinations: 0, a, b and a+b. Consequently, there are many comparisons 
with a tied score leading to a lower 𝑐𝑖.  
The 7-gene signature combined with clinical features  
In the next step, the gene signature and clinical features were combined. Since both models 
showed a good performance, a combined model may improve prognosis further. 
Furthermore, the shortcoming of the 𝑐𝑖 related to the binary features will be less important 
since they are combined with continuous features. 
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A multivariate Cox regression was performed with the 7-gene signature, i.e. HILPDA, TCF3, 
CD24 and the metagene of SERPINE1, INHBA, P4HA2 and ACTN1 as well as the 
localisation (arose from oral cavity) and ECE-status. The combined model showed a training 
𝑐𝑖 = 0.82 (0.77-0.89) and a validation 𝑐𝑖 = 0.71 (0.62-0.78). As for the other models, the 𝑐𝑖 
was based on the whole training or validation cohort, respectively, while the 95%-CI was 
based on 1000 bootstrap samples of the particular cohort. The parameters of the Cox 
regression are shown in Table 4.11. The addition of clinical parameters did not change the 
regression coefficients of the 7-gene signature considerably, which may indicate that the 
clinical features do not add additional information to the model. This is also underlined by 
the low correlation between the gene expressions and the clinical features, shown for the 
whole cohort and the HPV16 DNA negative patients in Supplementary Table 6. However, 
the clinical features showed no significant correlation to LRC, see Table 4.11. 
 
 
Table 4.11. Coefficients of the Cox regression of the final 7-gene signature predicting LRC 
for patients treated with postoperative radio(chemo)therapy. META(SERPINE1) denotes 
the median gene expression of SERPINE1, INHBA, P4HA2 and ACTN1. Significant p-
values are marked via bold font. In the bottom part of the table, the performance of the 
Cox regression is evaluated by the ci in the training cohort (internal validation) and on the 
validation cohort. For the interval validation and the 95% confidence interval (95%-CI), 
1000 bootstraps were performed.  
Gene β Exp(β) = HR p-value 
HILPDA 0.417 1.518 0.041 
META(SERPNE1) 0.683 1.980 0.026 
TCF3 -0.594 0.552 0.031 
CD24 -0.366 0.693 0.083 
ECE-Status 0.336 1.400 0.43 
Localisation (Oral cavity) 0.242 1.274 0.61 
𝑐𝑖 (95%-CI) (training) 0.82 (0.77-0.89) 
𝑐𝑖 (95%-CI) (ext. validation) 0.71 (0.62-0.78) 
Internal validation 𝑐𝑖 (95%-CI) based on bootstrap samples 
𝑐𝑖bag̅̅ ̅̅ ̅̅  (95%-CI) 0.83 (0.77-0.88) 
𝑐𝑖oob̅̅ ̅̅ ̅̅  (95%-CI) 0.76 (0.62-0.87) 
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The prognostic indices assigned by the Cox regression were used to stratify the patients into 
low and high risk groups. An optimal cut-off based on the obtained prognostic indices of the 
training cohort was determined by evaluating each possible cut-off as described in section 
3.3.4. The optimal cut-off was determined at 0.37, i.e. every patient with a smaller prognostic 
index than 0.37 is considered as a low risk patient. The same stratification was performed 
on the validation cohort and the results are shown in Figure 4.11 A and B. For both cohorts 
the stratifications are highly significant with p < 0.001 and the confidence interval of the 𝑐𝑖 is 
above 0.5. The validation was successful. However, as for the 7-gene signature alone the 
resulting risk groups of the validation cohort were imbalanced. This may be caused by shifts 
in the gene expressions shown in Table 4.12, and will be discussed later in detail. 
As the validation cohort precedes the training cohort by several years (t: 2004-2012, v: 1999-
2006, see Table 3.2 and Supplementary Table 3), treatment options differed between 
cohorts. An example is the use of chemotherapy, which was performed for all patients of the 
training cohort, but only for 31 of 121 patients of the validation cohort. Therefore, validation 
was also performed separately for this subgroup leading to a 𝑐𝑖 = 0.72 (0.43-0.90). While 
 
Figure 4.11. Kaplan-Meier estimators of loco-regional tumour control for the patients 
treated with PORT-C stratified using the 7-gene signature extended with clinical features. 
The patients of the training (A) and validation cohort (B, C) were assigned to different 
groups: HPV pos. – the patients with HPV16 DNA positive tumours; low risk (LR) – the 
HPV 16 DNA negative patients with a prognostic index ≤ 0.37 and high risk (HR) – the 
patients with a prognostic index > 0.37. The validation cohorts’ gene expressions are 
normalized based on the training cohort (B) or to mean 0 and standard deviation 1 (C) 
(Schmidt et al., 2018). 
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the 𝑐𝑖 was slightly higher than for all validation patients, the model was not validated for that 
subgroup, due to the low number of patients included in that group leading to large 
confidence intervals. Regarding the stratification in low and high risk groups – 24/31 patients 
were considered as high risk group, including 4/6 patients with a local recurrence.  
Another reason for the different patient stratification between the training and validation 
cohort may be the molecular analyses. Even though both analyses were performed as 
nCounter® gene expression analyses, the gene-panel composition differed. The CD44 
probe design of the training cohort was invalid and some other genes were exchanged after 
the PORT-C (training) cohort analyses were finished. A degradation of the tissue of the 
samples due to the long storage time is unlikely, which will be discussed later in section 5.1. 
Table 4.12. Mean x̅ and median x̃ gene expressions of the final 7-gene signature are 
shown together with the corresponding standard deviation (sd) and the range of the 
training and validation cohort (patients with HPV16 DNA negative tumours only). The p-
value is based on the Mann-Whitney-U test and significant differences are marked with 
bold font. 
Gene Training cohort Validation cohort p-value 
 ?̅? (sd) ?̃? (range) ?̅? (sd) ?̃? (range)  
ACTN1 
-0.89  
(0.74) 
-0.9  
(-2.40-1.13) 
-0.82  
(0.76) 
-0.78  
(-2.85-0.76) 
0.45 
CD24 
-6.63  
(0.87) 
-6.62  
(-10.3-(-2.50)) 
-5.12  
(0.87) 
-5.27  
(-6.93-(-2.17)) 
<0.001 
HILPDA 
-4.20  
(0.91) 
-4.29  
(-5.68-(-1.99)) 
-3.66  
(0.95) 
-3.79  
(-6.21-(-1.14)) 
<0.001 
INHBA 
-2.23  
(1.61) 
-2.01  
(-7.94-(0.83)) 
-1.38  
(1.37) 
-1.15  
(-5.25-1.3) 
<0.001 
P4HA2 
-2.92  
(0.71) 
-4.16  
(-5.67-(-2.85)) 
-2.47 
 (0.67) 
-4.18 
(-5.61-(-2.37)) 
<0.001 
SERPINE1 
-1.44 
 (1.52) 
-1.36  
(-5.84-2.64) 
-0.92  
(1.52) 
-0.84  
(-4.60-2.06) 
0.008 
TCF3 
-3.29  
(0.55) 
-3.35  
(-4.57-(-0.23)) 
-2.28  
(0.67) 
-2.35  
(-3.60-0.24) 
<0.001 
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Comparison to previously defined models 
In previous publications of Linge et al. they showed and validated the prognostic value of 
CSC markers and the hypoxia-associated gene signatures for the patients of the PORT-C 
training cohort with HPV16 DNA negative tumours (Linge, Löck, Gudziol et al., 2016; Linge, 
Löck, Krenn et al., 2016). The best performing model consisted of the two clinical parameters 
ECE-status, tumour localization (oral cavity vs other) and binary classifiers based on CD44 
(> 0.2) and the 15-gene hypoxia-associated signature (Toustrup et al., 2011). A Cox 
regression was performed using these parameters. The model was applied to the whole 
validation cohort and 1000 bootstraps samples of the cohort, resulting in a successful 
validation (𝑐𝑖 = 0.65 (0.54-0.74)). However, the combination of 7-gene signature and clinical 
parameters performed better, indicated by the higher validation 𝑐𝑖 = 0.71. 
Renormalization of the validation cohort 
The genes selected in the 7-gene signature showed significantly different expressions 
between the training and validation cohort, see Table 4.12. The Cox model is a linear model 
and those differences will be directly translated to the prognostic index. The standard 
deviations of the gene expressions were similar between both cohorts, but the mean gene 
expressions were different.  
The risk of the validation cohort is shifted towards lower values, i.e. more patients are 
regarded as low risk patients. The application of a cut-off, however, is based on the 
assumption of similar gene expressions in both cohorts. To fulfil the assumption of similar 
expressions, Chen et al. proposed a procedure to remove batch effects, which adjusts the 
gene expressions to the same scale (Chen et al., 2011). Therefore, the genes of the 
validation cohort were z-normalized based on their mean gene expressions and standard 
deviations. The 7-gene signature was applied to the z-normalised validation data, and the 
cohort was split using the cut-off 0.37. The results are shown in Figure 4.11 C. Now both 
cohorts are nearly equally sized, like the training cohort (compare Figure 4.11 A and C). Still, 
the low and high risk groups show a significant difference in LRC.  
Application of the combined model to other endpoints 
In the previous sections, a signature that allows the stratification of patients into groups with 
low and high risk of loco-regional recurrence was developed. In this subsection, the 
performance of the signature regarding the secondary endpoints OS and DM will be 
evaluated. 
 Identification of gene expression signatures as prognostic biomarkers 
 nCounter® gene expression based signatures 
77 
The 7-gene signature was used to train a multivariate Cox regression model using the 
PORT-C patient cohorts with respect to the secondary endpoints OS and DM. The results 
of the multivariate regressions are shown in Supplementary Table 7 (OS) and 
Supplementary Table 8 (DM). Regarding OS, the model reached 𝑐𝑖 = 0.67 (0.61-0.75) in the 
training and 𝑐𝑖 = 0.62 (0.55-0.69) in the validation cohort. The 𝑐𝑖 of the models trained for 
DM were slightly lower with 𝑐𝑖 = 0.60 (0.56-0.73) for the training and 𝑐𝑖 = 0.59 (0.51-0.69) 
for the validation cohort. 
Furthermore, combined multivariate Cox model was trained based on the combination of 
gene signature and clinical parameters localisation and ECE-status. This combined model 
showed an increased performance compared to the models based on clinical factors or the 
7-gene signature alone (OS: t: 𝑐𝑖 = 0.71 (0.65-0.79); v: 𝑐𝑖 = 0.64 (0.57-0.70); DM: t: 𝑐𝑖 = 0.69 
(0.64-0.80), v: 𝑐𝑖 = 0.63 (0.52-0.73)). The results are also presented in Supplementary Table 
7 (OS) and Supplementary Table 8 (DM). The corresponding stratifications are shown in 
Figure 4.12 (OS: A, B; DM: C, D). Both stratifications were significant in training and 
validation. Furthermore, the imbalance between the different risk groups in training and 
validation cohort was lower compared to LRC. 
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Figure 4.12. Kaplan-Meier estimators of loco-regional tumour control for the patients 
treated with PORT-C stratified using the 7-gene signature extended with clinical features 
applied to the secondary endpoint overall survival (OS) and freedom from distant 
metastasis (DM). For OS, the cut-off 0.60 was applied to the training (A) and validation 
cohort (B). For DM, the cut-off 0.71 was applied to the training (C) and validation cohort 
(D). The HPV16 DNA positive patients are shown for comparison (Schmidt et al., 2018). 
 
4.3 GeneChip® gene expression-based signatures 
4.3.1 Pre-selection 
Besides the nCounter measurements, gene expressions were also obtained using 
GeneChip® analyses. As described in section 2.4.3, a single GeneChip® measurement 
reveals the expression of several thousand genes simultaneously. This is a two-edged 
sword: On the one hand, unknown genes and new pathways can be identified. On the other 
hand, there are over 10000 possible genes and less than 100 events. From a statistical 
perspective, it is very unlikely not to find a highly significant set of genes for a certain 
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outcome. The selection process in this thesis is based on statistical correlation but not on a 
functional correlation. Thus, it may be possible to select only genes which show a high 
statistical correlation in the training cohort but have no relation to HNSCC development or 
radiochemosensitivity. Such genes would not be appropriate to create a generalizable 
model. 
Several thousand genes obtained in the analyses are not known to be correlated with 
HNSCC specific properties. If the feature selection algorithm would select those genes, the 
connection would likely be random instead of functional. To decrease the chance of selecting 
those irrelevant genes, a pre-selection based on the databases Gene Ontology (Ashburner 
et al., 2000; The Gene Ontology Consortium, 2019) and gene enrichment set analyses 
(GESA) (Mootha et al., 2003; Subramanian et al., 2005) was performed. A subset of 3085 
genes was selected. All genes were reported to be connected to cell cycle regulation, 
proliferation, invasion, metastases, epithelial-mesenchymal transition, immune response, 
tumour hypoxia, CSC, DNA repair or resistance against chemotherapy or radiation. The 
used sets are shown in Supplementary Table 9. 
The reduced set of 3085 genes was put into the framework to identify gene signatures and 
prognostic models. Even though, several thousand genes were already dismissed, the 
remaining set of 3085 genes may still include irrelevant features. Therefore, an additional 
pre-selection step (filtering) was added in the framework before the feature selection. The 
framework includes two different filtering methods: a univariable regression and a variance 
filter, see page 27. 
Discussion of the results 
The previously presented models and signatures obtained from nCounter® measurements 
were validated using a independent validation cohorts (section 4.2). Unfortunately, no 
validation data were available for the GeneChip® measurements and no independent 
validation could be performed. However, the performance of the internal validation of the 
models will be compared to the models reported previously.  
4.3.2 Patients treated with primary radiochemotherapy 
Model training 
The models based on nCounter® measurements did not perform well, neither the gene 
signatures nor the combination of signature and clinical features. The GeneChip® 
measurements may provide additional information due to the increased number of available 
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features. Both pre-selection filters were applied to the 3085 selected genes. The variance 
filter kept the 200 genes with the largest variance, whereas, the univariable regression kept 
genes with a with p < 0.1 in Cox regression for LRC. Subsequently, the best signature size, 
gene signature and prognostic model were identified for the endpoint LRC as described for 
the nCounter® data. Briefly, 111 times repeated 3-fold CV were performed. On each of the 
resulting 333 subsets a signature with a predetermined size was selected based on the 
feature selection algorithm and the signature was used to train a prognostic model. The 
signature size was varied between 3 and 7 genes. Based on the validation folds of the 3-
fold CV, the ensemble signatures were determined. Subsequently, 200 bootstrap samples 
were created to compare the performance of the determined ensemble signatures and the 
corresponding prognostic model using the out-of-the-bag (oob) data by calculating the 𝑐𝑖oob̅̅ ̅̅ ̅̅ . 
In general, the slightly better results for predicting LRC were obtained using the data filtered 
by the univariable filter, e.g. the potential signatures obtained by the variance filter showed 
a higher variability after the cross validation. This was indicated by more genes occurring as 
potential candidates with a higher signature importance score compared to the univariable 
filter based selections. Hence, the univariable filter was selected to create the signature. The 
best internal validation 𝑐𝑖oob̅̅ ̅̅ ̅̅  was achieved with signature size 6. In Figure 4.13 the results 
of the bootstraps for signature size 5 (Figure 4.13 A) and 6 (Figure 4.13 B) are shown. Two 
different signature model combinations seem to give the most promising results MRMR & 
Surv.-Regr. and Net-Cox & Cox. The MRMR & Surv.-Regr. combination seems to give good 
results even for the 5-gene signature (Figure 4.13 A), whereas, the Net-Cox & Cox signature 
increases its performance when increasing the signature size to 6. Both signatures with 
signature size 6 will be compared in the following section.  
Minimum redundancy maximum relevance & survival regression signature (6 genes) 
The signature (MCTS1, HIVEP1, FBXL3, TMEM45A, NFIA, FGF19) obtained by the MRMR 
feature selection algorithm and the survival regression (Surv.-Regr.) performed showed the 
best performance for 5 genes (without FGF19, 𝑐𝑖 = 0.75 (0.67-80.3)) and belonged to the 
best performing models for signature size 6 (𝑐𝑖 = 0.76 (0.67-0.83)). For a better comparison 
the signature is used to train a survival regression and a Cox regression model.  
In contrast to the Cox regressions’ prognostic index, the prognostic index of the survival 
regression model is correlated to the absence of the event of interest, i.e. the resulting 
prognostic index is correlated with a better outcome. Thus, the algebraic signs of the 
coefficients βsurvReg must be inverted to make them comparable to those of the Cox 
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regression model. The results of the regressions are shown in Table 4.13. The second and 
third columns show the results of the survival regression and the last columns those of the 
Cox regression. As expected, the algebraic signs of the coefficients are opposed. All genes 
except for FGF19 are significantly related to LRC. The gene FGF19 does not seem to be 
important for the signature, which is in line with the results of Figure 4.13. Since the 
performance increase between 5 and 6 genes in the signature is small (5 genes: 𝑐𝑖oob = 0.75 
(Figure 4.13 A, Surv.-Regr. & MRMR) vs. 6 genes: 𝑐𝑖oob = 0.76 (Figure 4.13 B, Surv.-Regr. 
& MRMR)). While the performance of the internal validation is promising, it should not be 
overestimated due to the risk biases as the signature was identified on the whole training 
cohort. 
Net-Cox & simple Cox regression signature (6 genes) 
In contrast to the MRMR & Surv.-Regr. signature (MCTS1, HIVEP1, FBXL3, TMEM45A, 
NFIA and FGF19), the performance of this signature (HIVEP1, FBXL3, AEN, YIPF6, NFIA) 
increased after including the 6th gene (5-gene: 𝑐𝑖 = 0.73 (0.63-0.81); 6-gene: 𝑐𝑖 = 0.76 (0.68-
0.84)). The resulting model parameters are presented in Table 4.14. All 6 genes are 
important for the model, which is represented by the significant p-values of all regression 
coefficients. The overall performance of the internal validation is similar to the MRMR & 
Surv.-Regr. signature and the small difference is likely to be caused by overfitting.  
The corresponding Kaplan-Meier estimators of both 6-gene signatures are presented in 
Figure 4.14. For both signatures an optimal cut-off was determined as described in section 
3.3.4. 
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Table 4.13. Regression results of the minimum redundancy maximum relevance (MRMR) 
& survival regression signature (6 genes). The second and third columns show the results 
of the full parametric survival regression, whereas, the last three columns show the results 
of the Cox regression. The regression coefficients β and the hazard ratios (HR) are 
presented with the p-values, significant p-values are marked via bold font. The 
performance of the Cox regression model was assessed on the whole training cohort. For 
the interval validation and the 95% concordance index (95%-CI), 200 bootstraps were 
performed. Genes also selected in the Net-Cox & Cox regression signature are marked 
via (*). 
Gene βsurvReg  p-value β Exp(β) = HR p-value 
MCTS1 -0.611 <0.001 0.448 1.565 0.001 
HIVEP1(*) 0.729 0.002 -0.557 0.573 0.006 
FBXL3(*) -0.525 0.002 0.425 1.53 0.005 
TMEM45A -0.470 0.006 0.364 1.439 0.014 
NFIA(*) 0.515 0.009 -0.474 0.622 0.005 
FGF19 -0.181 0.30 0.114 1.121 0.45 
Intercept 4.548 <0.001 - - - 
Scale 1.13 - - - - 
𝑐𝑖 (95%-CI) 
(train) 
0.77 (0.71-0.82) 0.78 (0.73-0.84) 
Internal validation 𝑐𝑖 (95%-CI) based on bootstrap samples 
𝑐𝑖bag̅̅ ̅̅ ̅̅  (95%-CI) 0.79 (0.72-0.84) 0.79 (0.73-0.84) 
𝑐𝑖oob̅̅ ̅̅ ̅̅  (95%-CI) 0.76 (0.67-0.83) 0.75 (0.66-0.82) 
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Figure 4.13. Performance of the ensemble signatures with signature size 5 (A, C) and 6 (B, 
D). The signatures are based on the given feature selection algorithm and model 
combination. The mean ci of the 3-fold cross validation are shown in the first row (A, B). The 
111 repetitions were used to calculate the 95% confidence interval. In the second row (C, 
D), the out of the bag (oob) samples of 200 bootstrap samples were used to calculate the 
mean cioob̅̅ ̅̅ ̅̅  with its 95% confidence interval. 
 
Model and signature discussion 
Out of the 6 genes in each signature, HIVEP1, FBXL3, AEN, YIPF6, NFIA and BCAT1 vs. 
MCTS1, HIVEP1, FBXL3, TMEM45A, NFIA and FGF19, both signatures have 3 genes in 
common: HIVEP1, FBXL3 and NFIA. They are marked with a (*) in Table 4.13 and Table 
4.14. The algebraic sign of the coefficient is equal in both models, but the magnitude differs. 
HIVEP1, also known as MBP-1, was reported to behave as a general transcriptional 
repressor and can induce cell death (Ghosh et al., 2002; Steele et al., 2010). For prostate 
cancer cells, an increase in MBP-1 gene was associated with a slowed down tumour growth 
(Steele et al., 2010). Similar results were obtained for other tumour cell lines, like non-small 
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lung cancer cells (Ghosh et al., 2006) or gastric cancer cells (Hsu et al., 2009). Also, in the 
presented models a higher HIVEP1 expression was related to less loco-regional 
recurrences. 
FBXL3 is an essential part of the circadian clock oscillation and regulates the speed and the 
robustness of this oscillator (Busino et al., 2007; Yoo et al., 2013; Scott et al., 2016). In a 
study of Kelleher et al. mice with a defect circadian clock had an increased tumour growth 
(Kelleher et al., 2014). In general, a defect circadian clock may lead to malignant cell growth 
but this needs to be explored in more detail (Lahti et al., 2012; Zhiwei Wang et al., 2014). 
However, based on the information about the role of FBXL3 and the circadian clock, it seems 
reasonable that FBXL3 was selected for both signatures. The algebraic sign, in contrast, 
seems to be wrong since FBXL3 is supposed to limit the tumour formation (Huber et al., 
2016). In both models FBXL3 increases the risk for a loco-regional recurrence. Nothing is 
known about its role in radiotherapy, yet. 
NFIA, the nuclear factor I A, is part of the family of transcription factors (Bernard et al., 2009). 
All members of this family are associated with various cell processes e.g. NFIA participates 
in the development of the brain (das Neves et al., 1999; Lu et al., 2007; Wong et al., 2007). 
Liu et al. reported that a knock down of NFIA in cell lines led to a decreased proliferation 
and an accumulation of cells in the G0/G1 phase (Liu et al., 2015). Hence, a low expression 
of NFIA would be preferable, which is contradictory to the regression coefficients. In the 
model a higher expression of NFIA would be preferable. 
The three common genes are likely important for patient stratification, given existing 
evidence. Each gene plays a role in the development of tumours. However, the algebraic 
sign of regression coefficients is not convincing. Only the contribution of HIVEP1 
corresponds to previous findings. However, the role of FBXL3 and NFIA in HNSCC has not 
been established. 
Out of the nine selected genes, three were selected in both signatures, but the remaining 
six were not. One explanation might be that the genes are mutually correlated and may be 
exchangeable. However, statistical correlations between these genes were low (max. 0.17) 
and this explanation does not hold. The lack of statistical correlation, however, does not 
preclude the possibility of functional correlations. 
 
 Identification of gene expression signatures as prognostic biomarkers 
 GeneChip® gene expression-based signatures 
85 
Table 4.14. Results of the Net-Cox & Cox regression signature (6 genes). The regression 
coefficients β and the hazard ratios (HR) are presented with the p-values. Significant p-
values are marked via bold font. The performance of the Cox regression was assessed on 
the whole training cohort. For the interval validation and the 95% concordance index (95%-
CI), 200 bootstraps were performed. Genes also selected in the MRMR & survival regression 
signature are marked via (*). 
Gene β Exp(β) = HR p-value 
HIVEP1(*) -0.645 0.525 0.001 
FBXL3(*) 0.407 1.503 0.002 
AEN 0.444 1.559 0.002 
YIPF6 0.405 1.500 0.005 
NFIA(*) -0.365 0.694 0.029 
BCAT1 0.304 1.355 0.041 
𝑐𝑖 (95%-CI) (train) 0.79 (0.75-0.85) 
Internal validation 𝑐𝑖 (95%-CI) based on bootstrap samples 
𝑐𝑖bag̅̅ ̅̅ ̅̅  (95%-CI) 0.80 (0.75-0.85) 
𝑐𝑖oob̅̅ ̅̅ ̅̅  (95%-CI) 0.76 (0.68-0.84) 
 
 
 
Figure 4.14. Kaplan-Meier estimators of loco-regional tumour control for the patients 
treated with pRCTx stratified using the 6-gene signature identified with the combination of 
(A) minimum redundancy maximum relevance (MRMR) & survival regression (cut-off: -
0.8) and (B) Net-Cox & Cox regression signature (cut-off: -0.5). 
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MCTS1 is part of the cell cycle regulation and behaves as tumour suppressor gene (Shi et 
al., 2003). In breast cancer it is reported to be associated with high aggressiveness and 
decreased apoptosis (Hachem and Nandi, 2007). TMEM45A is part of the transmembrane 
protein family. Flamant et al. proposed it to be a potential biomarker for breast cancer, since 
they associated a high TMEM45A expression with hypoxia and an increased therapy 
resistance (Flamant et al., 2012). Sun et al. reported similar findings for glioma cells: after 
knocking down TMEM45A tumour cell migration and invasion decreased (Sun et al., 2015). 
FGF19 is related to growth factor activity. Several publications reported an upregulation of 
FGF19 in HNSCC compared to the surrounding tissue, even compared to other tumour 
types (Birkeland and Brenner, 2015; Tillman et al., 2016; Gao et al., 2018). However, in this 
thesis the regression coefficient did not differ significantly from 0 (p = 0.45). 
AEN, the apoptosis enhancing nuclease, is connected to the autophagy of the cell which is 
induced by p53 after DNA damage (Sui et al., 2011). In cancer, autophagy can lead to cell 
death or promote the tumour cell survival (Ding et al., 2008; Rosenfeldt and Ryan, 2011). 
The exact role depends on the context (Liu and Ryan, 2012). Yet, nothing is known about 
its connection to HNSCC. YIPF6 is supposed to be involved in the vesicle transport, i.e. the 
internal cell transport mechanisms (Djusberg et al., 2017). Vainio et al. reported about the 
effect of YIPF6 in prostate cancer cell lines. They found an increased expression of YIPF6 
in tumour cells compared to normal tissue. Furthermore, they knocked down YIPF6 in 
prostate cancer cell lines and the cells showed a decreased amount of living cells (Vainio et 
al., 2012). BCAT1 encodes a protein that initiates the catabolism of branched-chain amino 
acids, which is essential for cell growth (Tönjes et al., 2013). Several cancer types were 
associated with an overexpression of BCAT1, e.g. glioblastoma, gastric cancer or breast 
cancer (Tönjes et al., 2013; Hattori et al., 2017; Thewes et al., 2017; Xu et al., 2018). This 
is in line with the regression coefficient assigned by the Cox model. 
Taking everything into account, none of the six genes selected for only one of the signatures 
seem to be correlated in a functional way. Both signatures describe different biological 
processes, but their radiobiologic relevance to is unknown. An independent or external 
validation would allow for comparing the performance of both models and may identify the 
better performing model. If those validation are successful, a the radiobiologic relevance 
should be examined. However, this analysis showed that there are several signatures which 
may be equivalent for stratifying patients but describe different biological processes. A 
potential way of combining these models will be presented later in section 4.4.  
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Before further development, the presented gene signatures need to be validated. After that, 
a combination with clinical parameters may be performed. 
4.3.3 Patients treated with postoperative radiochemotherapy 
Model training 
Similar as for the analyses of the pRCTx GeneChip® data, a pre-selection was performed 
on the gene data of the PORT-C cohort. The 3085 genes were selected and the filtering 
methods, i.e. the variance filter and the univariable regression filter, were applied. The 
variance filter kept the 200 genes with the largest variance, whereas, the univariable 
regression kept genes with a with p < 0.1 in Cox regression for LRC.  
To identify the ensemble signatures 333 3-fold CV were performed on the HPV16 DNA 
negative patients of the PORT-C cohort. The HPV16 DNA positive patients were already 
considered as low risk patients. For each feature selection algorithm and prognostic model, 
an ensemble gene signature was created. Subsequently 500 bootstrap samples were 
created, and each prognostic model and signature combination was used to train the 
corresponding models. The oob-data were used for internal validation of the model 
performance. The described procedure was performed for signature sizes ranging from 1 up 
to 7. In general, the univariable regression filter led to better results of the 𝑐𝑖oob̅̅ ̅̅ ̅̅ . The best 
signature model combination was obtained for the signature size 5, the Net-Cox based 
feature selection and the Cox regression. The signature was composed of the genes JUN, 
ASPH, KLHL15, PCGF5 and IFNA16 (𝑐𝑖oob̅̅ ̅̅ ̅̅  = 0.90 (0.84 - 0.95)). Highly correlated genes 
were searched that may be combined to metagenes that might improve the 𝑐𝑖oob̅̅ ̅̅ ̅̅ ̅, but none 
were found. The normalized genes were used to train the final multivariate Cox model and 
the results of the regression are presented in Table 4.15. In the upper part, the coefficients 
of the multivariate Cox regression of the whole PORT-C cohort (HPV16 DNA negative) are 
presented together with the training 𝑐𝑖 and its 95% confidence interval. To evaluate the 
performance, the training and oob 𝑐𝑖 of the bootstrap samples are shown in the lower part 
of the table. Still, the same cohort was used to identify the signature and to perform the 
internal validation. The mean training 𝑐𝑖bag̅̅ ̅̅ ̅̅  is bigger than the internal validation 𝑐𝑖oob̅̅ ̅̅ ̅̅ ̅, 
indicating that the model may be slightly overfitted, but still it has a very good performance 
since the oob-data were not used for training directly. However, the complete data set was 
used to identify the gene signature. The 𝑐𝑖oob is not representative and can only give an 
indication of the generalizability of the final model. The corresponding Kaplan-Meier 
estimators for the 5-gene signature are shown in Figure 4.15 A. 
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Table 4.15. Coefficients of the Cox regression of the final 5-gene signature predicting LRC 
for HPV16 DNA negative patients treated with primary radio(chemo)therapy.  
Gene β Exp(β) = HR p-value 
JUN 1.076 2.934 <0.001 
ASPH 1.129 3.092 <0.001 
KLHL15 -0.802 0.448 0.005 
PCGF5 -0.840 0.432 <0.001 
IFNA16 0.753 2.124 <0.001 
𝑐𝑖 (95%-CI) (train) 0.90 (0.84 - 0.95) 
Internal validation 𝑐𝑖 (95%-CI) based on bootstrap samples 
𝑐𝑖bag̅̅ ̅̅ ̅̅  (95%-CI) 0.90 (0.84 - 0.95) 
𝑐𝑖oob̅̅ ̅̅ ̅̅  (95%-CI) 0.87 (0.78 - 0.95) 
 
 
 
Figure 4.15. Kaplan-Meier estimators of loco-regional tumour control for the patients 
treated with PORT-C stratified using the 5-gene signature (A) and the 5-gene signature 
extended with clinical features (B). For the 5-gene signature, the cut-off -0.50 and for the 
extended 5-gene signature, the cutoff 0.51 was applied to the training cohort. The Kaplan  
(Schmidt et al., 2018). 
 
Selected genes 
Proteins encoded by the JUN gene, e.g. c-jun, and parts of the FOS family form the 
transcription factor AP-1. AP-1 is a crucial part of several cellular processes like apoptosis, 
differentiation or the reaction to external stimuli, e.g. stress or infections (Ameyar et al., 2003; 
Hess et al., 2004).  Riva et al. reported that an increased expression of JUN is correlated 
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with a higher resistance against chemotherapy (Riva et al., 1995). In other tumour types, 
like non-small cell lung cancer or breast cancer, a high expression of JUN was reported to 
be correlated with growth of metastases or tumour growth (Szabo et al., 1996; Vleugel et 
al., 2006). These results support the selection of JUN into the signature and they support 
also the regression parameter 𝛽 of JUN. The positive regression parameter 𝛽 indicates a 
higher risk if the expression is high. 
The ASPH gene encodes the HAAH enzyme (Lim et al., 2000) that was used as an indicator 
for carcinomas in humans. Nowadays, ASPH is reported to be correlated with several 
malignancies and plays an important role regarding cell invasiveness or mortality 
(Lavaissiere et al., 1996; Liang et al., 2012). In a gene profile expression study of Dumur et 
al., the gene expressions from tumour samples of 14 patients were classified into groups of 
responders and non-responders to radio(chemo)therapy. They identified 120 important 
genes in 6 functional clusters and ASPH as part of the cell death and cellular movement 
cluster (Dumur et al., 2009). Hence, the selection of ASPH is reasonable and the influence 
on the prognostic index, higher expression leading to higher risk, is supported by the 
presented studies. 
The KLHL15 gene belongs to the family of the Kelch(-like) proteins, a family of proteins 
which is often associated with DNA repair after radiation induced damage (Yoshida, 2005; 
Ferretti et al., 2016). The impact of KLHL15 on cancer was already assumed some time ago 
(Yoshida, 2005), but not much is known about the genes’ influence in HNSCC. Feretti et al. 
irradiated different cell lines with and without knocked down KLHL15 (Ferretti et al., 2016). 
They showed a link between KLHL15 and CtIP, an essential part of the DNA repair after 
double strand brakes (Makharashvili and Paull, 2015). Feretti et al. concluded that a 
changed concentration of KLHL15 changes balance between the different DNA repair 
mechanisms (Ferretti et al., 2016). Recently, Yen et al. showed for small-cell lung cancer 
that a higher expression of KLHL15 was associated with improved survival (Yan et al., 2018). 
This underlines the negative regression factor assigned by the Cox-model, indicating that a 
high concentration of KLHL15 results in a decreased risk for loco-regional tumour 
recurrence. 
The PCGF5-gene (also known as RNF159) encodes the polycomb group RING finger 
protein 5. It may depend on the surrounding tissue if the overexpression of the gene is 
favourable or not. While a PCGF5 overexpression was reported to be correlated with Barrett 
oesophagus and oesophageal carcinoma (Xing Wei Wang et al., 2014), Nagel et al reported 
an overexpression may be favourable for T-cell leukaemia. The PCGF5/RNF159 protein 
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belongs to the polycomb group (PcG), more exactly to the posterior sex combs (Psc) family, 
a subgroup of the polycomb repressive complex 1 (PRC1) (Maertens et al., 2009). Little is 
reported about the special role of PCGF5/RNF159 in this group, but other members of this 
family, like MEL18/RNF110, are known to act as tumour suppressor genes (Gil et al., 2005). 
The regression factor assigned by the Cox model indicates a similar behaviour for PCGF5, 
since a high expression related to a more favourable outcome. 
Interferon alpha-16 or IFNA16 is a protein which is encoded by the IFNA16-gene. The 
interferon alpha (IFN-α) family belongs to the immune response to viral infections. The HPV 
E6 protein targets the IFN pathways to avoid the escape the immune response (Rautava 
and Syrjänen, 2012). However, only HPV16 DNA negative patients were used to create this 
signature. To our knowledge, no publication showed a direct correlation between HPV16 
DNA negative head and neck cancers and IFNA16, yet. The processes in which the IFN-
family are included may provide further information. Suomela et al. reported about the 
upregulation of the IFN-α inducible protein IFI27 in some skin and epithelial cancers 
(Suomela et al., 2004) and Hatano et al. reported about the upregulation of the IFN-induced 
transmembrane protein 1 (IFITM1) in HNSCC (Hatano et al., 2008). Those upregulations 
may be caused by an upregulation of an IFN family member, in this case IFNA16. On the 
other hand, the connection between LRC and IFNA16 might just be caused by a statistical 
not a causal correlation. 
In summary, the signature and the corresponding regression factors seem to be reasonable. 
However, more information is needed to explain this signature completely, especially 
concerning KLHL15, PCGF15 and IFNA16. As a first step, an external validation of the 
signature should be performed. If this validation is successfully, those genes should be 
investigated in more detail. 
Extension with clinical parameters 
Like the 7-gene signature based on nCounter® data, the 5-gene signature was extended 
with the clinical parameters ECE-status and localisation. The regression parameters of the 
final model trained on the whole training cohort is presented in the upper half of Table 4.16. 
Like in the gene-only model, negative regression coefficients were assigned to KLHL15 and 
PCGF5. In contrast to the 7-gene signature, the ECE-status is now significantly different 
from 0. Both signatures seem to benefit from the clinical features, since the 𝑐𝑖oob̅̅ ̅̅ ̅̅  slightly 
increases after including those features from 0.87 to 0.88. The corresponding Kaplan-Meier 
estimators for the 5-gene signature extended by clinical features are shown in Figure 4.15B. 
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Table 4.16. Coefficients of the Cox regression of the final 5-gene signature combined with 
ECE-status and localisation predicting LRC for HPV16 DNA negative patients treated with 
primary radio(chemo)therapy. 
Gene β Exp(β) = HR p-value 
JUN 1.229 3.419 <0.001 
ASPH 1.410 4.095 <0.001 
KLHL15 -0.909 0.403 0.002 
PCGF5 -0.869 0.420 <0.001 
IFNA16 0.818 2.266 <0.001 
ECE-status 1.578 4.845 0.003 
Localisation (Oral cavity) -0.597 0.550 0.22 
𝑐𝑖 (95%-CI) (train) 0.90 (0.86 – 0.96) 
Internal validation 𝑐𝑖 (95%-CI) based on bootstrap samples 
𝑐𝑖bag̅̅ ̅̅ ̅̅  (95%-CI) 0.91 (0.86 - 0.95) 
𝑐𝑖oob̅̅ ̅̅ ̅̅  (95%-CI) 0.88 (0.79 – 0.95) 
 
 
4.4 Combined models for PORT-C 
In the previous sections several models were presented for the pRCTx and PORT-C cohorts 
that successfully stratified the patients into low and high risk groups for LRC. The assigned 
risk group of each patient depended on characteristics of the used model, and the used 
gene signature. For example in section 4.1 hypoxia-associated gene signatures were 
studied, in section 4.2.4 the 7-gene signature was developed based on nCounter® gene 
expression data and in section 4.2.5 a 5-gene signature was presented based on data 
obtained via GeneChip® analyses. A more robust stratification may be obtained by creating 
an ensemble of different models  and assigning the patients to different risk groups using a 
consensus approach, which is a well-known statistical approach (Dietterich, 2000). In this 
section a combination of the models, obtained for the PORT-C training cohort, will be 
presented.  
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4.4.1 Creation of a consensus model 
Model combination 
Each model presented earlier was built to stratify patients into two distinct groups. Briefly, 
the cohorts were classified into a low and a high risk group. These binary classifications will 
be the parameters for the model combination. For each patient all risk classifications are 
collected. The better performing group for LRC is regarded as a low risk group with 
parameter 0 and the group with the poorer LRC is regarded as a high risk group with 
parameter 1. For each patient the combined risk group is calculated by averaging the 
parameter of all considered models. This is shown exemplarily for 3 patients in Table 4.17. 
The nCounter® 7-gene signature and the GeneChip® 5-gene signature are only trained for 
patients who have a HPV16 DNA negative tumour. This was done since patients with HPV16 
DNA positive tumours were considered to be at low risk for loco-regional recurrences. 
Therefore, the low risk groups of the models based on the nCounter® 7-gene signature and 
the GeneChip® 5-gene signature consist of the patients with HPV16 DNA negative tumours 
stratified as low risk and the patients with a HPV16 DNA positive tumour. 
Table 4.17. Assignment to combined risk groups. The models assign a risk group to each 
patient, the group with a poorer outcome is considered as the high-risk group, represented 
by 1. The low risk group is represented by 0. By averaging over all considered models, 
the combined risk group is calculated. 
Patient 
15-gene hypoxia 
signature 
26-gene hypoxia 
signature 
nCounter® 
signature 
GeneChip® 
signature 
Combined 
risk 
A 1 (more hypoxic) 1 (more hypoxic) 1 (high risk) 1 (high risk) 1.0 
B 1 (more hypoxic) 0 (less hypoxic) 1 (high risk) 0 (low risk) 0.5 
C 0 (less hypoxic) 0 (less hypoxic) 0 (low risk) 0 (low risk) 0.0 
 
 
A combined risk group is then assigned to each patient. Depending on the number of 
included models, the amount of possible combined risk groups can differ. To finally stratify 
patients into risk groups, cut-offs must be defined. The cut-offs are chosen based on the 
purpose of the model. Three possibilities seem to be the most feasible: (i) the high risk, (ii) 
the low risk and (iii) the intermediate risk approach, which will be presented in the following. 
(i) The high risk approach 
The cut-off is close or equal to 1.0 leading to a classification as high risk if almost all models 
assign the patient to the high risk group. After the application of the cut-off, the resulting risk 
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groups will have a poorer outcome than the low and high risk groups of the single models. 
The resulting combined low risk group will be bigger, and the combined high risk group will 
be smaller than in the individual models. This can be used for example, to identify high risk 
patients which may benefit from a therapy intensification. 
(ii) The low risk approach 
The approach is similar to the high risk approach, but the cut-off is close or equal to 0. This 
reveals patients which were considered as low risk by almost all models. The resulting 
groups will have a generally better outcome than in the individual models, especially the 
combined low risk group. This approach may be used to identify the patients who may benefit 
from a therapy de-escalation to decrease side effects. 
(iii) The intermediate risk approach 
Three risk groups are identified simultaneously by combining both previously presented 
approaches. Briefly, two cut-offs are applied, one for a combined low and one for a combined 
high risk group. All remaining patients are assigned to the intermediate risk group, which 
may be used for further stratifications. The patients of this intermediate group are often very 
close to the used cut-offs in the single models, which may increase the probability for a 
misclassification. 
4.4.2 Consensus model based on 2 models 
In a first step, two models based on nCounter® or GeneChip® measurements will be 
combined following the (i) high risk approach. For nCounter® measurements, patients will 
be identified as combined high risk if 
• the patient specific prognostic index assigned by the LRC 7-gene signature model 
with clinical parameters is above  0.37 (Schmidt et al., 2018), and 
• they are stratified as hypoxic by the 15-gene hypoxia signature (Linge, Löck, Krenn 
et al., 2016; Linge, Löck, Gudziol et al., 2016). 
 
Based on GeneChip® measurements, the classification for the patients are assigned to the 
combined high risk group if: 
• the patient specific prognostic index assigned by the LRC 5-gene signature model 
with clinical parameters is above 0.51, and 
• the patients are stratified as hypoxic by the 15-gene hypoxia signature based on 
GeneChip® gene expression data. 
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Patients with HPV16 DNA positive tumours are considered as low risk by the LRC models 
but are shown as a separate group. Furthermore, only those patients are considered who 
have a complete GeneChip® and nCounter® data set. This may lead to differing patient 
numbers in figures presented in this section even though the same parameters and 
stratifications are shown. 
Combining the 15-gene hypoxia-associated signature & LRC-signature based models 
The Kaplan-Meier estimators of more and less hypoxic tumours are shown in Figure 4.16 (B 
and E). Figure 4.16 (A and D) show the stratification based on the LRC specific signatures, 
extended by clinical parameters assessed for nCounter® (A) and GeneChip® 
measurements (D). The less hypoxic tumours and the low risk groups of each measurement 
method have a similar behaviour, i.e. they are nearly equal or just slightly below the Kaplan-
Meier estimator of the HPV16 DNA positive patients. Less than 10% of the patients have a 
loco-regional recurrence. The groups of more hypoxic tumours and the high risk patients of 
the gene signatures are very similar, too. All 4 groups show a significant difference (p < 0.01) 
to their corresponding less hypoxic or low risk group. Still, only 25-35% patients of these 
high risk groups have a loco-regional failure. 
In Figure 4.16 (C and F) the combined model, according to the high risk approach is 
presented, i.e. only patients who have a more hypoxic tumour and who are considered as 
high risk by the LRC-specific models are classified as high risk. The resulting low and high 
risk groups are still significantly different (p < 0.001). Furthermore, the combined high risk 
group shows a poorer outcome, than the high risk or the more hypoxic group of the individual 
models. The expected decline of the combined low risk group did only occur for the 
GeneChip® data. The combined low risk group based on the nCounter® measurements 
was similar to the individual model’s low risk and less hypoxic groups. This may be explained 
by the worse stratification of the 15-gene hypoxia-associated signature based on the 
GeneChip® expression data, see section 5.2.3. 
The model combination based on the nCounter® measurements was also applied to the 
validation cohort. All patients assigned to the high risk group by the 7-gene signature with 
clinical features were also assigned into the more hypoxic group by the 15-gene hypoxia 
signature, see Supplementary Figure 2 A-C. After the independent normalization, the 
combined risk group shows a similar LRC compared to the 7-gene signature alone but less 
patients are assigned to the high risk group, see Supplementary Figure 2 D-F. 
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Figure 4.16. Kaplan-Meier estimators of loco-regional tumour control for the patients of 
the PORT-C cohort stratified according to different models. Patients with HPV16 positive 
tumours are represented by the brightest colour in each Kaplan-Meier estimator. The used 
models are trained on nCounter® gene data in the first row and on GeneChip® data in 
the second row. The HPV16 DNA negative patients are stratified based on the LRC 
specific models (A, D), their hypoxia status (B, E) or a combination of both models (C, F). 
The combined high risk (comb. HR) is composed of patients who have a more hypoxic 
tumour and who are in the high risk group of the LRC specific model. The p-value is based 
on the comparison of the HPV16 DNA negative patient risk groups. 
  
Identification of gene expression signatures as prognostic biomarkers  
Combined models for PORT-C  
96 
Combining LRC signatures 
In the following subsection, the high risk approach will be used based on the stratification of 
both LRC specific gene signatures: 7-gene and 5-gene signature. Both measurement 
methods will be combined, i.e. the low and high risk status is assessed by each model on 
its specific gene expression data, respectively. The obtained signature includes different 
biological mechanisms. A combination may show an improved performance for patient 
stratification. 
In Figure 4.17 (A and B) the same stratifications as in Figure 4.16 (B and E) are presented 
for better visualisation. The combination of both models is presented in Figure 4.17 C. The 
combined low and high risk groups are significantly different (p < 0.001). In contrast to the 
expectation, the combined low risk group did not show a poorer outcome compared to the 
individual models, even though some former high risk patients are now included in the 
combined low risk group. As expected, the combined high risk group (40 patients) is smaller 
than the individual high risk groups (7 genes: 57 patients, 5 genes: 65 patients) and shows 
a poorer outcome compared to the individual models.  
 
Figure 4.17. Kaplan-Meier estimators of loco-regional tumour control for the patients of 
the PORT-C cohort stratified according to different LRC-specific models. Patients with 
HPV16 DNA positive tumours are represented by the grey lines. The used models are (A) 
the 7-gene signature trained on nCounter® gene data and (B) the 5-gene signature trained 
on GeneChip® data. Both models are combined in (C). Patients who are classified as high 
risk in (A) and (B) are stratified into the combined high risk group (comb. HR). The other 
patients are grouped together as combined low risk (comb. LR). 
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4.4.3 Consensus model based on more than 2 models 
Promising results were obtained for the combination of 2 models that were specific for 
different characteristics of the tumour. Now, more than 2 models will be combined. In a 
recent publication of Linge et al. the importance of putative CSC markers for the PORT-C 
cohort has been shown (Linge, Löck, Gudziol et al., 2016) and validated (Linge, Löck, Krenn 
et al., 2016). These markers will now be added as additional parameters. The used 
stratifications will be based on the HPV16 DNA negative patients of the PORT-C cohorts. 
Besides the putative CSC markers, the hypoxia-associated signatures (15-gene & 26-gene) 
and the 7-gene LRC signature with the clinical parameters ECE-status and oral cavity were 
combined using the intermediate risk approach. 
Risk 1 – Equal combination of risk parameters from different cellular processes 
In the first step, the 7-gene signature, the putative CSC marker SLC3A2 and the 15-gene 
hypoxia-associated signature were combined. The high risk assignment is based on the 
following criteria: 
• LRC 7-gene signature model, if the patient specific prognostic index is above 0.37 
(Schmidt et al., 2018) 
• 15-gene hypoxia signature, if the patient is stratified as hypoxic (Linge, Löck, Krenn 
et al., 2016; Linge, Löck, Gudziol et al., 2016) 
• SLC3A2, if the gene expression is above -3.135 (Linge, Löck, Krenn et al., 2016; 
Linge, Löck, Gudziol et al., 2016)  
The combined risk groups were created based on these criteria. Patients with none or one 
high risk assignment were stratified into the combined low risk (CLR) group, whereas 
patients with 3 high risk assignments were considered as members of the combined high 
(CHR) risk group. All other patients were included in the intermediate risk (IMR) group. The 
results for the corresponding Kaplan-Meier estimators of LRC are presented in Figure 4.18 
for the training (A) and validation cohort (C). In both cohorts, the Kaplan-Meier estimators of 
the CLR and IMR group show a similar behaviour and may be combined. The CHR in 
contrast, is significantly different to the CLR and IMR in both cohorts (p < 0.005). The CHR 
of the validation cohort is small (13/121), which may be caused by the low correlation of 
SLC3A2 with hypoxia classification and the 7-gene signature and may reduce the usefulness 
of this approach. 
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Risk 2 – Weighted combination of risk parameters from different cellular processes 
In the second step, the risk parameters are extended. The LRC 7-gene signature is used as 
before, but criteria for CSC markers and hypoxia classifications now constructed using 
multiple signatures or gene expressions. The following criteria are applied for assigning a 
patient to the combined risk groups: 
• for 7-gene signature (as before) if the patient specific prognostic index is above 0.37 
(Schmidt et al., 2018) 
• for CSC markers: if the gene expression of SLC3A2 is above -3.135 or MET is above 
-4.135 (Linge, Löck, Krenn et al., 2016; Linge, Löck, Gudziol et al., 2016) 
• for hypoxia classification: if the patient is stratified as hypoxic by (at least) one of the 
15-gene or 26-gene hypoxia signatures (Linge, Löck, Krenn et al., 2016; Linge, 
Löck, Gudziol et al., 2016) 
None or one high risk assignment was combined to the CLR group and 3 high risk 
assignments were combined to the CHR group. The corresponding Kaplan-Meier estimators 
are presented in the second column of Figure 4.18 (B and D). Even though the CLR and 
IMR groups are still not significantly different, the CLR groups show a better loco-regional 
tumour control up to 36 months after the start of treatment. The CLR group is smaller 
compared to the Risk 1 approach (training: 32<49, validation 17<40) and only one event 
occurs in this cohort (Figure 4.18 B). The CHR groups, now slightly bigger (training: 56 > 44, 
validation 15 > 13) than in Risk 1, are still significantly different to the CLR and IMR groups 
(p < 0.02). 
Risk 3 – Just combining the available risk parameters from different cellular 
processes 
In this approach all 5 available risk parameters were included as single and independent 
risk factors, i.e. a patient is considered as high risk 
• for the LRC 7-gene signature model, if the patient specific prognostic index is above 
0.37 (Schmidt et al., 2018) 
• for SLC3A2 if the gene expression is above -3.135 (Linge, Löck, Krenn et al., 2016; 
Linge, Löck, Gudziol et al., 2016) 
• for MET if the gene expression is above -4.135 (Linge, Löck, Krenn et al., 2016; 
Linge, Löck, Gudziol et al., 2016) 
• for the 15-gene hypoxia signature, if the patient is classified as hypoxic (Linge, Löck, 
Krenn et al., 2016; Linge, Löck, Gudziol et al., 2016) 
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• for the 26-gene hypoxia signature if the patient is classified as hypoxic (Linge, Löck, 
Krenn et al., 2016; Linge, Löck, Gudziol et al., 2016) 
The CLR group is defined as before, i.e. the patients classified as high risk by none or only 
one of the biomarkers are included. All patients classified as high risk by 4 or 5 parameters 
were included into the CHR group and all other patients were considered as the intermediate 
risk group. The results are presented in the last column of Figure 4.18 (C and E).  
For the training cohort, the resulting risk groups are similar to the Risk 2 approach, even 
though the CHR has a slightly higher LRC after 5 years. Still, the CHR is significantly different 
from the CLR and IMR groups, which are still similar. However, the validation cohort shows 
a different behaviour. None of the resulting groups is significantly different to one of the 
remaining groups (not even CLR and CHR), indicating a poor stratification. This may be 
caused by overfitting, noise and redundancy.  
All parameters were identified on the training cohort. Therefore, a good performance of a 
combination of these parameters can be expected in this cohort in all three approaches. The 
Risk 3 approach differed from Risk 1 and 2, since the included biomarkers were just included 
in the model without any further information. Several parameters for same biological 
processes were included as independent risk factors, which may be avoided since they give 
redundant information. In approaches 1 and 2 the included risk parameters were grouped 
based on a molecular process, which can be interpreted as a weighted combination and, 
thus, may result in improved performance.  
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Figure 4.18. Kaplan-Meier estimators of loco-regional tumour control of the PORT-C 
cohort (HPV16 DNA negative tumours), stratified by different risk parameter combinations. 
The training (upper row) and the validation cohort (bottom row) are shown. The patients 
were stratified into a combined low risk (CLR), intermediate risk (IMR) and combined high 
risk (CHR) group according to different rules. Risk 1 combines the high risk classification 
of the 7-gene signature, the 15-gene hypoxia signature status and the SLC3A2 expression 
status. Risk 2 combines the high risk classifications of the 7-gene signature, the hypoxia 
status (hypoxic if 15-gene or 26-gene hypoxia signature status is hypoxic) the CSC status 
(SLC3A2 > -3.135 or MET > -4.135). All risk parameters were included equally in Risk 3. 
Patients were classified as CLR if they were at high risk in one or less of the single models 
(Risk 1 and Risk 2). Patients were classified as CHR if they were at high risk in 3 (Risk 1 
and Risk 2) or more than 3 (Risk 3) of the single models.  
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4.4.4 Discussion and summary of model combination 
In this section, different models were combined that were based on the patients of the PORT-
C cohort. A classification approach based on a majority consensus was performed.  
The HPV16 DNA negative patients were stratified based on the high risk approach of two 
models, i.e. patients who were considered as high risk by both models were classified as 
combined high risk. As expected, the combined high risk group showed a worse outcome 
than the high risk group of the separate models. Similar results were obtained for the 
combined high risk group of more than 2 models. These results are not surprising since all 
considered models represent important biomarkers and the underlying models were trained 
on this cohort. However, this approach may help in future clinical routine. More and more 
models are published that can be used for stratification. By combining different models, it 
may be possible to overcome the shortcomings of individual models. The results of this 
section underline this assumption. The loco-regional tumour control of the combined low risk 
group did not differ much compared to the low risk groups of the individual models, but it 
included up to 30% more patients. 
Besides the advantages of model combination, the combined risk groups also revealed 
potential shortcomings when relying on single models: Up to 20% of all patients would be 
classified differently if a single model was used compared to the classification of the 
combined model. This may be explained by the chosen cut-off, e.g. for the LRC signatures, 
or by the model, which may be too simple to describe the complexity of the tumour 
behaviour. A better cut-off or a more complex model may be created based on a larger 
training cohort. Furthermore, different models that are trained to predict different tumour 
characteristics may be combined. 
If two or more models are combined, the tumour biology must be considered. To get a good 
consensus model, the different risk assignments should be combined according to their 
biology, e.g. the combination of one CSC model and five different hypoxia classifiers may 
not lead to new results since the hypoxia classifiers may be redundant. A hierarchical 
combination of these parameters, like a decision tree, may be a proper solution. To 
guarantee a certain robustness in describing a biological process, several biomarkers for 
this process should be included. 
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5 Stability of gene expression-based biomarkers 
In clinical routine, some tumour characteristics, such as the tumour size or the presence of 
metastases, are already applied to assign patients to different treatments. To improve the 
individualized patient stratification in the future, gene signatures, like the signatures 
presented in the previous chapter, may be included in this stratification process. Therefore, 
the signatures and gene expressions need to fulfil several quality criteria, like temporal 
stability and reproducibility of the measurement results. Furthermore, methods that are used 
to identify putative biomarkers may differ from methods that are used in clinical routine. In 
this chapter, the time stability of nCounter® measurements will be analysed and evaluated. 
Subsequently, nCounter®, GeneChip® and RT-PCR measurement results will be 
compared.  
5.1 Reproducibility depending on time of nCounter® 
To evaluate the reproducibility of the nCounter® measurements, nCounter® analyses of the 
FFPE samples of 6 patients of the pRCTx validation cohort were performed 3 times. 206 
genes were available in these 3 measurements of the nCounter® assay. The first 
measurement (A) was performed in 2016 and the repeated measurements (B and C) were 
performed in the summer of 2018. The Spearman rank correlation between the 
measurements A vs. B (𝜌AB), A vs. C (𝜌AC) and B vs. C (𝜌BC) were calculated. The results 
are shown in Figure 5.1 A-C. The distributions of the correlation coefficients show a left 
skewness, i.e. the majority of genes have a higher correlation than the mean correlation. A 
small number of genes with a very low correlation between the different methods have a 
strong impact on the mean correlation, shown as a solid black line. Only 6 patients were 
used to calculate the correlation for each gene. Due to this small number of patients, the 
median correlation may be a better criterion to evaluate the reproducibility since the median 
is less affected by potential outliers. The median correlations were 𝜌AB̃ = 0.88 (lower quartile: 
0.68, upper quartile: 0.96), 𝜌AC̃ = 0.89 (0.69, 0.97) and 𝜌BC̃ = 0.87 (0.56, 0.96). All median 
values are nearly equal. The low correlation of some genes may be explained by the small 
number of patients or by a lower gene expression of these genes (close to the noise level).  
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Figure 5.1. Relative number of genes in dependency of the Spearman rank correlation of 
gene expressions between different measurements. The measurement A was performed 
in 2016, whereas, measurements B and C were performed in 2018. (A) shows the 
correlations ρAB between measurements A and B, (B) shows the correlation ρAC between 
measurements A and C, and (C) shows the correlation ρBC between the measurements B 
and C. The median (black line) is shown together with the first and third quartile (dashed 
lines). The mean is marked with the grey dash-dotted line. 
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To investigate the connection between gene expression and correlation, all measurements 
were combined. For each gene the mean gene expression was calculated over all patients 
and all measurements, and for each gene, the mean of the three obtained correlations (𝜌AB, 
𝜌AC and 𝜌BC) was calculated. In Figure 5.2 A the results are depicted. Most of the genes that 
were poorly reproducible had gene expressions lower than -3. Furthermore, a Bland-Altman 
analysis was performed, shown in Figure 5.2 B-D. The difference Δ𝑒 between each 
measured gene expression is shown depending on the mean gene expression ?̅? for each 
patient, e.g. for each patient the difference and mean expression of SERPINE1 is calculated 
between measurement A and B as follows:  
Δ𝑒AB(SERPINE1) = 𝑒A(SERPINE1) − 𝑒B(SERPINE1), (43) 
𝑒AB(SERPINE1)̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ =
𝑒A(SERPINE1) + 𝑒B(SERPINE1)
2
. (44) 
This is repeated for each patient and each other gene, resulting in 1236 ( = 206*6) data 
points, shown in Figure 5.2 B-D. A slight shift may be visible between the measurements A 
and B (0.22) and between A and C (0.20), but it is not significant. Genes with a mean gene 
expression less than -3 have a higher variance between the measurements and genes with 
an expression below -5 may not be reliable. 
The presented results are similar to previous studies, in which a high reproducibility was 
reported for highly expressed genes e.g. (Veldman-Jones, Brant et al., 2015; Veldman-
Jones, Lai et al., 2015). Veldman-Jones et al. performed several quality analyses for the 
nCounter® technology from nanoString (Veldman-Jones, Brant et al., 2015). They found a 
weak reproducibility for genes with an expression below the detection limit, especially for 
FFPE tissue. The detection limit was defined as the average of the negative controls plus 
two times the according standard deviation (Veldman-Jones, Brant et al., 2015). A minimum 
of 25 ng of FFPE were necessary to ensure that ~80% of the genes were above the detection 
limit, while 10 ng of fresh tissue were sufficient to obtain the same number of reproducible 
genes. For the presented nCounter® analyses 40-60 ng of FFPE material were used. 
According to Veldman-Jones et al. this amount would lead to a sufficient yield (Veldman-
Jones, Brant et al., 2015). Furthermore, they stated that some areas of the tumour may not 
express enough of some genes or the gene at all. The above reasons may explain the low 
correlations of some genes. 
In summary, the repeated measurements showed a high reproducibility in general. In the 
next chapter the transferability between different measurement methods, e.g. to GeneChip® 
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data, will be discussed. The reader may keep in mind that even within the nCounter® 
measurements, only a mean correlation of about 0.75 and a median correlation of about 
0.87 was reached. 
 
 
Figure 5.2. Comparison of repeated gene expression measurements. A Mean gene 
correlation depending on the mean gene expression for all 3 comparisons. B-D Bland-
Altman analyses of the different measurements. The difference between the 
measurements is shown depending on the mean gene expression of the both results. The 
mean values (dashed lines) are shown together with their 95% confidence interval (dotted 
lines). 
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5.2 Comparison of nCounter® and GeneChip® gene 
expression 
5.2.1 Introduction 
In the previous chapter the gene expressions assessed via nCounter® and GeneChip® 
measurements were analysed separately. In this chapter, 158 genes available in both 
measurement methods and both training cohorts (PORT-C and pRCTx) will be compared to 
evaluate the correlation between both gene expression measurement methods. Every 
method has its own advantages and disadvantages, e.g. the GeneChip® measurements 
need less tumour material and can give information about much more genes than nCounter® 
measurements. In contrast, nCounter measurements are cheaper (Galbraith, 2003; 
Kulkarni, 2011) and show a higher correlation with PCR measurements, the clinical standard 
method. 
In the following chapter, only those patients of the PORT-C (Lohaus et al., 2014; Linge, Löck, 
Gudziol et al., 2016; Linge et al., 2018) and the pRCTx (Linge, Lohaus et al., 2016; Linge et 
al., 2018) training cohort that have a complete data set of nCounter® and GeneChip® 
measurements were included. The Real-time polymerase chain reaction (RT-PCR) 
measurement results were only available for a smaller subset of patients of the PORT-C 
training cohort. For comparison with RT-PCR, patients with a complete data set for 
nCounter®, GeneChip® and RT-PCR were considered. All comparisons were performed for 
each cohort individually. 
The results of this chapter were also submitted to The Journal of Molecular Diagnostics in 
March 2019 (Schmidt et al., 2019). 
5.2.2 Correlation analyses 
For the common set of 158 genes, the correlation between the gene expressions assessed 
by nCounter® and GeneChip® analyses was evaluated using the Spearman rank correlation 
coefficients 𝜌. The mean correlations for both cohorts were 𝜌nC & GC = 0.63 (95%-CI: 0.11-
0.89) for the PORT-C cohort and 𝜌nC & GC = 0.63 (95%-CI: 0.07-0.90) for the pRCTx cohort, 
respectively, see Figure 5.3 A and B.  
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Figure 5.3. Correlation of gene expressions between different methods. In the subfigures 
A, C and D the results for the PORT-C training cohort are presented. In A the correlation 
between nCounter® and GeneChip® analyses is shown, in C the correlation between RT-
PCR and nCounter® is shown, and in D the correlation between RT-PCR and GeneChip® 
is shown. In B the correlation between the nCounter® and GeneChip® for the patients of 
the pRCTx cohort is shown. In all subfigures, the median correlation (black line), the lower 
and upper quartiles (dashed black lines), as well as the mean (grey dash-dotted line) are 
marked. 
 
For the PORT-C cohort the Spearman rank correlation was assessed for the 37 genes 
analysed with RT-PCR for all 3 methods. A slightly higher correlation 𝜌nC & GC = 0.69 (0.22-
0.88) between nCounter® and GeneChip® measurement was obtained (not shown). As 
expected, the highest correlation, 𝜌nC & PCR = 0.83 (0.54-0.96), was found between 
nCounter® and RT-PCR analyses. The correlation between GeneChip® and RT-PCR, 
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𝜌GC & PCR = 0.64 (0.35-0.86), was similar to the correlations between nCounter® and 
GeneChip® for all 158 genes in both cohorts. All results are presented as histograms in 
Figure 5.3. For better visualization of the data, the mean (grey line) and median correlation 
(black line) are marked along with the lower and upper quartiles (dashed black lines). As in 
the previous section, all histograms show a left skewness, indicating the median correlation 
?̃? (black line) is bigger than the mean correlation ?̅? (grey line). Still, the difference is rather 
small (|?̃? − ?̅?|<0.06), especially for the RT-PCR and nCounter® measurements (Figure 5.3 
C, |?̃? − ?̅?| ≤ 0.03). More patients than in the previous section were used to calculate the 
correlations between the different measurements. Hence, there is a higher chance that 
potential outliers may be caused by systemic differences.  
These observed results are in line with earlier studies of Chen et al. and Huet et al. Chen et 
al. compared the results of nCounter® analyses to gene expressions measured by 
GeneChip® (Affymetrix Human Genome U133 Plus 2.0) for 68 paired samples of colorectal 
cancer (Chen et al., 2016). More than 400 genes were analysed and a slightly lower mean 
correlation 𝜌nC & GC = 0.50 compared to our results was obtained (Chen et al., 2016). In the 
more recent study of Huet and his colleagues, they evaluated a LRC-associated gene 
signature for patients with follicular lymphoma with nCounter® and GeneChip® (Affymetrix 
Human Genome U133 Plus 2.0). The signature contained 95 genes and was developed 
using the GeneChip® analyses measurements. For 53 patients the gene expression data 
were also obtained with nCounter® measurements (Huet et al., 2018). Huet et al. compared 
the correlation for each gene individually and only 23 of the genes showed a correlation 
above 0.75. which is slightly below our results (Huet et al., 2018). This may be explained by 
the different GeneChip® design or the lower number of patients. 
5.2.3 Model and biomarker transfer 
Several biomarkers were presented in the previous chapter that were used to stratify both 
training cohorts regarding LRC. Mostly, those stratifications were first performed on 
nCounter® measurements. In the following section, those stratifications will be transferred 
to the GeneChip® data. By this, the transferability of single genes and gene signatures will 
be compared. Based on the previous results, it may be expected that gene signatures should 
lead to more reproducible results than the single genes. 
Single biomarkers - putative CSC 
The putative CSC markers SLC3A2, MET (only PORT-C cohort) and CD44 (only pRCTx 
cohort) were used to stratify the patients into two subgroups of high and low gene 
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expression, respectively. The resulting subgroups differed significantly in LRC (Linge, Löck, 
Gudziol et al., 2016; Linge, Lohaus et al., 2016; Linge, Löck, Krenn et al., 2016). 
Univariable Cox regressions were performed based on the continuous gene expressions 
obtained by GeneChip® measurements. The results are shown in Table 5.1. Regarding the 
PORT-C cohort, MET was highly significant (p < 0.001) for LRC and SLC3A2 (p = 0.082) 
showed a statistical trend. For the pRCTx cohort, no association between LRC and SLC3A2 
or CD44 was found.  
Furthermore, the training cohorts were stratified into patients with a higher and a lower 
expression of the corresponding putative CSC marker based on nCounter® data. To transfer 
this stratification to GeneChip® data, two methods were applied: 
(i) The cut-offs based on the nCounter® data 𝑐nC were transferred to GeneChip® data 𝑐GC 
using linear regression: 
𝑐GC = 𝑚𝑐nC + 𝑛 
(45) 
The regression parameters 𝑚 and 𝑛 were obtained for each putative CSC and are presented 
in Table 5.2. The corresponding patient stratifications are presented as the subfigures B and 
E of Figure 5.4 and Figure 5.5. 
(ii) New cut-offs were defined based on the method used for the cut-offs of the nCounter® 
measurements (see section 3.3.4 for details). Briefly, all possible cut-offs were applied to 
1000 bootstrap samples of the training cohort. The resulting groups were compared using a 
log-rank test and the portion of significant stratifications was counted. The cut-off with the 
highest fraction of significant stratifications was chosen as final cut-off. The corresponding 
results are presented in Table 5.2 and the stratifications are presented as subfigures C and 
F of Figure 5.4 and Figure 5.5. 
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Table 5.1. Correlation analyses and univariable Cox regressions for biomarkers assessed 
by different gene expression measurements. The first column shows the (mean) 
Spearman correlation ρnC&GC  between nCounter® (nC) and GeneChip® (GC) analyses 
of single genes and gene signatures. In the following columns, the hazard ratios (HR) of 
the univariable Cox regression are shown for the respective measurement method. For 
the gene signatures, patient classification was used as a binary parameter in Cox 
regression. The upper part shows the results for the patients treated with postoperative 
radiochemotherapy (PORT-C), whereas, the patients treated with primary 
radiochemotherapy (pRCTx) are shown in the bottom part of the table (Schmidt et al., 
2019). 
 
Parameter 𝝆nC&GC̅̅ ̅̅ ̅̅ ̅̅ ̅̅  HRnC  p-value HRGC p-value HRRT-PCR  p-value 
PORT-C 
SLC3A2 0.56 2.15  0.007 11.4  0.082 - - 
MET 0.87 2.14  0.002 3.63  <0.001 - - 
15-gene hypoxia 
signature 
0.73 3.57  0.010 2.84  0.008 3.27  0.010 
26-gene hypoxia 
signature 
0.67 9.42  0.002 3.48  0.002 5.99  0.003 
30-gene hypoxia 
signature 
- - - 2.47  0.020 - - 
7-gene signature 0.68 5.52  <0.001 3.93  0.002 - - 
pRCTx 
SLC3A2 0.69 1.72  0.007 2.48  0.24 - - 
CD44 0.72 1.41  0.14 1.09  0.44 - - 
15-gene hypoxia 
signature 
0.75 1.34  0.30 1.39  0.23 - - 
26-gene hypoxia 
signature 
0.67 1.39  0.28 1.58  0.095 - - 
30-gene hypoxia 
signature 
0.66 1.48  0.18 0.87  0.62 - - 
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Table 5.2. Cut-offs for high and low expressions of putative CSC markers transferred from 
nCounter® data to GeneChip® data for the patients of the PORT-C and the pRCTx 
training cohort. The first columns show the transfer (i) from the original cut-off 𝑐nC based 
on nCounter® measurements to a new cut-off 𝑐GC for GeneChip® data using the 
parameters of the linear regression, see equation (45), are presented. In the last column, 
the cut-off 𝑐GC with the highest power based on the GeneChip® data is shown (approach 
(ii)). For each cut-off, the corresponding p-value of the resulting patient stratification is 
shown (Schmidt et al., 2019). Significant stratifications are marked with bold font. 
Gene 
Cut-off based on 
nCounter® 
Linear regression 
parameters 
Transferred  
cut-off 
New calculated 
cut-off 
 𝑐nC p-value 𝑚 𝑛 𝑐GC p-value 𝑐GC p-value 
PORT-C 
SLC3A2 -3.135 <0.001 0.11 6.21 5.87 0.30 5.78 0.044 
MET -4.135 0.009 0.43 7.89 6.11 0.009 5.85 <0.001 
pRCTx 
SlC3A2 -2.135 <0.001 0.16 5.999 5.66 0.26 5.42 0.058 
CD44 1.400 0.021 1.53 10.91 13.05 0.35 11.83 0.015 
 
 
Both methods, (i) and (ii), were able to transfer the cut-off for MET successfully from 
nCounter® to GeneChip® data, since all stratifications remained significant. In contrast to 
MET, none of the other 3 putative CSC could be transferred successfully using the linear 
regression approach (i). Stratifications showing a significant difference regarding LRC or at 
least a statistical trend were obtained for the newly defined cut-offs of SLC3A2 and CD44 
(PORT-C: SLC3A2, p = 0.044; pRCTx: CD44, p = 0.015; SLC3A2, p = 0.058; approach (ii)). 
However, even though the differences in LRC between the resulting risk groups of the linear 
regression approach (i) were not significant, the group of patients with a higher CSC marker 
expression had more loco-regional recurrences than the patients with a lower CSC marker 
expression, see subfigures B and E of Figure 5.4 and Figure 5.5. 
This behaviour may be explained by the smaller number of patients in the pRCTx cohort that 
was used for identification of the cut-off. Furthermore, the correlation may be the only 
important factor for the transfer by linear regression. 
The transferred cut-off of MET, which had the highest Spearman rank correlation between 
both measurement methods, 𝜌nC & GC = 0.87, led to the best stratification indicated by the 
lowest p-value. SLC3A2 had the lowest correlation coefficients of all CSC markers  
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(PORT-C: 𝜌nC & GC = 0.56, pRCTx: 𝜌nC & GC = 0.69), but the transferred cut-off led to a better 
stratification of the pRCTx cohort, indicated by a lower p-value, than the transferred cut-off 
of CD44 (pSLC3A2 = 0.24<pCD44 = 0.44), with a higher correlation coefficient (𝜌nC & GC = 0.72). 
This may be explained by the uneven distribution of risk groups resulting of the CD44 based 
stratification (nCounter®: 122 low risk vs 14 high risk; GeneChip® 115 low risk vs 21 high 
risk). In the bigger GeneChip® low risk group, patients are included, who were considered 
as high risk in the nCounter® measurements, leading to less separated Kaplan-Meier curves 
(Figure 5.5). In the PORT-C cohort, the patient distribution is more equal (nCounter®: 91 vs 
100; GeneChip® 113 vs 78) and there were more patients available to identify the cut-off 
(PORT-C: 191 vs pRCTx: 136). In summary, the transfer of a cut-off between both methods 
is possible and may be successful, but a bigger cohort and a high correlation is needed to 
identify a more reliable cut-off. 
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Figure 5.4. Kaplan-Meier estimators of loco-regional tumour control for the PORT-C 
cohort. The patients were stratified by the putative CSC markers MET (top row) and 
SLC3A2 (bottom row) assessed with either nCounter® (blue) or GeneChip® analyses 
(orange). The first column (blue lines) shows the original stratification, based on 
nCounter® measurements (Linge, Löck, Gudziol et al., 2016). In the middle column, the 
cut-off used in nCounter® measurements was transferred to GeneChip® expression via 
linear regression. In the last column, the patients are stratified according to a new cut-off, 
which was determined on the GeneChip® data measurements (Linge, Löck, Gudziol et 
al., 2016; Schmidt et al., 2019). 
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Figure 5.5. Kaplan-Meier estimators of loco-regional tumour control for the pRCTx cohort. 
The patients were stratified by the putative CSC markers CD44 (top row) and SLC3A2 
(bottom row) assessed with either nCounter® (blue) or GeneChip® analyses (orange). 
The first column (blue lines) shows the original stratification, based on nCounter® 
measurements (Linge, Lohaus et al., 2016). In the middle column, the cut-off used in 
nCounter® measurements was transferred to GeneChip® expression via linear 
regression. In the last column, the patients are stratified according to a new cut-off, which 
was determined on the GeneChip® data (Linge, Lohaus et al., 2016; Schmidt et al., 2019). 
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Multiple biomarkers – hypoxia signatures 
In this paragraph results of hypoxia classification will be compared between gene expression 
measurement methods. The same classification method that was performed on nCounter® 
data was applied to the GeneChip® data – 𝑘-means clustering. Briefly, this algorithm 
stratifies the patient cohort in 𝑘 distinct groups with similar gene expressions. Afterwards, 
the results of the stratification into more and less hypoxic tumours were compared between 
both methods. 
For the PORT-C cohort, only the 15-gene and 26-gene hypoxia-associated signatures were 
available (Toustrup et al., 2011; Eustace et al., 2013; Toustrup et al., 2016) while for the 
pRCTx cohort also the 30 gene signature was available (Lendahl et al., 2009). For both 
cohorts the mean correlation 𝜌nC & GC of the genes within the hypoxia-associated signatures 
ranged from 0.67 up to 0.75, see Table 5.1. This is higher than the mean correlation 
𝜌nC & GC = 0.63 of all genes and similar to the correlation 𝜌nC & GC within the putative CSC 
markers ranging from 0.56 up to 0.87. The correlations between RT-PCR and GeneChip® 
measurements (15-gene signature: 0.64, 26-gene signature: 0.63) were smaller than the 
correlation between RT-PCR and nCounter® measurements (15-gene signature: 0.87, 26-
gene signature: 0.80). This was expected since the mean correlation between those 
measurement methods was already higher and recent publications stated a high correlation 
between those methods, too (Geiss et al., 2008; Malkov et al., 2009; Reis et al., 2011; 
Richard et al., 2014). 
For all signatures 𝑘-means clustering was performed on both cohorts to classify less and 
more hypoxic tumours. The resulting Kaplan-Meier estimates of LRC are presented in Figure 
5.6 for the PORT-C cohort and in Figure 5.7 for the pRCTx cohort. Regarding the patients 
of the pRCTx cohort, Linge et al. showed that the stratification becomes significant, when 
only small tumours are considered. Therefore, this patient subgroup with a tumour 
volume ≤ 19cm³ is presented inSupplementary Figure 3, using the same hypoxia 
classification as in Figure 5.7. 
In all stratifications, the resulting groups of less hypoxic patients showed a better LRC than 
the patients classified as more hypoxic, even though the differences were not always 
significant. Especially for the pRCTx cohort, only the 15-gene hypoxia-associated signature 
showed a significant difference for the small tumours. For the PORT-C cohort, the resulting 
Kaplan-Meier estimators obtained from the nCounter and RT-PCR data were almost 
identical (Figure 5.6 A and C, D and F). In general, about 70% of the tumours were classified 
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to the same hypoxia group using nCounter® and GeneChip® data. Details are given in Table 
5.3 and Table 5.4. This indicates that the classification based on the hypoxia signatures is 
quite robust and that gene sets can be transferred between different gene measurement 
methods, even though corresponding prognostic models may require recalibration. 
 
Figure 5.6. Kaplan-Meier estimators of LRC of the patients of the PORT-C cohort stratified 
by their hypoxia status (Schmidt et al., 2019). The cohort was stratified using the hypoxia-
associated gene signatures obtained by nCounter® (A, D), GeneChip® (B, E) and RT-
PCR (C, F) measurements. In the upper row (A, B, C) the stratification based on the 15 
hypoxia-associated gene signature (Toustrup et al., 2011; Toustrup et al., 2016) is shown. 
In the bottom row (D, E, F), the cohort is stratified based on the 26-gene signature 
(Eustace et al., 2013). 
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Figure 5.7. Kaplan-Meier estimates for LRC of the pRCTx cohort stratified by the hypoxia 
status (Schmidt et al., 2019). The hypoxia classification was performed using gene 
expressions obtained by nCounter® analyses (A, C, E) and GeneChip® (B, D, F). The 
columns show the stratifications based on the different hypoxia-associated gene 
signatures: (A, B) the 15-gene (Toustrup et al., 2011; Toustrup et al., 2016); (C, D) the 26-
gene (Eustace et al., 2013) and (E, F) the 30-gene (Lendahl et al., 2009) hypoxia-
associated signature.  
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Table 5.3. Cross tables of patient stratification determined from nCounter®, GeneChip® 
and RT-PCR analyses. (A) The stratification into more and less hypoxic tumours based on 
RT-PCR is compared with the stratification based on nCounter® (left column) and 
GeneChip® (right column) measurements for the PORT-C cohort, which is shown in Figure 
5.6 (Schmidt et al., 2019). 
  Stratification of PORT-C cohort based on 
  GeneChip®  nCounter® 
  gene expression data 
  Low High Low High 
Stratification 
based on 
RT-PCR gene 
expression 
data 
 15-gene hypoxia signature 
Corresponding 
figure 
Figure 5.6 B & C Figure 5.6 A & B 
Low 71 10 69 12 
High 38 69 8 99 
 26-gene hypoxia signature 
Corresponding 
figure 
Figure 5.6 E & F Figure 5.6 D & E 
Low 61 7 61 8 
High 53 66 6 112 
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Table 5.4. Cross tables of patient stratification determined from nCounter® and 
GeneChip® analyses. The stratifications based on nCounter® (rows) and GeneChip® 
(columns) are shown. The tumours are classified as more or less hypoxic using the 
corresponding gene signatures. In the last row, the stratification of the 7-gene signature is 
presented for the HPV16 DNA negative patients. The given corresponding figures show 
the analysed stratifications (Schmidt et al., 2019). 
  PORT-C pRCTx 
  
Stratification based on GeneChip® gene expression 
data 
  Low High Low High 
Stratification 
based on 
nCounter® 
gene 
expression 
data 
 15-gene hypoxia signature 
Corresponding 
figure 
Figure 5.6 A & B Figure 5.7 A & B 
Low 69 9 49 5 
High 41 72 34 48 
 26-gene hypoxia signature 
Corresponding 
figure 
Figure 5.6 D & E Figure 5.7 C & D 
Low 63 8 41 5 
High 54 66 35 55 
 
HPV16 DNA negative 
7-gene signature 
30-gene hypoxia 
signature 
Corresponding 
figure 
Figure 5.8 A & B Figure 5.7 E & F 
Low 59 9 46 6 
High 10 47 38 46 
 
 
Multiple biomarkers – 7-gene signature 
In the previous chapter, a 7-gene signature (extended with clinical parameters) for patients 
with HPV16 DNA negative tumours treated by PORT-C (Schmidt et al., 2018) was 
presented. The signature was determined based on nCounter® gene expressions. The 
genes within the signature show a correlation of 𝜌nC & GC = 0.68, more than the average 
correlation. To assess the robustness of the 7-gene signature extended by clinical 
parameters, it was used to stratify the patients based on GeneChip® data. Therefore, the 
gene expressions were z-normalized and the metagene for SERPINE1 was created by 
calculating the median of the normalized expressions of SERPINE1, ACTN1, INHBA and 
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P4HA2. The independent z-normalization of both data sets is similar to a linear regression. 
Subsequently, the trained model, presented in Table 4.11 (page 73), can be applied directly 
and a prognostic index is assigned to each patient. All patients with a prognostic index ≤ 0.37 
are regarded as low risk patients (as for the nCounter® model). The Kaplan-Meier estimators 
of both resulting risk groups, presented in Figure 5.8, are almost equal using nCounter® (A) 
and GeneChip® data (B). Both stratifications result in highly significant (p < 0.001) 
differences in LRC and nearly equally sized risk groups. In the cross table, Table 5.4, the 
patients’ risk assignment is depicted in detail. About 85% of the patients were stratified 
equally based on the different gene expression data. Thus, the 7-gene LRC signature 
showed an even higher reproducibility than the hypoxia signatures. 
 
Figure 5.8. Kaplan-Meier estimates of LRC for the 7-gene signature extended with clinical 
factors. The 7-gene signature combined with tumour localization (oral cavity: yes or no) and 
extracapsular extension status (ECE-status) was applied to patients with HPV16 DNA negative 
tumours of the PORT-C cohort using gene expressions from (A) nCounter® (Schmidt et al., 
2018) and (B) GeneChip®. Only patients with both available analyses were included (Schmidt 
et al., 2019). 
 
Discussion of model transfer 
In this section, stratifications of biomarkers regarding LRC were transferred between the 
different gene expressions obtained by nCounter®, GeneChip® and RT-PCR analyses. 
Single genes, i.e. putative CSC markers, showed a high variability, whereas, the 
stratification using gene signatures seemed to be more robust. 
Regarding the single genes, only the putative CSC marker MET was transferred 
successfully, i.e. the cut-off was transferred from nCounter® gene expression data to 
GeneChip® gene expression data via linear regression and still showed significant 
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differences in LRC. New cut-offs were found for the other single gene biomarkers CD44 and 
SLC3A2 resulting in groups with significantly different LRC. However, between 18.8 % and 
43.3 % of the patients were assigned to different risk groups by the different cut-offs. 
The gene signatures showed an improved transferability between the measurement 
methods. The best results were obtained between the gene expression data obtained by 
nCounter® and RT-PCR. Less than 15% of the patients were classified differently. The 
transferability between GeneChip® and nCounter® or RT-PCR was slightly lower, but still 
most patients were assigned to the same risk group. RT-PCR is referred to as the clinical 
standard for RNA analyses (Beersma et al., 2005; Ferris et al., 2011; Laco et al., 2011). 
Besides the best transferability, the average correlation between RT-PCR and nCounter® 
was also higher than the correlations between GeneChip® and RT-PCR or nCounter® 
based expression data. Similar findings were reported before (Geiss et al., 2008; Reis et al., 
2011) and may be explained by the probe set design. The TaqMan assay of RT-PCR and 
the nCounter® analyses cover similar regions of the gene and may be more sensitive for 
specific isoforms. The GeneChip® analysis, in contrast, includes several primer pairs that 
are specific for different regions of a gene. Therefore, the measured expression of the genes 
may differ due to the differing expressions of isoforms. Furthermore, it is very likely that the 
used FFPE material contains fragmented, short RNA sections. This may lead to inconsistent 
results that are based on only one set of primers or probes, as compared to results based 
on multiple probes (Chen et al., 2016) or multiple primer pairs (GeneChip®). 
Regarding the distribution of the resulting hypoxia classification, the stratifications based on 
GeneChip® measurements lead to more patients assigned to the less hypoxic groups 
compared to nCounter® data. This may be explained by the different scales of the gene 
expression data, which were handled differently by the 𝑘-means algorithm or occurred by 
chance. 
For the 7-gene signature similar results were obtained. The model was trained on the 
nCounter® data and was applied to the GeneChip® data. Only 15% of the patients were 
assigned to a different risk group. During pre-processing, a z-normalization of both data sets 
was performed, i.e. a linear regression transferring both data sets to the same scale. 
Compared to the single-gene based stratification, the signatures showed a higher 
robustness. This was also reported before (Abraham et al., 2010; Altenbuchinger et al., 
2017). Abraham et al compared different gene classifiers from 5 different studies in breast 
cancer (Abraham et al., 2010). Single genes and gene signatures led to similar results, but 
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the signatures’ results were more stable. In a more recent study, Cantini et al. have shown 
that functional redundancy is very prominent in informative gene signatures. Therefore, they 
compared 962 different gene signatures with respect to genetic composition, i.e. same 
genes in different signatures, and functional redundancy, i.e. different genes connected to 
one pathway. This ensures that the pathway of interest may be identified, even though, 
specific genes may be altered due to tumour heterogeneity (Cantini et al., 2018).  
In summary, results based on single genes may be transferred between different 
measurement methods, but cut-offs should be handled carefully. Signatures seem to be 
more robust when they are transferred between the different gene expression measurement 
methods than single genes (Abraham et al., 2010). Compared to the GeneChip® analyses, 
a higher correlation was obtained between RT-PCR and nCounter® gene expression 
measurements that may be due to their higher dynamic range (Malkov et al., 2009) and less 
steps during sample preparation (Richard et al., 2014). However, meta-analyses of 
biomarkers should be performed very carefully since the results depend strongly on the used 
method. When performing multi-centric studies, the biomarker analyses should be 
performed using the same technology. Furthermore, the technology should be chosen with 
respect to clinical applicability. 
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6 Conclusion and outlook 
Genomics are a powerful tool that can be applied to identify the biological characteristics of 
cancer. In this thesis gene expression signatures were identified that can be applied in 
prognostic models to stratify patients with locally advanced head and neck squamous cell 
carcinoma (HNSCC) into groups of low and high risk of loco-regional recurrences. The gene 
expressions were obtained via nCounter® or GeneChip® analyses from tumour biopsies of 
patients treated with either primary (pRCTx) or postoperative radiochemotherapy (PORT-
C). Independent validation was performed for cohorts with available nCounter® 
measurements. 
In the first part of this thesis several signatures were identified, which stratified the patients 
of the pRCTx training cohort into groups of low and high risk for loco-regional recurrences. 
However, no gene signature was validated successfully. A baseline signature, consisting of 
N-stage, p16 status and logarithmised tumour volume, outperformed the gene expression-
based signatures. The tumour volume seemed to be the most important prognostic factor 
for patients with locally advanced HNSCC treated with primary radiochemotherapy. In an 
independent validation of previously published biomarkers it was shown that the prediction 
of the baseline signature can be improved by adding the CD44 protein status assessed via 
immunohistochemistry. 
A 7-gene signature was identified based on nCounter® measurements for HNSCC patients 
with HPV16 DNA negative tumours treated with PORT-C. The model based on this signature 
was prognostic for loco-regional tumour control. The model’s performance could be further 
improved by adding the extracapsular extension status (ECE) and the tumour localization, 
i.e. oral cavity vs others. The signature was validated successfully and was applied to the 
secondary endpoints overall survival and freedom of distant metastasis. We also identified 
a gene signature based on GeneChip® gene expression measurements. Internal validation 
of this signature showed promising results. 
The obtained results showed that there is usually more than one applicable signature for 
each endpoint. Furthermore, different biological characteristics are described with different 
signatures and models. A consensus model strategy was presented to combine different 
signatures and models. Models were combined to identify groups of patients with a 
combined low or a combined high risk, who may benefit from treatment de-escalation or 
escalation, respectively. This approach might be beneficial to combine several aspects of 
the heterogeneous tumour biology. 
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The second part of this thesis focussed on the transferability of gene signatures. Therefore, 
different nCounter® measurements of the same patients were compared. The 
measurements showed a high correlation that decreased with a decreasing gene 
expression. Additionally, gene expressions measured by nCounter®, GeneChip® and real-
time PCR measurements were compared. The available gene expressions of the PORT-C 
and pRCTx cohort were compared pairwise between the different methods. All comparisons 
showed a high correlation, indicating a good portability of findings. The correlation between 
nCounter® and RT-PCR® measurements was higher than between nCounter® and 
GeneChip® measurements or GeneChip® and RT-PCR measurements. Stratifications 
based on gene signatures and biomarkers that were obtained from nCounter® 
measurements were transferred to GeneChip® measurements, but single-gene biomarkers 
showed a higher variability in the resulting stratifications than gene signatures. Hence, gene 
signature-based biomarkers seem to be more robust and may be used with different 
measurement methods. 
All gene signatures showed promising results based on the internal validations. However, to 
include the gene signatures into clinical routine, external validation as well as the inclusion 
in prospective clinical trials is urgently needed. Regarding the PORT-C signatures, external 
validation shall be performed in ongoing studies within the German Cancer Consortium 
Radiation Oncology Group (DKTK-ROG). If the validation is successful, the gene signature 
with its corresponding model may be included in interventional studies on dose escalation, 
similar to the currently recruiting DELPHI study (NCT03396718), where HPV-positive 
oropharyngeal tumours receive a de-escalated radiation dose. 
In addition to the putative CSC markers and gene signatures, further potential biomarkers 
were identified based on the PORT-C and pRCTx training cohort at other DKTK-ROG 
partner sites. All these markers shall be compared and combined in order to find the optimal 
biomarker set for these patients. 
The overall aim of personalized radiotherapy is still far away: The individualized treatment 
of the patient whose treatment is completely adapted to each peculiarity of his disease, 
regardless how unique this peculiarity is. Based on the findings presented in this, we may 
have gotten a small step closer to this goal.  
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Zusammenfassung 
Der Therapieerfolg bei der Behandlung von lokal fortgeschrittenen Kopf-Hals 
Plattenepithelkarzinomen (HNSCC) variiert stark aufgrund der heterogenen Tumorbiologie. 
Nur etwa die Hälfte dieser Patienten lebt noch 5 Jahre nach der Therapie. Die 
Behandlungsergebnisse zu verbessern ist ein Ziel, das über die Anpassung der Therapie 
an die Tumorbiologie erreicht werden soll. Ein erster Schritt auf dem Weg zur kompletten 
individualisierten Therapie ist die Einteilung von Tumoren mit ähnlichem Therapieergebnis. 
In dieser Arbeit wurden maschinelle Lernverfahren genutzt um Gen-Signaturen zu 
identifizieren. Mit Hilfe dieser Signaturen können Patienten mit lokal fortgeschrittenem 
HNSCC in Gruppen mit hohem, bzw. niedrigem Risiko, ein loko-regionäres Rezidiv zu 
entwickeln, eingeteilt werden. 
Im ersten Teil dieser Arbeit wurden Gensignaturen auf Basis von nCounter® und 
GeneChip®-Analysen von Tumorbiopsien entwickelt. Die Patienten (mit lokal 
fortgeschrittenem HNSCC) sind nach der Biopsieentnahme entweder mit postoperativer 
(PORT-C) oder primärer Radiochemotherapie (pRCTx) behandelt worden. Für die Analysen 
waren insgesamt vier Kohorten, je ein Paar für pRCTx bzw. PORT-C, verfügbar. Von diesen 
Paaren wurde je eine Kohorte (Trainingskohorte) zur Identifikation der Signaturen und zum 
Training der Modelle verwendet, wohingegen die andere Kohorte (Validierungskohorte) zur 
Validierung der Signaturen und Modelle verwendet wurde. 
Für die Patienten der pRCTx Trainingskohorte konnten verschiedene Signaturen auf Basis 
der nCounter® und GeneChip®-Messungen identifiziert werden. Auch wenn alle Signaturen 
im Training geeignet waren, die pRCTx Trainingskohorte in Gruppen mit guter und 
schlechter loko-regionärer Kontrolle (LRC) einzuteilen, konnte keine der gefundenen 
Gensignaturen erfolgreich validiert werden. Die Validierungen für die GeneChip®-Signatur 
stehen jedoch noch aus. Eine Basissignatur, bestehend aus N-Status, p16-Status und dem 
logarithmierten Tumorvolumen, war in der Validierung den genbasierten Signaturen 
überlegen. Das Tumorvolumen schien der wichtigste Parameter dieses Basismodells zu 
sein. Weiterhin wurde die unabhängige pRCTx Validierungskohorte genutzt, um Biomarker 
und Modelle zu validieren, die bereits publiziert wurden. Es konnte gezeigt werden, dass die 
Basissignatur durch die Erweiterung mit dem CD44-Protein-Status noch weiter verbessert 
werden kann. 
Dass HPV16 DNA positive HNSCC ein besseres Therapieergebnis zeigen, als HPV16 DNA 
negative ist bereits bekannt. Ein Ziel dieser Arbeit war es daher, eine Gensignatur zu finden, 
die vor allem Patienten mit HPV-negativem Tumor in Risikogruppen mit guter und schlechter 
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LRC einteilen kann. Auf der Grundlage der nCounter® Analysen wurde aus dem 
hypothesen-basierten Set von 178 Genen eine 7-Gen Signatur identifiziert. Auf Basis dieser 
Signatur und der PORT-C Trainingskohorte (HPV16 DNA negative Tumore) wurde ein 
prognostisches Modell mit dem Endpunkt LRC erstellt. Die Aussagekraft dieses Modells 
konnte durch die Erweiterung der Signatur um die klinischen Parameter ECE-Status und 
Lokalisierung des Tumors (Mundhöhle ja vs. nein) verbessert werden. Die Gensignatur und 
die erweiterte Gensignatur sowie die jeweils zugehörigen Modelle wurden auf der 
unabhängigen PORT-C Validierungskohorte erfolgreich validiert. Zusätzlich konnte gezeigt 
werden, dass die Signatur auch für die sekundären Endpunkte Überleben und Freiheit von 
Fernmetastasen verwendet werden kann. 
Neben den nCounter®-Analysen, waren auch GeneChip®-Analysen für die PORT-C 
Patientenkohorte verfügbar. Auf Grundlage dieser Daten wurde eine weitere Gensignatur 
mit vielversprechenden Ergebnissen in der internen Validierung identifiziert. 
All diese Resultate zeigten, dass es möglicherweise mehr als eine geeignete Signatur für 
jeden Endpunkt gibt. Zusätzlich können auch noch unterschiedliche biologische 
Eigenschaften durch verschiedene Signaturen und Modelle beschrieben werden. In dieser 
Arbeit wurde daher eine Konsensus-Modellierungs-Strategie vorgestellt, um verschiedene 
Signaturen und Modelle zu kombinieren. Dieser Ansatz könnte benutzt werden, um 
verschiedene Aspekte zu kombinieren, welche die heterogene Tumorbiologie beschreiben. 
Im zweiten Teil dieser Arbeit wurde der Fokus auf die Reproduzierbarkeit und 
Übertragbarkeit von Gensignaturen gelegt. Zuerst wurden dazu wiederholte nCounter®-
Messungen von einigen Patienten verglichen. Die Resultate zeigten eine hohe Korrelation 
zwischen den Ergebnissen der einzelnen Messungen, die jedoch von der einzelnen 
Genexpression abhängig war.  
GeneChip®-Analysen geben mit einer Messung über mehr Gene Auskunft als nCounter® 
oder Echtzeit-PCR (RT-PCR) Messungen, was insbesondere für breit aufgestellte 
investigative Analysen über Genexpressionen von Vorteil sein kann. In der klinischen 
Routine werden jedoch meist andere Methoden eingesetzt. Um die Übertragbarkeit von 
Ergebnissen zwischen verschiedenen Methoden zu untersuchen, wurden exemplarisch 
Ergebnisse der nCounter®, GeneChip® und RT-PCR-Analysen für die PORT-C und pRCTx 
Kohorte paarweise verglichen. Alle Vergleiche zeigten hohe Korrelationen, die für eine gute 
Übertragbarkeit der Ergebnisse sprechen. Der Vergleich von Daten aus nCounter® und RT-
PCR-Analysen zeigte aber höhere Korrelationen als die Vergleiche mit den GeneChip®-
Analysen. 
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Klassifizierungen, die auf Gensignaturen und Biomarkern aus nCounter®-Analysen 
basieren, wurden auf die Messdaten von GeneChip®-Analysen transferiert. Dabei war bei 
den Klassifizierungen, die auf einzelnen Genen beruhen, eine höhere Variabilität zu 
beobachten, als bei Klassifizierungen, die auf Basis von Gensignaturen durchgeführt 
wurden. Folglich scheinen Gensignaturen robuster zu sein, falls die Ergebnisse zwischen 
verschiedenen Messmethoden transferiert werden müssen. 
Die Signaturen, die in dieser Arbeit entwickelt wurden, könnten nach weiteren erfolgreichen 
Validierungen in klinischen Studien verwendet werden, um dem Ziel, der personalisierten 
Radioonkologie, näher zu kommen. 
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Summary 
Due to heterogeneous tumour biology, the treatment response of locally advanced head and 
neck squamous cell carcinoma (HNSCC) shows different results between patients, resulting 
in a mean 5-year survival of about 50%. The improvement of treatment outcome is the 
overall goal, which may be achieved by adapting the treatment more to the properties of the 
tumour, such as its therapy resistance, which must be assessed before treatment. A first 
step to achieve this goal is to identify similar tumours with respect to their therapy outcome. 
In this thesis, machine learning algorithms were used to identify gene expression signatures 
that can stratify patients with locally advanced head and neck squamous cell carcinoma in 
groups of low and high risk of loco-regional tumour recurrence (LRC). 
In the first part of this thesis gene expression signatures were identified based on data 
obtained via nCounter® or GeneChip® analyses from tumour biopsies of patients treated 
with either primary (pRCTx) or postoperative radiochemotherapy (PORT-C). For each 
treatment two cohorts were available. One cohort (training cohort) was used to identify the 
gene signatures and to train the models, while the other cohort (validation cohort) was used 
to validate the findings. 
Several signatures were identified, which stratified the patients of the pRCTx training cohort 
into groups of low and high risk for loco-regional recurrences. However, no gene signature 
could be validated successfully. A baseline signature, consisting of N-stage, p16 status and 
logarithmised tumour volume, outperformed the gene expression-based signatures. The 
tumour volume seemed to be the most important prognostic factor for patients with locally 
advanced HNSCC treated with pRCTx. In an independent validation of previously published 
biomarkers it was shown that the prediction of the baseline signature can be improved by 
adding the CD44 protein status assessed via immunohistochemistry. 
It is well known that patient with HPV16 DNA positive tumours have a superior outcome 
compared to the patients with HPV16 DNA negative tumours. One goal of this thesis was to 
develop a gene signature that further stratifies patients with HPV16 DNA negative tumours, 
e.g. into a subgroup with similar outcome as in HPV16 DNA positive tumours and a subgroup 
with a higher probability of a loco-regional tumour recurrence. Out of the hypothesis driven 
set of 178 genes analysed by nCounter® measurements, a 7-gene signature was identified. 
The signature and the patients of the PORT-C cohort (HPV16 DNA negative tumours) were 
used to create a prognostic model for loco-regional tumour control. The model’s 
performance could be further improved by adding the clinical parameters extracapsular 
extension status (ECE) and tumourlocalization, i.e. oral cavity vs others. The (extended) 
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signature and the resulting model were validated successfully using an independent 
validation cohort. Furthermore, the signature was successfully applied to the secondary 
endpoints overall survival and freedom of distant metastasis.  
Besides the nCounter® gene expressions, measurements from GeneChip® analyses were 
available. An additional signature could be identified based on those measurements, which 
showed promising results in internal validation. 
The obtained results showed that there may be more than one applicable signature for one 
specific endpoint. Furthermore, different biological characteristics are described with 
different signatures and models. A consensus model strategy was presented to combine 
those different signatures and models. This approach might be beneficial to combine several 
aspects of the heterogeneous tumour biology.  
The second part of this thesis focussed on the transferability of gene signatures. Therefore, 
different nCounter® measurements of the same patients were compared. The 
measurements showed a high correlation that depended on the gene expression level.  
In contrast to nCounter® and RT-PCR measurements, GeneChip® analyses provide 
information about several thousand genes in a single measurement, which may be used to 
identify novel gene signatures. For clinical routine, however, nCounter® or real time-PCR 
(RT-PCR) may be preferable. To evaluate the transferability of results between different 
gene expression measurement methods, gene expressions obtained from nCounter®, 
GeneChip® and RT-PCR analyses were compared. All comparisons showed a high 
correlation, indicating a good portability of findings. The correlation between nCounter® and 
RT-PCR measurements was higher than between nCounter® and GeneChip® 
measurements or GeneChip® and RT-PCR measurements. Stratifications based on gene 
signatures and biomarkers that were obtained from nCounter® measurements could be 
transferred to GeneChip® measurements. Single-gene biomarkers showed a higher 
variability in the resulting stratifications than gene signatures. Hence, gene signature-based 
biomarkers seem to be more robust and may be used with different measurement methods. 
Overall, the gene signatures developed in this thesis may be used in interventional clinical 
trials after additional validation and thus support the current goal to personalise radiotherapy. 
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Appendix 
A. Supplementary Figures 
 
Supplementary Figure 1. Kaplan-Meier estimators of loco-regional tumour control of 
patients in the pRCTx cohort with a small tumour (≤ 19 cm³)(Linge, Lohaus et al., 2016), 
stratified into more and less hypoxic tumours based on the 15-gene (A,B), 26-gene (C,D) 
and 30-gene signature (E,F) (Lendahl et al., 2009; West et al., 2009; Sørensen et al., 
2010; Toustrup et al., 2011; Eustace et al., 2013; Toustrup et al., 2016). In subfigures A, 
C and E, the training cohort is shown (Linge, Lohaus et al., 2016), whereas subfigures B, 
D and F show the validation cohort (Linge et al., 2019). The p-value of the log-rank test is 
shown in the bottom left corner. 
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Supplementary Figure 2. Kaplan-Meier estimators of loco-regional tumour control for the 
patients of the PORT-C validation cohort stratified according to the 7-gene signature and 
15-gene hypoxia associated gene signature based on nCounter® gene expression data. 
Patients with HPV16 positive tumours are represented by the brightest colour in each 
Kaplan-Meier estimator. The 7 gene signature was applied to the validation cohort 
normalized either based on the training cohorts gene expression data (A, C) and based 
on its own gene expression data (D, E). The HPV16 DNA negative patients are stratified 
based on the 7-gene signature extended with clinical features (A, D), their hypoxia status 
(B, E) or a combination of both models (C, F). The combined high risk (comb. HR) is 
composed of patients who have a more hypoxic tumour and who are in the high risk group 
of the LRC specific model. The p-value is based on the comparison of the HPV16 DNA 
negative patient risk groups. 
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Supplementary Figure 3. Kaplan-Meier estimates for LRC of the patients of the pRCTx 
cohort with a small tumour (volume ≤ 19 cm³) stratified by the hypoxia status. The hypoxia 
classification was performed using gene expressions obtained by nCounter® analyses (A, 
C, E) and GeneChip® (B, D, F). The columns show the stratifications based on the 
different hypoxia-associated gene signatures: (A, B) the 15-gene (Toustrup et al., 2011; 
Toustrup et al., 2016); (C, D) the 26-gene (Eustace et al., 2013) and (E,F) the 30-gene 
(Lendahl et al., 2009) hypoxia-associated signature (Schmidt et al., 2019).  
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B. Supplementary Tables 
Supplementary Table 1. The composition of the 15-, 26- and 30-gene hypoxia-
associated signatures are shown in the second, third and fourth column, respectively 
(Lendahl et al., 2009; West et al., 2009; Sørensen et al., 2010; Toustrup et al., 2011; 
Eustace et al., 2013; Toustrup et al., 2016). Overlapping genes are marked with * (also 
included in 30-gene hypoxia signature), # (also included in 26-gene hypoxia signature) 
and + (also included in 15-gene hypoxia signature). 
Number 
15-gene hypoxia 
signature 
26-gene hypoxia 
signature 
30-gene hypoxia 
signature 
1 ADM* ALDOA+ ADM+ 
2 ALDOA# ANGPTL4 ALDOC 
3 ANKRD37 ANLN ATF7IP 
4 BNIP3* BNC1 BNIP3+ 
5 BNIP3L* CA9 BNIP3L+ 
6 EGLN3 CDKN3 
DHX34 (not used for 
classification in this thesis) 
7 FAM162A COL4A6 DDIT4 
8 KCTD11# DCBLD1 ENO2 
9 LOX ENO1 ERO1A 
10 NDRG1* FAM83B GBE1 
11 P4HA1*# FOSL1 GLRX 
12 P4HA2 GNAI1 HILPDA# 
13 PDK1* HILPDA* HK2 
14 PFKFB3 KCTD11+ HMMR 
15 SLC2A1# KRT17 INSIG1 
16   LDHA INSIG2 
17   MPRS17 KDM3A 
18   MRGBP MAFF 
19   P4HA1*+ MXI1 
20   PGAM1 MYCBP 
21   PGK1 NDRG1+ 
22   SDC1 P4HA1#+ 
23   SLC16A1 PDK1+ 
24   SLC2A1+ PPFIA4 
25   TPI1 SLC26A2 
26   VEGFA SLC7A1 
27     SOX4 
28     VEGFA 
29     WSB1 
30     ZNF654 
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Supplementary Table 2. Used programs and packages. 
Program Package Version used 
R-statistics 3.3.2 ggplot2 2.1.0 
 data.table 1.9.8 
 survival 2.40-1 
 foreach 1.4.3 
 nnet 7.3-12 
 glmnet 2.0-5 
 mboost 2.7-0 
 doSNOW 1.0.14 
 XML 3.98-1.5 
 party 1.1-2 
 ipred 0.9-5 
 randomForestSRC 2.4.1 
 parallel 3.3.1 
 MASS 7.3-45 
 plyr 1.8.4 
Python 2.7 numpy 1.9.2 
 shutil n.a. 
 pandas 0.16.2 
 lifelines 0.9.1.0 
 
matplotlib 1.4.3 
scipy 0.16.0 
SPSS  23.0 
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Supplementary Table 3. Patient characteristics for the patients treated with postoperative 
radio(chemo)therapy, PORT(-C), of the training and validation cohort. 
* Comparison based on log-rank test for time-to-event data, + 95% confidence interval. 
 Training cohort Validation cohort  
 2004-2012 1999-2006  
Characteristics Median (range) Median (range)  
Follow-up (months) 56.7 (11.5 – 94.5)+ 61.7 (24.7 – 153.0)+ <0.001* 
Age (years) 57.0 (24.0 – 75.2) 52.6 (36.3 – 71.0) 0.007 
Dose (Gy) 64.0 (56.0 – 68.0) 64.0 (60.0 – 66.0) 0.002 
 Patients (%) Patients (%) p-value 
Gender Male / female 156 / 39 80.0 / 20.0 119 / 23 
83.3 / 
16.2 
0.37 
Chemother
apy 
Yes / no 195 / 0 100.0 / 0.0 38 / 104 
26.8 / 
73.2 
<0.001 
Localization Oropharynx 112 57.4 43 30.3  
 Oral cavity 56 28.7 79 55.6  
 Hypopharynx 27 13.8 13 9.2  
 Larynx 0 0.0 7 4.9 <0.001 
HPV16 
DNA status 
Neg. / pos. 130 / 65 66.7 / 33.3 121 / 21 
73.2 / 
26.8 
<0.001 
ECE-status Neg. / pos. 88 / 107 45.1 / 54.9 97 / 45 
68.3 / 
31.7 
<0.001 
Loco-regional recurrences 28 14.4 36 25.4 0.010* 
Distant metastases 37 19.0 32 22.5 0.26* 
Deaths 64 32.8 78 54.9 0.004* 
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Supplementary Table 4. Genes available in GeneChip® and nCounter® analyses for the 
training and validation cohorts of the patients treated with either postoperative or primary 
radiochemotherapy. A similar list was published in the supplementary files of (Schmidt et 
al., 2018). Some genes which were also available for Real Time (RT)-PCR are highlighted 
using bold font. The genes are shown in clusters according to their function, together with 
one exemplarily reference. Every gene occurs only once in the table, even though it may 
also be involved in other biological processes. 
Functions Group of genes References 
Cancer stem  ALCAM (Yan et al., 2013) 
cells ALDH1A1 (Koukourakis et al., 2012) 
 ALDH1A3 (Kurth et al., 2015) 
 ALDH3A1, SNAI1 (Chinn et al., 2012) 
 BMI1 (Major et al., 2013) 
 CBX4 (Ismail et al., 2012) 
 MET (Sun and Wang, 2011) 
 SLC3A2 (Martens-de Kemp et al., 2013) 
 TCF3 (Zhang et al., 2012) 
Chemotherapy 
resistance 
BCL2L1 (Michaud et al., 2009) 
BIRC5 (Khan et al., 2012) 
 BSG (Huang et al., 2013) 
 CD24 (Modur et al., 2016) 
 CYP1B1 (McFadyen et al., 2001) 
 MME (Fukusumi et al., 2014) 
 NOTCH1 (Gu et al., 2010) 
 RAC1 (Skvortsov et al., 2014) 
 SERPINB2 (Huang et al., 2014) 
 SFN (Han et al., 2009) 
 YAP1 (Akervall et al., 2014) 
DNA repair AKT1, ATM, CDKN2A, ERCC4, 
ERCC5, MAPK3, RAD51, XPA, 
XPC, XRCC1 
(Jenkins et al., 2013) 
 CBX4 (Ismail et al., 2012) 
 CHK2 (Zannini et al., 2014) 
 HSPA4 (Gehrmann et al., 2014) 
 NBN (Yang et al., 2006) 
 PSMD9 (Langlands et al., 2014) 
 PTEN (Mriouah et al., 2014) 
 MRE11A, RAD23B, RAD50, RFC4, 
RPA2, PCNA, XRCC4, XRCC5 
(Curtin, 2012) 
 Appendix 
137 
DNA repair RMI2, FANCA, PRKDC (Deans and West, 2013) 
(continuation) SMG1 (Gubanova et al., 2012) 
Epithelial-
mesenchymal 
transition 
ATP5G3 (Chung et al., 2006) 
SIRT (Tanaka et al., 2014) 
SNAI1, LOXL2 (Millanes-Romero et al., 2013) 
HPV association ASS1 (Slebos et al., 2006) 
 CENPK, EHHADH, MCM6, MYNN, 
NR1D2, RIBC2, SYNGR3 
(de Jong, Pramana, Knegjens et 
al., 2010) 
Metabolism HK2 (Peschiaroli et al., 2013) 
 IDH1 (Sandulache and Myers, 2012) 
 GPI (Shen et al., 2015) 
 SDHA (Gao et al., 2014) 
Migration, invasion, 
metastases 
ACTN1 (Hirooka et al., 2011; Kim et al., 
2012) 
ADM (Oehler et al., 2003) 
ANXA5 (Peng et al., 2014) 
CAV1 (Nohata et al., 2011) 
 CLDN4 (Akervall et al., 2014) 
 CXCL12, CXCR4 (Albert et al., 2013) 
 EPOR (Mohyeldin et al., 2005) 
 FLT1 (Van Limbergen et al., 2014) 
 HSPB1 (Zhu et al., 2010) 
 ITGB1 (Neal et al., 2011) 
 ITGB2 (Xu et al., 2008) 
 MAP2K1, MAP2K2 (Caunt et al., 2015) 
 MMP2, MMP7, MMP9, MMP10, 
MMP13 
(Rosenthal and Matrisian, 2006) 
 MTOR, STAT3 (Normanno et al., 2006) 
 MUC1 (Rabassa et al., 2006) 
 MYC (Bhattacharya et al., 2009) 
 RASSF6 (Volodko et al., 2014) 
 RELA (Sharma and Narayanan, 1996) 
 SLC5A1 (Hanabata et al., 2012) 
 SMDT1 (Gao et al., 2014) 
 SPP1 (Le et al., 2003) 
 SYK (Luangdilok et al., 2007) 
 TGFB1 (White et al., 2010) 
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Hypoxia 
 
 
 
ALDOA, ANGPTL4, ANKRD37, 
ANLN, BNC1, BNIP3, BNIP3L, 
CA9, CDKN3, COL4A6, DCBLD1, 
EGLN3, ENO1, FAM162A, 
FAM83B, FOSL1, GNAI1, HILPDA, 
KCTD11, KRT17, LDHA, LOX, 
MPRS17, MRGBP, NDRG1, 
P4HA1, P4HA2, PDK1, PFKFB3, 
PGAM1, PGK1, SDC1, SLC16A1, 
SLC2A1, TPI1, VEGFA 
(Buffa et al., 2010; Toustrup et 
al., 2011) 
 ARNT (Harris, 2002) 
 ENO2 (Sena et al., 2014) 
 HIF1A (Beasley et al., 2002) 
 LGALS1 (Saussez et al., 2007) 
 LIMD1 (Ghosh et al., 2010) 
Proliferation ATR, E2F1, MDM2, RB1, TP53 (Harris and Levine, 2005) 
 CCND1 (Rittà et al., 2009) 
 DKK3 (Veeck and Dahl, 2012) 
 EGFR (Bentzen et al., 2005) 
 EGR1 (Yan et al., 2007) 
 EIF4A1 (Lai et al., 2010) 
 EPHA1, EPHA2 (Wu et al., 2011) 
 ERBB2, ERBB3, ERBB4 (O-charoenrat et al., 2002) 
 FGF2, FGFR1, FGFR3, IGF1R (Marshall et al., 2011) 
 FN1, PLAU, SERPINE1 (Jerhammar et al., 2010) 
 INHBA (Akervall et al., 2014) 
 KDR (Koutsimpelas et al., 2008) 
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Supplementary Table 5. Hyper-parameters used for the feature selection algorithms and 
predictive models. 
Purpose Method Parameter 
Feature selection 
Pearson - 
Spearman - 
Mutual information matrix (MIM) - 
Mutual information feature 
selection (MIFS) 
Top features = 20 
Minimum redundancy maximum 
relevance (MRMR) 
Top features = 20 
Univariable Cox Regression 
Iterations = 10 
Folds = 2 
Net-Cox 
α = 0 
Folds = 5 
λ = “lambda.min” 
Statistical model 
(signature size  
was varied) 
Random survival forest 
nTrees = 1501 
mTry = 20 
Node size = 7 
Node depth = 5 
nSplit = 5 
Bootstrap Method = “by.root” 
Cox regression Iterations = 1000 
Net-Cox 
α = 0 
Folds = 5 
λ = “lambda.min” 
Survival regression 
Iterations = 1000 
Dist = “weibull“ 
BGLM-Cox 
Nu = 0.01 
mStop = 200 
λ = “lambda.min” 
BGLM-Weibull 
Nu = 0.01 
mStop = 200 
λ = “lambda.min” 
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Supplementary Table 6. Spearman rank correlation coefficients of the 7-gene signature 
and the clinical features for the HPV16 DNA negative patients of the PORT-C training 
(upper part, grey) and validation cohort (lower part, blue). Correlation coefficients 
significantly different from zero are marked via bold font. 
 HILPDA SERPINE1 ACTN1 INHBA P4HA2 TCF3 CD24 ECE 
Oral 
Cavity 
 Training cohort 
HILPDA  0.28 0.23 0.36 0.34 0.20 -0.01 -0.05 0.10 
SERPINE1 0.11  0.73 0.78 0.72 -0.15 -0.27 0.00 0.31 
ACTN1 0.11 0.70  0.82 0.69 -0.04 -0.19 0.02 0.30 
INHBA 0.08 0.74 0.78  0.71 -0.08 -0.21 0.00 0.31 
P4HA2 0.28 0.66 0.59 0.59  -0.05 -0.16 0.02 0.23 
TCF3 0.12 -0.13 -0.16 -0.02 0.01  0.28 0.09 -0.21 
CD24 0.21 -0.36 0.33 -0.32 -0.11 0.25  0.02 -0.06 
ECE 0.03 0.14 0.11 0.07 0.12 0.01 -0.11  0.23 
Oral 
Cavity 
0.09 0.22 0.24 0.18 0.22 -0.31 -0.17 -0.04  
 Validation cohort 
 
 
  
 Appendix 
141 
Supplementary Table 7. Multivariate Cox regression of the 7-gene signature for the 
secondary endpoint overall survival (OS). The upper part of the table shows the 
regression of the 7-gene signature only, the middle part the regression of the clinical 
parameters only and the bottom part of table shows the regression parameters of the 
complete model, including gene expressions and clinical parameters. The performance 
was assessed by the concordance index 𝑐𝑖. The training and external validation 𝑐𝑖 are 
based on the whole training or validation cohort, respectively (HPV16 DNA negative 
patients). The corresponding 95% confidence interval (95%-CI) is based on 1000 
bootstraps of the corresponding cohort (Schmidt et al., 2018). 
Gene β Exp(β) = HR p-value 
 7-gene signature only 
Metagene from SERPINE1, INHBA, 
ACTN1 and P4HA2 
0.45 1.57 0.019 
HILPDA 0.24 1.27 0.079 
CD24 -0.16 0.85 0.28 
TCF3 -0.10 0.91 0.57 
𝑐𝑖 (95%-CI) (train) 0.67 (0.61-0.75) 
𝑐𝑖 (95%-CI)  
(external validation) 
0.62 (0.55-0.69) 
𝑐𝑖 (95%-CI)  
(external validation, only chemotherapy) 
0.72 (0.56-0.84) 
 Clinical parameters only 
ECE-status 0.61 1.84  0.034 
Localization oral cavity 0.61 1.83  0.029 
𝑐𝑖 (95%-CI) (train) 0.63 (0.55-0.72) 
𝑐𝑖 (95%-CI) 
(external validation) 
0.60 (0.54-0.66) 
𝑐𝑖 (95%-CI)  
(external validation, only chemotherapy) 
0.64 (0.45-0.78) 
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Supplementary Table 7 (Continuiation) 
Gene β Exp(β) = HR p-value 
 7-gene signature and clinical parameters 
Metagene from SERPINE1, INHBA, 
ACTN1 and P4HA2 
0.38 1.46 0.054 
HILPDA 0.27 1.31 0.55 
CD24 -0.16 0.85 0.32 
TCF3 -0.09 0.92 0.63 
ECE-status 0.71 2.03 0.015 
Localization oral cavity 0.34 1.41 0.26 
𝑐𝑖 (95%-CI) (train) 0.71 (0.65-0.79) 
𝑐𝑖 (95%-CI)  
(external validation) 
0.64 (0.57-0.70) 
𝑐𝑖 (95%-CI)  
(external validation, only chemotherapy) 
0.72 (0.58-0.83) 
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Supplementary Table 8. Multivariate Cox regression of the 7-gene signature for the 
secondary endpoint freedom of distant metastases (DM). The upper part of the table 
shows the regression of the 7-gene signature only, the middle part the regression of the 
clinical parameters only and the bottom part of table shows the regression parameters of 
the complete model, including gene expressions and clinical parameters. The 
performance was assessed by the concordance index ci. The training and external 
validation ci are based on the whole training or validation cohort, respectively (HPV16 
DNA negative patients). The corresponding 95% confidence interval (95%-CI) is based 
on 1000 bootstraps of the corresponding cohort (Schmidt et al., 2018). 
Gene β Exp(β) = HR p-value 
 7-gene signature only 
Metagene from SERPINE1, INHBA, 
ACTN1 and P4HA2 
0.32 1.38 0.19 
HILPDA 0.19  1.21 0.30 
CD24 0.10 1.10 0.64 
TCF3 0.01  1.01 0.94 
𝑐𝑖 (95%-CI) (train) 0.60 (0.56-0.73) 
𝑐𝑖 (95%-CI)  
(external validation) 
0.59 (0.51-0.69) 
𝑐𝑖 (95%-CI) 
(external validation, only chemotherapy) 
0.74 (0.52-0.90) 
 Clinical parameters only 
ECE-status 1.02 2.77 0.014 
Localization oral cavity 0.31 1.37  0.40 
𝑐𝑖 (95%-CI) (train) 0.65 (0.56-0.75) 
𝑐𝑖 (95%-CI)  
(external validation) 
0.61 (0.52-0.71) 
𝑐𝑖 (95%-CI)  
(external validation, only chemotherapy) 
0.55 (0.31-0.75) 
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Supplementary Table 8 (Continuiation) 
Gene β Exp(β) = HR p-value 
 7-gene signature and clinical parameters 
Metagene from SERPINE1, INHBA, 
ACTN1 and P4HA2 
0.29 1.34 0.25 
HILPDA 0.24 1.27 0.23 
CD24 0.12 1.13 0.58 
TCF3 -0.05 0.95 0.83 
ECE-status 1.10 2.99 0.01 
Localization oral cavity 0.09 1.09 0.83 
𝑐𝑖 (95%-CI) (train) 0.69 (0.64-0.80) 
𝑐𝑖 (95%-CI) 
(external validation) 
0.63 (0.52-0.73) 
𝑐𝑖 (95%-CI) 
(external validation, only chemotherapy) 
0.64 (0.38-0.85) 
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Supplementary Table 9. Lists taken to perform the gene preselection for GeneChip® 
analyses. The upper part of the Table shows the lists which were taken from gene 
enrichment set analysis (GESA) (Mootha et al., 2003; Subramanian et al., 2005). For each 
list the “standard name” within GESA and the original publication is given. In the bottom 
part of the table, the lists taken from Gene Ontology (GO) are presented together with its 
corresponding GO number (###), accessible under 
http://amigo.geneontology.org/amigo/term/GO:### (Ashburner et al., 2000; The Gene 
Ontology Consortium, 2019). All lists were accessed on 24.05.2017  
Standard name Reference / GO number 
Gene enrichment set analysis 
AMUNDSON_GAMMA_RADIATION_RESISTANCE (Amundson et al., 2008) 
AMUNDSON_GAMMA_RADIATION_RESPONSE (Amundson et al., 2008) 
AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATI
ON_2G 
(Amundson et al., 2008) 
AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATI
ON_8G 
(Amundson et al., 2008) 
GHANDHI_BYSTANDER_IRRADIATION_DN (Ghandhi et al., 2008) 
GHANDHI_BYSTANDER_IRRADIATION_UP (Ghandhi et al., 2008) 
GHANDHI_DIRECT_IRRADIATION_DN (Ghandhi et al., 2008) 
GHANDHI_DIRECT_IRRADIATION_UP (Ghandhi et al., 2008) 
KYNG_DNA_DAMAGE_BY_4NQO_OR_GAMMA_RADIATIO
N 
(Kyng et al., 2005) 
KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION (Kyng et al., 2005) 
KYNG_DNA_DAMAGE_BY_GAMMA_RADIATION (Kyng et al., 2005) 
MONNIER_POSTRADIATION_TUMOR_ESCAPE_DN (Monnier et al., 2008) 
MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP (Monnier et al., 2008) 
RASHI_RESPONSE_TO_IONIZING_RADIATION_1 (Rashi-Elkeles et al., 2006) 
RASHI_RESPONSE_TO_IONIZING_RADIATION_2 (Rashi-Elkeles et al., 2006) 
RASHI_RESPONSE_TO_IONIZING_RADIATION_3 (Rashi-Elkeles et al., 2006) 
RASHI_RESPONSE_TO_IONIZING_RADIATION_4 (Rashi-Elkeles et al., 2006) 
RASHI_RESPONSE_TO_IONIZING_RADIATION_5 (Rashi-Elkeles et al., 2006) 
RASHI_RESPONSE_TO_IONIZING_RADIATION_6 (Rashi-Elkeles et al., 2006) 
SMIRNOV_RESPONSE_TO_IR_2HR_DN (Smirnov et al., 2012) 
SMIRNOV_RESPONSE_TO_IR_2HR_UP (Smirnov et al., 2012) 
SMIRNOV_RESPONSE_TO_IR_6HR_DN (Smirnov et al., 2012) 
SMIRNOV_RESPONSE_TO_IR_6HR_UP (Smirnov et al., 2012) 
TAKAO_RESPONSE_TO_UVB_RADIATION_DN (Takao et al., 2002) 
TAKAO_RESPONSE_TO_UVB_RADIATION_UP (Takao et al., 2002) 
TSAI_RESPONSE_TO_IONIZING_RADIATION (Tsai et al., 2006) 
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TSAI_RESPONSE_TO_RADIATION_THERAPY (Tsai et al., 2007) 
WARTERS_IR_RESPONSE_5GY (Warters et al., 2009) 
WARTERS_RESPONSE_TO_IR_SKIN (Warters et al., 2009) 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR (Zhou et al., 2007) 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_2HR (Zhou et al., 2007) 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR (Zhou et al., 2007) 
Gene Ontology 
Cellular response to gamma radiation 0071480 
Cellular response to ionizing radiation 0071479 
Cellular response to radiation 0071478 
Cellular response to DANN damage stimulus 0006974 
Response to gamma radiation 0010332 
Response to ionizing radiation 0010212 
Response to radiation 0009314 
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